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Abstract 
Obesity and type 2 diabetes are a growing concern worldwide and 
changes within adipose tissue are implicated in their development. Adipocytes 
contain a complete renin angiotensin aldosterone system (RAAS) implicated in 
obesity-related complications. The energy regulating kinase AMP-activated 
protein kinase (AMPK) has anti-inflammatory properties in adipose tissue and 
systemic insulin sensitising effects.  
Initial studies compared the human adipocyte model SW872 with the 
well-described murine 3T3-L1 adipocyte model. AMPK signalling in SW872 
adipocytes was evident with similar responses to two structurally-unrelated 
AMPK activators, AICAR and A769662 compared with 3T3-L1 adipocytes. Key 
components of the RAAS were present in SW872 adipocytes and induced upon 
adipocyte differentiation. AICAR and A769662 were found to negatively 
regulate classical RAAS components including the mineralocorticoid receptor 
and angiotensinogen whilst upregulating the ratio of expression of angiotensin 
converting enzyme-2 to angiotensin converting enzyme-1. However, AMPK 
activation increased aldosterone secretion and the downstream target SGK1. 
Interestingly, angiotensin II, likely via the type 2 angiotensin II receptor, and 
angiotensin 1-7, likely via the Mas receptor, both increased AMPK activity. 
Despite this AMPK activation there was no effect of angiotensin 1-7 seen on 
inflammatory processes or insulin signalling in adipocytes so the functional 
effects of this AMPK activation remain unknown. Wild type and AMPKα1-/- 
mice were subjected to 12 weeks of high fat diet (HFD) with no significant 
metabolic differences. Interestingly, the adipose tissue from AMPKα1-/- mice 
fed chow diet showed increased basal inflammatory signalling which 
decreased following HFD suggesting a possible pro-inflammatory effect of 
AMPK upon HFD exposure. However, the systemic RAAS appeared to be 
upregulated in the AMPKα1-/- HFD group. 
The cross-talk between AMPK and RAAS in adipose tissue likely has an 
important part to play in the development of obesity-related disorders and 
this work identifies several potential therapeutic avenues.  
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1 Chapter 1 – Introduction 
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1.1 The impact of obesity 
Obesity and diabetes are now two of the most important public health 
problems worldwide. In the UK, obesity and overweight associated problems 
cost the NHS £5 billion each year and diabetes treatment alone accounts for 
10% of the NHS budget in England and Wales (£14 billion). Diabetes affects an 
estimated 347 million people worldwide (Danaei et al. 2011), with type 2 
diabetes accounting for 90% of cases. Despite increased understanding of type 
2 diabetes and newer medications becoming available the associated 
mortality is predicted to continue to rise, predominantly in developing 
countries (Mathers and Loncar, 2006). This is an area in huge need of 
improved understanding of aetiology and development of cure. Chronic 
inflammation in adipose tissue is hypothesised to contribute to insulin 
resistance and therefore further understanding adipose tissue biology may be 
the key to a future without type 2 diabetes.  This chapter describes the 
relevant literature which had been reported prior to the outset of this study. 
 
1.1.1 Metabolic impact of chronic obesity 
Obesity is defined by a body mass index (BMI) greater than 30 kg/m2 and 
describes a heterogeneous group of individuals at risk of major metabolic 
disturbance. However, a proportion of obese and severely obese (BMI > 40 
kg/m2) individuals do not develop significant metabolic upset or health 
complications. For the 75% of obese individuals who develop metabolic 
problems there are several mechanisms which lead to these changes. Insulin 
resistance is the primary metabolic change resulting in type 2 diabetes, 
hyperlipidaemia, non-alcoholic fatty liver disease and cardiovascular disease 
and understanding its development is therefore crucial. Several mechanisms 
are associated with insulin resistance with varying significance and 
therapeutic potential, in reality the importance of each likely varies between 
individuals. Such mechanisms, which will be discussed further, include 
inflammation (systemic and tissue specific), mitochondrial dysfunction, 
altered adipokine secretion and sensitivity, and reactive oxygen species (ROS) 
(Reviewed in Xu et al. 2013). 
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1.2 Adipose Tissue 
Adipose tissue is a dynamic structure with a key role in energy homeostasis. 
Traditionally known as an energy storage tissue, its other properties such as 
the synthesis and secretion of hormones and cytokines have been well-
described (Guilherme et al. 2008; Kershaw and Flier, 2004). Adipocytes are 
the predominant cell type in adipose tissue which also consists of the stromal 
vascular fraction made up of fibroblasts, immune cells and connective tissue 
(Bijland et al. 2013).  
 
Adipose tissue is anatomically defined as visceral or subcutaneous, with 
visceral adiposity particularly associated with cardiovascular risk (Smith et al. 
2012). Histologically, it is recognized as white adipose tissue (WAT) or brown 
adipose tissue (BAT) due to differences in the adipocytes – a unilocular lipid 
droplet is seen in WAT and multilocular lipid droplets in BAT (Bijland et al. 
2013). Brown adipose tissue plays a major role in non-shivering thermogenesis 
and is reliant on uncoupling protein 1 (UCP-1) for this process (Bijland et al. 
2013). Beige adipocytes have more recently been defined as multilocular 
adipocytes present in WAT which are UCP-1 positive and may be amenable to 
manipulation in future treatments of obesity (Wu et al. 2013).  
 
1.2.1 Adipose tissue physiology 
Maintenance of energy homeostasis requires harmonious communication 
between several organs including adipose tissue, liver, pancreas, skeletal 
muscle and areas of the central nervous system concerned with appetite 
regulation and energy expenditure. The primary function of adipose tissue is 
to store energy for future use; lipid stores also provide support for visceral 
structures. Dietary glucose and lipids not immediately required are stored in 
WAT as triacylglycerol via the process of lipogenesis. 
 
1.2.1.1 Lipogenesis 
The majority of lipid stores originate from circulating lipids – chylomicrons 
and very low density lipoproteins (VLDL) release fatty acids in the presence of 
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lipoprotein lipase (LPL) at the surface of adipocytes (Sadur and Eckel, 1982). 
Fatty acids enter the adipocytes where they undergo esterification with 
Coenzyme A by fatty acyl-CoA synthetase (Watkins, 1997). Glyceryl phosphate 
acyltransferase catalyses the addition of two fatty acids to glycerol-3-
phosphate (G3P) forming phosphatidate. Phosphatidate is hydrolysed to 
diacylglycerol which is further acylated by diacylglycerol acyltransferase 
(DGAT) yielding triacylglcerol (TAG) (Coleman and Lee, 2004). 
 
Glucose is the other energy source stored as TAG in adipocytes. On entering 
the cytoplasm glucose undergoes glycolysis forming dihydroxyacetone 
phosphate (DHAP) which can be converted to G3P and therefore used to form 
phosphatidate as described above (Nye et al. 2008). Circulating glucose can 
also be utilized to form fatty acids for lipogenesis, whereby the 3 carbon 
intermediates continue through glycolysis to form pyruvate which is converted 
to acetyl-CoA in the mitochondria. After transfer of acetyl-CoA to the 
cytoplasm, acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) 
catalyse the conversion of acetyl-CoA and malonyl-CoA to long chain fatty 
acids (Tong, 2005). Figure 1.1 summarises the main steps in lipogenesis. 
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Figure 1.1 Key steps in lipogenesis 
Circulating fatty acids enter the adipocyte and combine with G3P to form 
triglyceride in the lipid droplet. Glucose undergoes glycolysis within the 
adipocyte which produces either DHAP or pyruvate. Pyruvate can be 
converted into acetyl CoA and go on to produce fatty acids. G3P and fatty 
acids are processed to lysophosphatidic acid (LPA), phosphatidic acid (PA), 
diacylglycerol (DAG) then triglyceride (TAG). Key enzymes in this process 
include glycerol-3-phosphate acyltransferase (GPAT), acylCoA acylglycerol-3-
phosphate acyltransferase (AGPAT), phosphatidic acid phosphatase (PAP-1) 
and diglyceride acyltransferase (DGAT). Figure compliments body text 
(Saponaro et al. 2015). 
 
1.2.1.2 Lipolysis 
In the fasted state energy can be released from stores in adipose or liver. 
Lipolysis, the breakdown of triglycerides to form glycerol and three free fatty 
acids, is a catabolic process under exquisitely tight inhibitory control by 
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insulin and stimulated by catecholamines (Czech et al. 2013). In adipocytes, 
an increase of intracellular cAMP in response to catecholamines leads to 
activation of protein kinase A (PKA) which subsequently phosphorylates 
hormone sensitive lipase (HSL) and perilipins (Collins et al. 2004).  The action 
of HSL is blocked when perilipins are in place covering the lipid droplet. Once 
HSL and perilipins are phosphorylated, HSL is free to hydrolyse TAG forming 
diacylglycerides and monoacylglycerides. Monoglyceride lipase is required for 
the final step of monoacylglyceride hydrolysis into non-esterified fatty acids 
(NEFAs) (Fredrikson et al. 1986). These steps are summarised in Figure 1.2. 
 
 
 
Figure 1.2 Key steps in lipolysis 
Triglycerides are broken down to form glycerol and fatty acids following 
catcholamine stimulation and the phosphorylation of HSL and Perilipin by 
cAMP. Insulin inhibits this process by suppressing cAMP levels. Key enzymes 
include adipose triacylglycerol lipase (ATGL), hormone sensitive lipase (HSL) 
and monoacylglycerol lipase (MGL) (Saponaro et al. 2015). 
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1.2.1.3 Regulation of lipogenesis and lipolysis by insulin 
Insulin is a key anabolic hormone facilitating lipogenesis and inhibiting 
lipolysis. Insulin signalling via phosphoinositol 3-kinase (PI3 kinase) facilitates 
glucose transporter GLUT4 translocation to the adipocyte plasma membrane 
allowing influx of glucose (Cheatham et al. 1994; Huang and Czech, 2007). 
Insulin also stimulates gene expression of FAS and activates ACC thus 
facilitating TAG synthesis.  As mentioned in 1.2.1.2, catecholamines stimulate 
beta-adrenergic G-protein coupled receptors leading to increased intracellular 
cAMP and PKA phosphorylation allowing HSL and perilipin phosphorylation and 
mobilisation of triglycerides. Insulin acts to inhibit lipolysis by decreasing 
intracellular cAMP and resultant PKA phosphorylation thereby preventing the 
action of HSL and allowing perilipins to block HSL access to TAGs (Czech et al. 
2013).  
 
1.2.1.4 Importance of adipose tissue 
The metabolic and immune functions of adipose tissue are abundant. Once 
calorific intake exceeds the storage capacity of adipose tissue or there is a 
lack of adipose tissue altogether, as in lipodystrophy, ectopic deposition of 
lipid has catastrophic effects. Storage of lipids in the liver, skeletal muscle 
and multiple other metabolic sites leads to gross dysregulation in glucose 
metabolism and severe impairment of insulin signalling in addition to causing 
liver disease including cirrhosis (Semple et al. 2011). Interestingly, leptin 
replacement in such indivisuals with lipodystrophy, where circulating leptin is 
absent or very low, improves the metabolic problems outlined above (Moon et 
al. 2013).  
 
1.2.2 Insulin, insulin resistance and type 2 diabetes 
Type 2 diabetes is a chronic metabolic disorder diagnosed when 
hyperglycaemia is detected. Glucose homeostasis is governed primarily by the 
peptide hormone insulin. Type 2 diabetes develops after years of insulin 
resistance and reactive hyperinsulinaemia when the pancreas can no longer 
produce enough insulin to meet the demands of peripheral tissues and 
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metabolic dysfunction ensues (van Greevenbroek et al. 2013).  Type 1 
diabetes is an autoimmune condition resulting in insulin deficiency and 
therefore hyperglycaemia (Vehik et al. 2013). 
 
1.2.2.1 Insulin 
Insulin is an essential peptide hormone released from β cells in the islets of 
Langerhans which consist of 2-3% of the pancreas volume. Insulin synthesis 
begins with pre-proinsulin (11.5kDa, 86 amino acids) which is cleaved to form 
proinsulin (9kDa). Proinsulin is then cleaved further to form insulin (a 21 
amino acid A chain bound to a 30 amino acid B chain by disulphide bonds) and 
c-peptide (30-35 amino acids). Insulin and c-peptide are stored together in 
secretory vesicles prior to release in response to secretagogues. Transcription 
of pre-proinsulin mRNA is stimulated by high circulating glucose 
concentrations. Furthermore, as the circulating glucose concentration rises it 
stimulates insulin secretion, with a threshold plasma glucose concentration of 
approximately 5mmol/l. In addition to glucose a number of other agents can 
stimulate or inhibit insulin secretion including amino acids, fatty acids and 
hormones. Insulin enters the portal circulation and binds membrane bound 
insulin receptors in target tissues (Reviewed in Holt et al. 2010). 
 
1.2.2.2 Insulin receptor and signalling 
The primary action of insulin is to regulate serum glucose levels. In response 
to high plasma glucose concentrations insulin acts to stop the production of 
glucose by the liver and increase glucose transit via the glucose transporter 
GLUT4 into cells of striated muscle and adipose tissue, thereby normalizing 
plasma glucose concentrations (van Greevenbroek et al. 2013). 
 
Circulating insulin mediates it’s action through the insulin receptor, a 
member of the receptor tyrosine kinase family formed of a heterotetramer 
consisting of two extracellular α subunits and two membrane spanning β 
subunits (Lee and Pilch, 1994). Binding to the receptor results in tyrosine 
kinase activation and autophosphorylation of the cytoplasmic domains of the 
β subunits. The phosphotyrosine residues act as binding motifs to allow 
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recruitment and subsequent phosphorylation of intracellular proteins such as 
the insulin receptor substrates (IRSs). IRSs are then able to recruit effector 
proteins such as PI3 kinase (Czech et al. 2013). 
 
In adipocytes insulin increases glucose uptake, stimulates adipogenesis and 
inhibits lipolysis. Following phosphorylation of IRS1 or IRS2, downstream 
signalling is mediated initially via PI3 kinase which catalyses the formation of 
phosphatidylinositol 3,4,5-trisphosphate, which acts to recruit and activate 
both atypical protein kinase C and Akt at the plasma membrane (Czech et al. 
2013). Akt is a serine/threonine protein kinase that phosphorylates and 
inactivates the Rab GTPase activating protein, AS160. As a consequence, Rab 
proteins remain GTP-bound and stimulate subsequent GLUT4 translocation to 
the cell surface. Glucose enters via GLUT4 and is then processed to form 
triacylglycerol as described in 1.2.1.1 (Figure 1.3).  
 
Insulin signalling can prevent catecholamine mediated lipolysis by influencing 
cAMP levels. This is mediated via Akt-mediated phosphorylation and 
activation of phosphodiesterase 3B which lowers cAMP levels. Secondly, 
insulin has been reported to activate adipose specific phospholipase A2 which 
inhibits adenylate cyclase, similarly reducing catecholamine-stimulated cAMP 
levels (Czech et al. 2013). 
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Figure 1.3 Insulin signalling 
Insulin binds to its tyrosine kinase receptor instigating a signalling cascade 
through PI3-kinase, Akt and AS160 to ultimately translocate vesicles 
containing GLUT4 to the cell membrane allowing glucose influx. 
 
1.2.2.3 Insulin resistance  
Insulin resistance occurs when cells no longer respond appropriately to 
insulin. It is associated with obesity, metabolic syndrome and is a key 
component of type 2 diabetes. Within adipose tissue, insulin resistance has 
been reported to occur when factors interfere with insulin receptor levels or 
the sensitivity of the insulin signalling pathway. Hyperinsulinaemia has been 
associated with reduced expression of insulin receptors leading to reduced 
insulin signalling (Puig and Tjian, 2005). Furthermore, inhibitory 
phosphorylation of IRS1 on serine residues has been proposed to occur in 
response to proinflammatory signalling, mediated by c-Jun N-terminal kinase 
(JNK) and inhibitor of kappa B kinase (IKK) (Copps and White, 2012). Selective 
insulin resistance plays a key role in the pathogenesis of diabetes 
complications. This was first described in the liver when the inhibitory effect 
of insulin on gluconeogenesis (via FoxO1) is impaired whilst the lipogenic 
effect (via SREBP-1c) is unimpaired leading to hyperglycaemic and lipotoxicity 
commonly seen in poorly controlled type 2 diabetes (Shimomura et al. 2000, 
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Brown and Goldstein, 2008). Laterally this concept has also been described in 
endothelial cells. Endothelial dysfunction is a key characteristic of type 2 
diabetes and contributes significantly to its cardiovascular complications. 
Insulin signalling in endothelial cells occurs via two pathways, on results in 
nitric oxide production and vasorelaxation (via PI3K) and the other results in 
endothelin-1 and vasoconstriction (via MAPK). Selective impairment of PI3K 
signalling is associated with type 2 diabetes leading to uncontrolled MAPK 
signalling and endothelial dysfunction (Muniyappa and Sowers, 2013). 
 
1.2.3 Adipose tissue as an endocrine organ 
In addition to the energy storage function of adipose tissue, recent decades 
have seen a substantial expansion in understanding of the dynamic role 
adipose tissue has in the regulation of metabolism. At least 600 factors are 
now known to be secreted by adipose tissue, termed adipokines, which may 
exert endocrine, paracrine and autocrine actions that influence metabolism 
(Blüher, 2012). 
 
1.2.3.1 Leptin 
The growing understanding of the secretory role of adipose tissue stems from 
the discovery of leptin in 1994 (Mantzoros et al. 2011).  Leptin is a member of 
the type 1 helical cytokine family (Denver et al. 2011) and plays a key role in 
the control of satiety acting as an anorexigenic stimulus to the hypothalamus. 
Children with leptin deficiency due to genetic mutation of the leptin gene 
also exhibit hyperphagia and obesity and respond very well to treatment with 
leptin (Farooqi et al. 2002). It is secreted by adipocytes and positively 
correlates with adipose mass, although with increasing obesity, resistance to 
its actions develops (Banks and Farrell, 2003). Leptin deficient ob/ob and 
leptin receptor deficient db/db mice are obese and insulin resistant (Lutz and 
Woods, 2012). Leptin has been reported to have pro-inflammatory actions, 
activating monocytes and macrophages to secrete interleukin-6 (IL-6) and 
tumour necrosis factor-α (TNF-α) (Paz-Filho et al. 2012). Unfortunately, the 
therapeutic use of leptin in this obesity-related leptin resistance has not been 
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successful and is likely related to alterations in the leptin receptor and 
downstream signalling changes (Moon et al. 2013). 
 
1.2.3.1.2 Central regulation of adipose tissue 
The hypothalamus contains both satiety and hunger centres under the 
influence of leptin, and other factors, via its receptor in the arcuate nucleus. 
A series of neuropeptide signals are activated by leptin via PI3K signalling 
culminating in the paraventricular nuclei. This activity in turn stimulates the 
autonomic nervous system to increase sympathetic stimulation of adipose 
tissue resulting in increased lipolysis and thermogenesis (Breton, 2013). Beta-
adrenergic stimulation of white adipose tissue also stimulates glucose uptake 
(Nonogaki, 2000). The parasympathetic nervous system plays a role in adipose 
tissue function with associated increased insulin sensitivity (Fliers et al. 
2003). 
 
1.2.3.2 Adiponectin  
Another key adipokine that regulates metabolism is adiponectin, the most 
abundantly produced of the adipokines. Levels of adiponectin are inversely 
related to adipose mass and insulin resistance (Díez and Iglesias, 2003). 
Adiponectin activates AMP-activated protein kinase (AMPK) and has anti-
inflammatory properties (Kadowaki et al. 2006). Expression of adiponectin is 
stimulated by peroxisome proliferator-activated receptor-γ (PPARγ) agonists 
and inhibited by pro-inflammatory mediators such as TNF-α, IL-6 and reactive 
oxygen species (ROS) (Kwon and Pessin, 2013). The use of adiponectin as a 
biomarker and as a therapeutic agent remains a topic of interest however one 
that has not been translated to the clinic (Padmalayam and Suto, 2013). 
 
1.2.4 Adipose tissue inflammation 
In addition to the adipokines described in 1.2.3, adipose tissue has also been 
shown to secrete several members of the cytokine family. In both animal and 
human studies adipose tissue inflammation has been closely correlated with 
obesity and insulin resistance (Glass and Olefsky, 2012; Guilherme et al. 
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2008). More recently it has been suggested that it is insulin resistance which 
underlies adipose tissue inflammation rather than inflammation leading to 
insulin resistance (Shimobayashi et al. 2018).  
 
1.2.4.1 Cytokines 
Cytokines are proteins with immunomodulatory properties which can have 
local or systemic actions. They may be pro- or anti-inflammatory and can be 
released from resident macrophages and/or adipocytes or other cell types in 
adipose tissue. Obesity is associated with an increased number of pro-
inflammatory cytokines including TNF-α, IL-6, interleukin-1β (IL-1β) and the 
chemokine monocyte chemotactic protein-1 (MCP-1) (Tateya et al. 2013). 
 
1.2.4.1.1 Tumour necrosis factor-α 
TNF-α is a pro-inflammatory cytokine secreted primarily by macrophages but 
can be released by multiple other cells (Qi and Pekala, 2000). Two TNF-α 
receptors have been identified – TNF receptors 1 and 2, with most known 
actions mediated via TNFR1 (Wajant et al. 2003). TNF-α is important in the 
acute phase immune response and governs cell survival, production of other 
cytokines and regulates inflammation at a local and systemic level (Haider 
and Knöfler, 2009). In adipose tissue, TNF-α mediates it’s actions via two 
complimentary pro-inflammatory signalling pathways which will be discussed 
in more detail later: the mitogen-activated protein kinases (MAPKs) and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
activation (Wajant et al. 2003). TNF-α levels are positively correlated with 
obesity and insulin resistance and rodent studies show insulin sensitising 
effects of TNF neutralisation (Hotamisligil et al. 1993). In humans anti-TNF 
therapies are used for a selection of chronic inflammatory disorders such as 
rheumatoid arthritis. In a group of obese individuals with type 2 diabetes, 4 
weeks of anti-TNF-α therapy did not improve insulin sensitivity (Ofei et al. 
1996). However, following 6 months of the TNF-α receptor fusion protein 
etanercept, a group of obese subjects with metabolic syndrome were found to 
have improved fasting glucose and increased adiponectin levels (Stanley et al. 
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2011). This suggests prolonged treatment is required to see a metabolic 
benefit. 
 
1.2.4.1.2 Interleukin-1β 
IL-1β is initially released as a proprotein by macrophages and is cleaved to its 
active form by caspase 1 (Denes et al. 2012). Early studies reported that IL-1β 
reduced both insulin-induced glucose transport and lipogenesis in murine and 
human adipocytes (Lagathu et al. 2006). Subsequently prolonged exposure of 
the 3T3-L1 adipocyte cell line to IL-1β was reported to lead to down-
regulation of IRS1 and reduced downstream activity of Akt and 
phosphorylation of AS-160, an effect not seen with short term exposure. 
Inhibition of ERK 1/2 signalling prevented the reduction in IRS-1 expression, 
suggesting a key role of ERK 1/2 in this process (Jager et al. 2007). In 
addition, Handa et al. reported that application of an anti-IL1β monoclonal 
antibody to 3T3-L1 cells treated with IL-1β prevented insulin resistance 
(Handa et al. 2013). 
 
1.2.4.1.3 Interleukin-6 
Interleukin-6 is another member of the cytokine superfamily implicated in 
obesity related adipose dysfunction and insulin resistance. IL-6 can be 
secreted by adipocytes and the stromal vascular fraction of adipose tissue 
(Kwon and Pessin, 2013). Visceral adipose tissue has been reported to secrete 
2-3 times more IL-6 than subcutaneous adipose (Fried, 1998). Circulating 
levels of IL-6 are positively correlated with obesity and insulin resistance and 
around one third of the circulating IL-6 originates from adipose tissue 
(Kershaw and Flier, 2004). There are a number of mechanisms proposed by 
which IL-6 promotes insulin resistance. IL-6 lowers adiponectin levels and 
induces SOCS3 which can attenuate insulin signalling (Kwon and Pessin 2013; 
Senn et al. 2003). Conversely, in the central nervous system IL-6 appears to 
stimulate exercise and lead to weight loss suggesting different roles centrally 
compared to the periphery (Wallenius et al. 2003). IL-6 signalling is mediated 
via the Janus Kinase and Signal Transducer and Activator of Transcription 
(JAK-STAT) pathway which is described in 1.2.4.2.4. 
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1.2.4.1.4 Monocyte chemoattractant protein-1  
Circulating levels of the chemokine MCP-1 are also positively correlated with 
obesity and insulin resistance (Panee, 2012). MCP-1 is one of the key stimuli 
for monocyte recruitment into adipose tissue and both adipocytes and 
macrophages may release MCP-1 (Gustafson, 2010). Overexpression of MCP-1 
in adipose tissue was associated with insulin resistance and adipose 
macrophage infiltration in a transgenic mouse model (Kamei et al. 2006). It 
signals to monocytes via the C-C motif receptor 2 (CCR2). Studies have 
suggested a key role for CCR2 in adipose tissue inflammation as knock-down in 
macrophages resulted in reduced inflammation in adipose tissue (Weisberg et 
al. 2006). 
 
1.2.4.2 Inflammatory signalling pathways 
As mentioned previously, there are different signalling pathways of interest in 
the development of adipose tissue inflammation, the MAPKs, NFκB and the 
JAK-STAT pathways. The MAPK and NFκB pathways culminate in the 
transcription of pro-inflammatory genes as summarised in Figure 1.4. 
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Figure 1.4 MAPK and NFκB signalling pathways 
Pro-inflammatory signalling stimulated by cytokines and other factors occurs 
following receptor binding.  The NFκB and MAPK pathways ultimately change 
gene transcription to increase production of pro-inflammatory proteins which 
may then enter the local and systemic environment. 
 
1.2.4.2.1 Mitogen-activated protein kinases 
MAPK signalling can be stimulated by a wide range of stimuli acting through 
cytokine or toll like receptors (TLRs) in order to regulate a multitude of 
functions such as proliferation, cell survival and gene expression (Thalhamer 
et al. 2008). The classic MAPKs require at least two phosphorylation events 
prior to activation, catalyzed by MAPK kinases (MAPKKs). MAPKs are present 
throughout eukaryotes and the principal types that regulate inflammatory 
pathways in humans are extracellular signal-regulated kinase 1/2 (ERK 1/2), 
JNK and p38. JNK activation is the MAPK most closely linked to insulin 
resistance (Tarantino and Caputi, 2011). JNK phosphorylates activator 
protein-1 (AP-1) resulting in the transcription of pro-inflammatory genes, it 
has also been proposed to directly phosphorylate IRS-1 on inhibitory Ser 
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residues, resulting in degradation and diminished insulin signalling (Aguirre et 
al. 2000). 
 
1.2.4.2.2 NFκB 
NFκB is recognized as a key pro-inflammatory transcription factor and 
mediator of TNF-α and IL-1β action (Salt and Palmer, 2012). It is regulated by 
inhibitor of NFκB (IκB) and IκB kinase (IKK). Under basal conditions, IκB binds 
to NFκB dimers, such that they are maintained in the cytoplasm and upon 
phosphorylation of IκB, NFκB dimers (such as p50-p65) are released and able 
to translocate to the nucleus resulting in transcription of pro-inflammatory 
genes. Within the nucleus NFκB can work in conjunction with AP-1 leading to 
transcription of κB regulated genes such as IL-6, TNF-α and IL-1β.  IKK 
activation is also associated with insulin resistance due to its potential 
phosphorylation of IRS-1 on inhibitory Ser residues (similar to JNK) (Gao et al. 
2002). 
 
1.2.4.2.3 JAK-STAT signaling 
IL-6 mediates its pro-inflammatory effects via JAK-STAT signalling involving 
increased phosphorylation of STAT3. JAK-STAT signaling is not always pro-
inflammatory and is a signalling mechanism also employed by the anti-
inflammatory cytokine IL-10 (Niemand et al. 2003). Binding of IL-6 to a trans-
membrane IL-6 receptor (a class 1 cytokine receptor) or a soluble IL-6 
receptor leads to homodimerisation of the signal transducing receptor gp130 
subunits, leading to activation of JAKs which phosphorylate tyrosine residues 
on the cytoplasmic domains of gp130 (Murakami et al. 1993). These phospho-
tyrosine motifs act as the docking site for STATs, (STAT3 in the case of IL-6) 
which undergo JAK-mediated phosphorylation resulting in STAT3 dimers which 
translocate to the nucleus and facilitate transcription of target genes 
including MCP-1. STAT3 activation also induces suppressor of cytokine 
signalling 3 (SOCS3), which acts as a negative feedback loop to interrupt JAK-
STAT signalling (Schmitz et al. 2000).  
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1.2.4.3 Reactive oxygen species 
Increased levels of ROS including superoxide, hydrogen peroxide and hydroxyl 
radicals are described in a rapidly expanding group of biological processes 
including diabetes (Sedeek et al. 2012). Production of ROS can be stimulated 
by a number of extra- and intracellular stimuli including the pro-inflammatory 
cytokines described above and ROS can stimulate pro-inflammatory signalling 
pathways which in turn increase production of these cytokines (Bashan et al. 
2009). ROS have been implicated in the pro-inflammatory state associated 
with obesity and the development of type 2 diabetes. In particular, NADPH 
oxidase (NOX), a key source of ROS, is a multiprotein complex which is 
upregulated in diet induced obesity in rats (Jiang et al. 2011). NOX4 is present 
in adipocytes and increases ROS in response to high glucose and palmitate 
(Han et al. 2008). The mitochondria are an additional source of ROS and 
particularly relevant in the context of mitochondrial dysfunction which is 
associated with insulin resistance (Fisher-Wellman & Neufer, 2012). ROS is 
reported to increase adipose insulin resistance and contribute to obesity 
(Rudich et al. 1998, Pires et al. 2013). 
 
1.2.4.4 Adipose tissue macrophages 
Macrophages are phagocytes which result from differentiation of monocytes 
when they are resident in tissues. The primary stimulus for recruitment into 
adipose is MCP-1 however other stimuli have been identified including 
activated T cells, endoplasmic reticulum stress and α4 integrin (Patel et al. 
2013). In lean adipose tissue, macrophages make up around 10% of the 
stromal vascular fraction and function in an alternatively activated capacity 
resulting in anti-inflammatory cytokine production, these have also been 
known as M2 macrophages. In obesity, it has been demonstrated that 
macrophage number increases to around 40% of adipose tissue cells and there 
is a phenotypic switch to M1, classically activated pro-inflammatory 
macrophages (Cildir et al. 2013). The key pro-inflammatory role of 
macrophages in WAT was first proposed by Xu et al who carried out profiling 
of multiple murine obesity and diabetes models (Xu et al. 2003). Interestingly, 
histological analysis of obese adipose tissue has identified discrete entities 
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named crown like structures where macrophages exist in clusters surrounding 
necrotic adipocytes (Cinti et al. 2005).  
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1.3 AMP- activated protein kinase 
AMPK was discovered following a series of experiments in the 1970s and 1980s 
by separate groups in which ATP was found to inactivate both ACC and HMG-
CoA reductase, subsequently the protein kinase AMPK was found to be 
responsible for both of these actions (Hardie, 2003). AMPK is a heterotrimeric 
serine/threonine protein kinase which acts as a key regulator of whole body 
energy status. It consists of 3 subunits: the catalytic alpha subunit of which 
there are two isoforms (α1 and α2) and the regulatory beta (β1, β2) and gamma 
(γ1, γ2, γ3) subunits. Therefore, 12 possible hetero trimer isoforms of this 
kinase exist which may determine behaviour. Indeed, distribution of the α1 
subunit is primarily found in adipose tissue, with α2 being found in striated 
muscle (cardiac and skeletal) (Bijland et al. 2013, Quentin et al. 2011). The γ 
subunit contains the AMP binding site for allosteric AMPK activation. Two AMP 
binding sites, known as Bateman domains, are present beyond a variable N-
terminal region on each γ subunit (Bateman, 1997). These sites have a high 
affinity for AMP and lower affinity for ATP therefore high concentrations of 
ATP may inactivate AMPK (Towler and Hardie, 2007). The structure of AMPK is 
depicted in Figure 1.5. 
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Figure 1.5 Structure of AMPK 
A. AMPK subunit isoforms and B. structure of human AMPK (α1β2γ1 complex). 
The two figures are colour-linked detailing common component structures. 
Mutations have been identified in the PRKAG2 gene encoding AMPK-γ2 
leading to cardiac conditions such as pre-excitation, excess glycogen storage 
and cardiac hypertrophy. CBM = carbohydrate binding molecule, CTD = C-
terminal domain, CBS = cystathionine β-synthetase. Figure adapted from Salt 
and Hardie, 2017. 
 
1.3.1 AMPK activation 
AMPK is activated by phosphorylation of the preserved Thr172 residue in the N 
terminus of the α subunit in addition to allosteric activation by 5’-AMP binding 
to the γ subunit. There are two upstream kinases known to phosphorylate 
Thr172: liver kinase B1 (LKB1) and calmodulin-dependent kinase kinase β 
(CaMKKβ) (Salt and Palmer, 2012). LKB1 is constitutively active and not 
affected by AMP levels (Sakamoto et al. 2004), Thr172 phosphorylation may 
be decreased, however, by phosphatases such as protein phosphatase 2C 
(PP2C). AMP binding to the γ subunit aids activation by enhancing Thr172 
phosphorylation and inhibiting PP2C. This property is antagonised by ATP 
which has a weaker affinity for the AMP binding site. The intracellular 
AMP:ATP ratio is therefore crucial for the activation status of AMPK. As 
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activation of AMPK is possible in the absence of LKB1, CaMKKβ was 
subsequently identified as an alternative upstream kinase, stimulated by 
increased intracellular Ca2+ concentrations (Hawley et al. 2005). 
 
1.3.2 Regulators of AMPK 
As described above, the ratio of AMP:ATP within cells is a crucial regulator of 
AMPK activation. Therefore, any process resulting in decreased ATP levels or 
increased AMP levels will lead to activation of AMPK. Stresses such as hypoxia, 
ischaemia and hypoglycaemia inhibit the production of ATP and thereby 
stimulate AMPK activation (Hardie, 2008). Consequently, exercise has also 
been shown to activate AMPK in skeletal muscle due to the increased 
consumption of ATP. This may mediate some of the beneficial metabolic 
effects of exercise including increased glucose uptake and fatty acid oxidation 
(Sakamoto et al. 2004). In addition to the energy status within cells, several 
circulating factors can regulate AMPK activation, which are described below. 
Figure 1.6 summarises the range of mechanisms regulating AMPK. 
 
1.3.2.1 Adipokines 
Adiponectin has been shown to activate both α1 and α2 containing AMPK 
heterotrimers in the liver and skeletal muscle mediating beneficial metabolic 
effects of this adipokine (Yamauchi et al. 2002). In the liver, AMPK activation 
by adiponectin inhibits gluconeogenesis and in skeletal muscle it facilitates 
glucose uptake. The experimental use of dominant negative mutants of AMPK 
confirmed this as the mechanism by which these effects were achieved 
(Andreelli et al. 2006).  
 
Leptin has also been demonstrated to activate AMPK within skeletal muscle 
(Steinberg et al. 2003), but this action is diminished in obese skeletal muscle 
(Steinberg et al. 2002). As described previously, obesity is associated with 
resistance to leptin. Leptin has the opposite effect on AMPK in the 
hypothalamus where it decreases appetite via AMPK inhibition (Lim et al. 
2010).  
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The pro-inflammatory cytokine TNF-α has been reported to decrease AMPK 
activation in skeletal muscle in vitro and in vivo, whereby the mechanism is 
proposed to be by increased transcription of the phosphatase PP2C leading to 
AMPK dephosphorylation and inactivation (Steinberg et al. 2006). 
 
1.3.2.2 Pharmacological activators 
AMPK activation has been demonstrated in response to several prescribable 
agents for type 2 diabetes, including metformin and thiazolidinediones. 
Interestingly these are the two agents with insulin sensitising properties. The 
anti-inflammatory agent salicylate, which is known to have metabolic 
benefits, has also been shown to activate AMPK (Steinberg et al. 2013). 
 
Metformin, a biguanide, is the first line oral medication for type 2 diabetes, it 
decreases hepatic gluconeogenesis however the exact mechanism of action 
has been somewhat elusive. It activates AMPK by interruption of the 
mitochondrial respiratory chain resulting in reduced ATP production and 
raised AMP:ATP ratio (Boyle et al. 2010). Metformin has been shown to 
activate AMPK in human adipose tissue from subjects with diabetes (Boyle et 
al. 2011). Despite this, data from mice lacking AMPK in the liver show that the 
metformin related reduction in hepatic gluconeogenesis is AMPK-independent 
and has been attributed to other mechanisms including reduced glucagon 
signalling (Rena et al. 2013). 
 
Thiazoladinediones (TZDs) are PPARγ agonists and potent insulin sensitisers 
used to treat type 2 diabetes and other insulin resistant conditions. Their 
clinical use has now reduced due to associated adverse effects including fluid 
retention which can precipitate heart failure and reduced bone mineral 
density. They have been shown to increase adiponectin production (Astapova 
and Leff, 2012) which has beneficial metabolic effects mediated through 
AMPK as previously described. Additionally, the TZD rosiglitazone shown to 
stimulate AMPK, via LKB1, in endothelial cells and increase nitric oxide 
synthesis in an AMPK-dependent manner (Boyle et al. 2008). Studies in 
cultured cells expressing an AMP-insensitive AMPKγ2 isoform have indicated 
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that troglitazone also activates AMPK by increasing AMP:ATP (Hawley et al. 
2010) 
 
Salicylate was shown to activate AMPK by Hawley et al. in vitro and in vivo, 
mediated primarily by prevention of Thr172 dephosphorylation. They found 
increased fatty acid utilisation in vivo with salicylate in wild type mice but 
not AMPK β1 knock-out mice, whereas improvements in carbohydrate 
metabolism were seen in both wild type and AMPK β1 knock-out mice, 
suggesting both AMPK-dependent and -independent effects of salicylate 
(Hawley et al. 2012).  
 
Experimentally two small molecule activators have been widely-used to 
manipulate AMPK activity. 5’-aminoimidazole-4-carboxamide riboside (AICAR) 
is a nucleoside that is converted to the AMP-mimetic ZMP within cells, and has 
been widely used in studies of AMPK both in vitro and in vivo. However, as it 
mimics AMP it has been shown to have a number of AMPK-independent effects 
(López et al. 2003) which may reflect actions on other AMP-dependent 
enzymes. The more specific activator A-769662 is a thienopyridine which 
binds to AMPK complexes containing the β1 subunit (Scott et al. 2008) 
resulting in allosteric activation and, similar to salicylate, inhibition of Thr172 
dephosphorylation. 
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Figure 1.6 Regulation of AMPK  
AMPK is activated by upstream kinases LKB1 and CaMKKβ or through 
allosteric AMP binding to the γ subunit. Phosphatases inactivate AMPK and 
are inhibited by AMP. Pharmacological agents such as metformin and AICAR 
act to increase AMP levels or mimic AMP whereas A769662 and salicylate bind 
to complexes containing the β1 subunit isoform. 
 
1.3.3 AMPK: regulator of metabolism 
The primary actions of AMPK are to conserve energy – this can be achieved by 
inhibiting anabolic pathways and stimulating catabolic activities (see Figure 
1.7). Two of the best-characterised substrates of AMPK are ACC and HMG-CoA 
reductase which are key steps in lipid metabolism and cholesterol synthesis 
respectively. Activation of AMPK leads to phosphorylation and inactivation of 
ACC resulting in increased fatty acid oxidation and reduced fatty acid and 
triglyceride synthesis (Bijland et al. 2013). 
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1.3.3.1 AMPK in liver metabolism 
AMPK activation can influence both lipid and glucose metabolism in the liver. 
Phosphorylation and inactivation of HMG-CoA reductase by AMPK reduces 
cholesterol and isoprenoid synthesis in the liver (Viollet et al. 2009). AMPK 
increases mitochondrial biogenesis and thereby increases fatty acid oxidation 
in hepatocytes (Towler and Hardie, 2007). Hepatic gluconeogenesis is an 
important contributor to hyperglycaemia in type 2 diabetes. Gluconeogenesis 
is inhibited by AMPK activation and this has been demonstrated in response to 
both AICAR and adiponectin. AMPK also regulates TORC2 which subsequently 
effects PGC-1α and alters the expression of gluconeogenic enzymes (Viollet 
and Andreelli, 2011). 
 
1.3.3.2 AMPK in cardiac and skeletal muscle metabolism 
In cardiac and skeletal muscle, AMPK activation can stimulate GLUT4 
translocation and expression resulting in increased glucose uptake 
independently of insulin (Viollet and Andreelli, 2011; Lim et al. 2010). This 
can be regulated both by exercise and pharmacological AMPK activation and 
appears to be reduced in obesity (Musi et al. 2001). AICAR was also shown to 
increase both membrane FA transporter translocation (FABPpm and FAT/CD36) 
and palmitate uptake in cardiac myocytes (Chabowski et al. 2005), indicating 
that AMPK stimulates both glucose and fatty acid uptake in striated muscle. 
 
1.3.3.3 AMPK in adipose tissue metabolism 
The role of AMPK in adipose tissue is less well studied than the liver and 
skeletal muscle. Interestingly, AMPK activation decreases insulin stimulated 
glucose transport, which although initially seems counterintuitive may 
actually be in keeping with energy preservation as it will reduce lipogenesis 
(Salt et al. 2000). It was also reported that AICAR reduces TNF-α mediated 
serine phosphorylation of IRS-1 and therefore attenuates the TNF-α mediated 
inhibition of insulin signalling (Shibata et al. 2013). In addition, AMPK-
mediated phosphorylation of HSL has been reported to impair stimulation of 
lipolysis, yet there is a somewhat conflicting literature regarding the role of 
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AMPK in lipolysis (Bijland et al. 2013; Ceddia, 2013). It has been demonstrated 
that AMPK activity is reduced in visceral adipose tissue of obese insulin 
resistant individuals with an associated increase in mRNA for angiotensinogen 
(Xu et al. 2013). 
 
 
 
Figure 1.7 The major metabolic effects of AMPK   
AMPK regulates key metabolic processes in skeletal muscle, adipocytes and 
the liver.  
 
1.3.4 AMPK: anti-inflammatory properties 
Metabolism and inflammation are related and there is therefore much interest 
in how AMPK may link the two entities. Over the past decade or so it has 
become clear from animal and cell culture work that AMPK may have an 
important anti-inflammatory role.  In 2004, Nagata et al. demonstrated that 
AICAR treatment reduced angiotensin II induced ERK activation in rat vascular 
smooth muscle cells. In addition they found that angiotensin II activated AMPK 
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via the AT1 receptor through activation of NADPH oxidase (Nagata et al. 
2004).  When ex-vivo human subcutaneous adipose tissue was incubated with 
AICAR, there was decreased secretion of TNF-α and IL-6 (Lihn et al. 2004). In 
mice with diet-induced obesity AICAR treatment led to reduced circulating 
pro-inflammatory cytokines such as TNF-α, IL-6 and MCP-1, which was 
associated with improved insulin sensitivity (Yang et al. 2012). Studies of 
transgenic mice lacking either AMPKα1 or AMPKα2 have revealed many 
interesting roles of AMPK. AMPKα1-/- mice demonstrated increased NOX 2 
expression and reactive oxygen species which was reversed by the NOX 
inhibitor apocynin (Schuhmacher et al. 2011).  
 
1.3.5. Genetic mouse models 
Mice lacking different AMPK subunits have increased our understanding of the 
role of AMPK in metabolic and other processes. As the combined lack of 
AMPKα1 and AMPKα2 is embryonically lethal, more selective deletion of AMPK 
isoforms has been performed. Initial studies utilised global knock-out models 
however transgenic models with tissue-specific loss of AMPK subunits have 
subsequently been generated and studied. The generation of AMPKα1-/- 
(Jorgensen et al. 2004) and AMPKα2-/- (Viollet et al. 2004) mice allowed the 
initial metabolic characterisation of global knock out of these catalytic 
subunits.  
 
AMPKα1-/- mice, which lack a basal metabolic phenotype, have smaller 
adipocytes with an increased rate of lipolysis (Daval et al. 2005). In contrast, 
AMPKα2-/- mice exhbit an insulin resistant phenotype and demonstrate 
increased adipose tissue mass due to an increase in adipocyte size when 
exposed to high fat diet (Villena et al. 2004). As AMPKα1 is predominant in 
adipose tissue in terms of total cellular AMPK activity (Bijland et al. 2013), it 
is proposed to have a key role in the regulation of lipolysis, however lack of 
AMPKα2 may contribute to the development of obesity (Viollet et al. 2009). 
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1.4 Renin angiotensin aldosterone system 
1.4.1.1 Angiotensins 
The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and 
fluid status with precision due to a negative feedback process. Low renal 
perfusion pressure sensed by the juxtaglomerular apparatus in the kidneys 
leads to release of renin, an aspartyl protease, allowing conversion of 
angiotensinogen to angiotensin I (Connell et al. 2008). Angiotensin I requires 
activation to angiotensin II, this is mediated by angiotensin converting enzyme 
(ACE), and angiotensin II activates the angiotensin II type 1 receptor (AT1) 
leading to vasoconstriction, water retention and the release of aldosterone 
from the adrenal cortex (Connell et al. 2008). Angiotensin II can also activate 
angiotensin II type 2 receptors (AT2) leading to opposing actions including 
vasodilation and anti-proliferation (Munzenmaier and Greene, 1996; Carey, 
2017). ACE 2 is an alternative form of ACE which acts to convert angiotensin II 
to angiotensin 1-7 (ang 1-7) and angiotensin I to angiotensin 1-9 (ang 1-9). Ang 
1-7 is a 7 amino acid peptide which acts predominantly on the G-protein 
coupled Mas receptor (Santos et al. 2008).  There are now several studies 
which suggest metabolic benefits of ACE 2 activity (Bindom et al. 2010) and 
ang 1-7 (Santos et al. 2008), described further in 1.4.4. Additional protective 
effects have been described associated with the complimentary RAAS 
mediated by ang 1-9 through AT2 receptors (Flores-Muñoz et al. 2011).  
 
1.4.1.2 Aldosterone 
Aldosterone is a steroid hormone synthesised in the adrenal cortex activates 
mineralocorticoid receptors (MR) within the kidneys leading to sodium and 
water retention, maintaining circulating volume and blood pressure (Connell 
et al. 2008). Its production and secretion are highly regulated by 3 main 
stimuli including angiotensin II, adrenocorticotrophic hormone (ACTH) and 
elevated serum potassium. These stimuli increase transcription and 
phosphorylation of the steroidogenic acute regulatory protein (StAR) leading 
to increased cholesterol transport into the mitochondria and therefore 
 50 
steroidogenesis (Miller and Auchus, 2011). The components of the RAAS are 
detailed in Figure 1.8 and aldosterone synthesis outlined in Figure 1.9. 
 
 
 
Figure 1.8 Principal components of the RAAS 
The RAAS begins with angiotensinogen which is made principally by the liver. 
This is converted to angiotensin I by kidney-derived renin and angiotensin I is 
then converted to angiotensin II by ACE. Angiotensin II stimulates aldosterone 
production by the adrenal gland. Angiotensin I and angiotensin II can both be 
converted to the alternative peptides ang 1-9 and ang 1-7 respectively by 
ACE2. 
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Figure 1.9 Aldosterone synthesis 
Aldosterone synthesis takes place in the zona glomerulosa of the adrenal 
cortex. Steroid acute regulatory protein (StAR), Endoplasmic reticulum (ER), 
outer mitochondrial membrane (OMM), inner mitochondrial membrane 
(OMM). Enzymes in italics. 
 
1.4.2.1 RAAS in cardiovascular disease 
Overactivation of the RAAS is implicated in the development of hypertension 
and cardiac failure. Drugs which modulate this system including ACE 
inhibitors, angiotensin receptor blockers (ARBs) and mineralocorticoid 
receptor (MR) blockers have been shown to improve mortality in cardiac 
diseases (Ma et al. 2010). Intriguingly, complications of diabetes can be 
modified by drugs blocking the RAAS and people with diabetes appear to 
respond favourably compared to those without diabetes when 
mineralocorticoid receptor blockers are used post-myocardial infarction 
(O’Keefe et al. 2008).   
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1.4.2.2 RAAS and complications of diabetes 
There has been much clinical interest into the use of RAAS blockers in 
diabetes. The well-known cardiovascular benefits of ACE inhibitors, ARBs and 
MR blockers are also seen in those with diabetes. Additionally, there is strong 
evidence supporting these medications in the treatment of diabetic 
nephropathy. Their use has been shown to both reduce progression of 
microalbuminuria to proteinuria and in some cases normalise it (ACE inhibitors 
in Diabetic Nephropathy Trialist Group, 2001).  
 
1.4.3 RAAS and diabetes prevention 
1.4.3.1 Clinical evidence 
The large cardiovascular studies assessing ACE inhibitors and ARBs were not 
designed to investigate new onset diabetes. Cumulative evidence, however, 
has shown an association with reduced risk of the incidence of diabetes 
(Abuissa et al. 2005). The results from studies such as CAPPP (Niklason et al. 
2004), HOPE (Yusuf et al. 2000), SOLVD (Vermes et al. 2003) and ALLHAT 
(Black et al. 2008) have been varied but agree that diabetes incidence is 
reduced. The first RCT designed specifically to answer this question, DREAM, 
did not show a significant reduction in new onset diabetes with ramipril (an 
ACE inhibitor) yet did find improved 2-hour blood glucose levels suggesting 
some effect on glycaemic control (Dagenais et al. 2008). In 2010 the 
NAVIGATOR study, another designed to look at new onset diabetes was 
published. In this case, valsartan (an ARB) was used in combination with 
lifestyle change and the findings agreed with the earlier suggestions such that 
a relative reduction of 14% in new diabetes was seen in those with obesity and 
impaired glucose tolerance (McMurray et al. 2010). It is not clear whether it is 
the effect of reducing angiotensin II or aldosterone or both which results in 
the main benefit. Certainly states of aldosterone excess such as primary 
aldosteronism (Conn’s syndrome) and idiopathic adrenal hyperplasia are 
associated with metabolic syndrome (Tirosh et al. 2010; Whaley-Connell, et 
al. 2010). Importantly, treatment with MR antagonists or cure with 
adrenalectomy has been shown to reverse metabolic consequences in 
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aldosterone excess. It is now recognised that states of aldosterone excess are 
under-diagnosed and may contribute to a substantial number of cases of 
‘essential’ hypertension.  
 
1.4.3.2 RAAS and glycaemia in vivo and in vitro 
Alongside the clinical trials there has been significant interest into the 
mechanisms underlying the benefits seen with RAAS blockade. This literature 
is somewhat heterogeneous but in general implicates angiotensin II and 
aldosterone in the development of insulin resistance and inflammation in 
adipose tissue and demonstrates clear benefits of antagonism of these 
hormones. These effects are summarised in Figure 1.10. 
 
1.4.3.2.1 Angiotensin II  
Angiotensin II has been shown to decrease insulin stimulated glucose transport 
in skeletal muscle in a study of ex-vivo rat skeletal muscle (Diamond-Stanic 
and Henriksen, 2010). It has also been shown to increase the production of 
pro-inflammatory cytokines from adipose tissue in both humans and rodents 
(Kalupahana and Moustaid-Moussa, 2012). In a very interesting study 
employing an adipose specific angiotensinogen over-expressing mouse, 
systemic insulin resistance was evident and this was reversed by the ACE 
inhibitor captopril. It was also demonstrated that the angiotensin II induced 
increase in MCP-1 in adipocytes was prevented by inhibitors of NOX and NFκB 
(Kalupahana et al. 2012). In another study, the ARB losartan improved glucose 
stimulated insulin release and proinsulin biosynthesis in a mouse model of 
obesity (db/db) (Chu et al. 2006). Other studies of ARBs have found reduced 
insulin resistance and inflammatory markers in humans (Pscherer et al. 2010) 
and decreased macrophage infiltration of adipose tissue in rats fed a high fat 
diet (Guo et al. 2008).  
 
1.4.3.2.2 Aldosterone   
Aldosterone excess is associated with insulin resistance and one mechanism 
for this has been proposed to be the degradation of IRS1 mediated by reactive 
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oxygen species. This was shown in 3T3-L1 adipocytes and was associated with 
increased phosphorylation of NFκB, associated with increased NFκB activity. 
When aldosterone signalling was analysed it appeared not to be mediated via 
the MR but the study suggested it was through the glucocorticoid receptor 
(Wada et al. 2009). There is much interest in aldosterone signalling in adipose 
and it is questioned as to whether there is an as yet undiscovered mechanism 
by which it mediates non-genomic effects (Nguyen Dinh Cat and Jaisser, 
2012). However, one study by Hirata et al. did show the MR blocker 
eplerenone to reduce insulin resistance and macrophage infiltration in adipose 
in the obese db/db and ob/ob mouse models (Hirata et al. 2009). Another 
transgenic model, the aldosterone synthase knock out mouse, has been 
reported to be less prone to the elevated glucose, adipose tissue macrophage 
infiltration and hepatic steatosis associated with high fat diet (Luo et al. 
2013). This clearly adds to the clinical data mentioned above and implicates 
aldosterone in the development of metabolic disorders. 
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Figure 1.10 Summary of effects of angiotensin II and 
aldosterone on inflammation and metabolism in 
adipocytes 
Angiotensin II and aldosterone have been shown to increase inflammation in 
adipocytes and contribute to insulin resistance.  
 
1.4.4 Local production of RAAS 
Over recent years it has become apparent that an autonomous/local RAAS can 
exist within many different tissues which could have varying degrees of 
clinical significance. With the increased understanding of the dynamic role 
adipose tissue can play in endocrine and immune functions there has been a 
focus on the local RAAS in at this site. Excitingly, there is now evidence that 
all components if the RAAS can be produced locally within adipose tissue (Jing 
et al. 2012, Marcus et al. 2012). 
 
Angiotensinogen was the first RAAS component to be localised in adipose 
tissue, when in 1987 it was demonstrated to be expressed in rat brown 
adipocytes from peri-aortic and peri-atrial areas (Campbell and Habener, 
1987). Subsequently, all other components including renin, angiotensin I and 
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angiotensin II and their receptors were reported to be expressed in adipose 
tissue of both rodents and humans (Marcus et al. 2012). In 2012 Briones et al. 
demonstrated production and secretion of aldosterone from 3T3-L1 adipocytes 
in addition to isolated human and murine adipocytes. Furthermore, they also 
described the autocrine and paracrine actions of adipocyte-derived 
aldosterone regulating adipogenesis and vascular tone (Briones et al. 2012). A 
complete RAAS can therefore exist within adipocytes and is likely to have 
auto- and paracrine effects and may contribute to the development of 
adipose inflammation.  
 
1.4.5 The alternative RAAS 
1.4.5.1 ACE 2 
The alternative arm of the RAAS was described following the discovery of ACE 
2 in 2000 (Donoghue et al. 2000). In 2010, it was reported that ACE 2 
overexpression via adenoviral infection improved fasting glucose and reduced 
pancreatic β cell apoptosis in db/db mice suggesting glycaemic benefits of 
ACE 2 (Bindom et al. 2010). Another group found that the absence of ACE 2 
led to impaired glucose tolerance in mice fed high fat, high sucrose diet 
compared to mice with ACE 2 present (Takeda et al. 2012). Additionally, 
when pioglitazone (an AMPK activating TZD) was used to treat high fat diet 
induced hepatic steatosis in rats, metabolic improvements were associated 
with increased serum and hepatic ACE 2 along with serum ang 1-7, whilst 
downregulating components of the classic RAAS (Zhang et al. 2013). These 
studies suggest a role for ACE 2 in the prevention and treatment of obesity-
related diabetes. 
 
1.4.5.2 Ang 1-7 
In keeping with the above, ang 1-7 has also been shown to have some 
metabolic benefits including improved glucose tolerance in rats fed a high 
fructose diet (Giani et al. 2009). The mechanisms underlying these benefits 
may be related to inflammation. One study reported that ang 1-7 treatment 
reduced body weight, abdominal fat mass and adipose tissue IL-1β (Santos et 
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al. 2012) whilst another study from the same group showed down-regulation 
of the resistin/TLR4/NFκB pathway using an oral ang 1-7 formulation which 
suggests great therapeutic promise (Santos et al. 2013). In an earlier study 
Santos et al. reported that mice with global Mas receptor knock out had 
impaired insulin and glucose metabolism including reduced adipose GLUT4 
and increased abdominal fat mass (Santos et al. 2008). Collectively these 
findings support a key role for ang 1-7/Mas signalling in maintaining metabolic 
health and controlling adipose tissue inflammation.  
  
1.5 Cross-talk between AMPK and RAAS 
Prior to the start of this work a small literature was available regarding the 
cross-talk between AMPK and RAAS. The majority of this, which is described 
below and summarised in Figure 1.11, relates to vascular tissues and there 
were no data relating to AMPK and RAAS in adipose, which is the proposed 
area of investigation in this project. Although angiotensin II may increase or 
decrease AMPK activity depending on cell type, AMPK activation consistently 
appears to decrease the effects of angiotensin II. 
 
1.5.1 Vascular cells 
As mentioned in 1.3.4, AICAR was reported to attenuate angiotensin II induced 
ERK activation in injured vascular smooth muscle cells (VSMCs). This in turn 
was related to a reduction in intimal hypertrophy following injury. The same 
study found that angiotensin II activated AMPK within VSMCs (Nagata et al. 
2004). Another study assessed the effects of angiotensin II infusion in AMPKα1-
/- mice and found increased endothelial dysfunction in the KO mice infused 
with angiotensin II, an effect which appeared related to increases in NOX2 
and was partially prevented by the NOX inhibitor apocynin (Schuhmacher et 
al. 2011). The same study found that AMPK phosphorylation was increased in 
aorta samples from angiotensin II treated WT mice (Schuhmacher et al. 2011). 
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1.5.2 Cardiomyocytes 
Two studies relate AMPK and angiotensin II in primary rat neonatal 
cardiomyocytes. The first of these published in 2008 found that, similar to 
VSMCs, activation of AMPK with AICAR decreased angiotensin II mediated 
expression of hypertrophy markers. Conversely, angiotensin II reduced AMPK 
activity, an opposite effect to that seen in VSMCs (Stuck et al. 2008). In 2009, 
Wang et al. demonstrated that globular adiponectin was able to reduce 
angiotensin II mediated cardiac hypertrophy via AMPK activation (Wang et al. 
2010).  
 
1.5.3 Renal 
The only study to investigate aldosterone and AMPK was carried out in a renal 
model of fibrosis using HK2 tubular epithelial cells. Published in 2013, this 
study demonstrated that angiotensin II and aldosterone both led to renal 
fibrosis and that this process could be limited by both AICAR and metformin. 
This was shown to be mediated by AMPK with the use of AMPK inhibitor 
compound C and siRNA which negated the beneficial effects of metformin. 
The mechanism involved was proposed as increasing haemoxygenase 1 and 
thioredoxin leading to reduction of ROS. They also found that AMPK activity 
was reduced by angiotensin II (Lee et al. 2013).  
 
1.5.4 Skeletal muscle 
AMPK activity was decreased in gastrocnemius samples from mice following 
angiotensin II infusion, this was associated with muscle wasting and ATP 
depletion (Tabony et al. 2011). Interestingly, AICAR restored AMPK activity 
and also reversed the effects of angiotensin II (Tabony et al. 2011).  
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Figure 1.11 Interactions between angiotensin II and 
AMPK in renovascular tissues 
AMPK activation reverses the effects of angiotensin II in disease models in 
VSMCs, cardiomyocytes and kidney cells. Angiotensin II activated AMPK in 
VSMCs but decreases AMPK activity in kidney and cardiac models.  
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1.6 Summary 
Despite the known anti-lipogenic, anti-inflammatory actions of AMPK and the 
pro-inflammatory actions of local RAAS components in adipose tissue, there is 
a shortage of published work concerning whether these two important 
pathways are fundamentally linked in adipose tissue. As a consequence, the 
principal objectives of this study were: 
 
1. To determine the effect of AMPK activation upon adipocyte and 
adipose tissue RAAS. 
2. To characterise the effects of the RAAS on AMPK activity in adipocytes. 
3. To assess how downregulation of adipose tissue AMPK influences the 
RAAS and metabolism in vivo. 
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2 Chapter 2  - Materials and Methods 
  
 62 
2.1 Materials 
2.1.1 List of materials and suppliers  
Abcam, Cambridge, UK 
A769662 (6,7-Dihydro-4-hydroxy-3-(2`-hydroxy[1,1`-biphenyl]-4-yl)-6-oxo-
thieno[2,3-b]pyridine-5-carbonitrile) 
A 779, Asp-Arg-Val-Tyr-Ile-His-D-Ala 
 
Anachem, Luton, UK 
DNAreleasy 
 
Bachem, Bubendorf, Switzerland 
Angiotensin I/II (1-7) 
 
Bio-rad Laboratories Ltd, Hertfordshire, UK 
Mini-PROTEAN® TGXTM precast gels 
 
BIOS Europe, Lancashire, UK 
DPX mounting medium 
 
Cambridge Bioscience, Cambridge, UK 
Aldosterone EIA kit 
CXCL-10 EIA kit  
 
Cell Path Ltd, Powys, UK 
10% acetic zinc formalin 
 
Cell signalling Technology Inc, Danvers, MA, USA 
Interleukin -1β (IL-1β) 
 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
Ammonium persulphate (APS) 
RNAse away 
Tris base (tris(hydroxymethyl)aminoethane) 
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Invitrogen (Life Technologies Ltd), Paisley, UK 
High capacity cDNA reverse transcription kit 
TaqManTM gene expression assays 
TaqMan® Universal Master Mix II, no UNG 
 
Invitrogen (GIBCO Life Technologies Ltd), Paisley, UK 
Dulbecco’s modified Eagles media (DMEM) 
Foetal calf serum (FCS) (USA origin) 
Foetal calf serum (FCS) (EU origin) 
Newborn calf serum (NCS) 
Penicillin/streptomycin 
Trypsin 
 
Melford Laboratories Ltd, Chelsworth, Ipswich, Suffolk, UK 
Dithiothreitol (DTT) 
 
Merck Chemical LTd, Nottingham, UK 
Compound C 
Insulin ELISA kit 
 
National Diagnostics, Nottingham, UK 
Histoclear 
 
New England Biolabs, Ipswich, MA, USA 
Prestained protein marker, broad range (11-190 kDa) 
 
PALL Life Sciences, Pensacola, FL, USA 
Nitrocellulose transfer membrane, 0.45 µM pore size 
 
Perkin Elmer, Beaconsfield, Buckinghamshire, UK 
ATP,[ϒ-32P] 
2-[3H]-deoxy-D-glucose 
 
Premier International Foods, Cheshire UK 
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Dried skimmed milk 
 
Promega, Southampton, UK 
Go Taq amplification system 
 
Qiagen Ltd, Crawley, West Sussex, UK 
RNeasy Mini kit 
 
Raymond A Lamb Ltd, Eastbourne, UK 
Eosin 
Haematoxylin 
 
Severn Biotech Ltd, Kidderminster, Hereford, UK 
Acrylamide:Bisacrylamide (37.5:1; 30% (w/v) Acrylamide) 
 
Sigma-Aldrich Ltd, Gillingham, Dorset, UK 
Aldosterone 
Angiotensin II 
Bovine serum albumin 
Benzamidine 
Cytochalasin B 
Dexamethasone 
D-glucose 
D-mannitol 
DNA primers 
Ethylenediamine tetraacetic acid (EDTA) 
Ethylene glycol-bis (β-amino-ethylether)-N,N,N`,N`-tetraacetic acid (EGTA) 
Isobutylmethylxanthine (IBMX) 
Oil red O 
Phenylmethylsulphonyl fluoride (PMSF) 
Ponceau stain 
Porcine Insulin 
Soyabean trypsin inhibitor (SBTI) 
N,N,N`,N`-Tetramethylethylenediamine (TEMED) 
Triton X-100 
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Tumour necrosis factor-α 
Tween-20 
 
Tocris Bioscience, Bristol, UK 
Angiotensin II 
Troglitazone 
Toronto Research Chemicals Inc, Ontario, Canada 
AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) 
 
VWR International Ltd, Lutterworth, Leicestershire, UK 
Falcon tissue culture 10 cm dishes and 6 / 12 well plates 
HEPES (N-a-hydroxyethylpiperazine-N` 2-ethane sulphonic acid) 
 
Worthington Biochemical Corporation, Lakewood, NJ, USA 
Collagenase Type 1 
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2.1.2 List of specialist equipment and suppliers 
Abbott Diabetes Care, Maidenhead, UK 
Freestyle glucose monitor 
Glucose monitor strips 
 
Alpha Innotech Corporation, San Leandro, USA 
Alpha Innotech digital imaging system 
 
Beckman CoulterTM, High Wycombe, UK 
Multi-Purpose scintillation counter LS 6500 
 
Bio-Rad Laboratories, Hemel Hempstead, UK 
Protein gel casting and Western blotting equipment (Mini Protean III) 
 
BMG Labtech, Germany 
FLUOstar OPTIMA microplate reader   
 
Fisher Scientific, Loughborough, UK 
Leica Finesse 325 Microtome 
Shandon Histocenter 3 
 
Thermo Fisher, Paisley, UK 
ABI-PRISM 7900HT Sequence Detection System 
MJ Research PTC-225 Peltier thermal cycler 
 
Thermo Scientific, Waltham, MA, USA 
Nanodrop spectrophotometer 
 
WPA, Cambridge, UK 
S2000 spectrophotometer 
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2.1.3 List of cells and suppliers 
American Type Culture Collection, Manassas, VI, USA 
3T3-L1 preadipocytes 
SW872 preadipocytes 
 
Institut Cochin, Paris, France 
AMPKα1-/-AMPKα2-/- knock out and wild type mouse embryonic fibroblasts, a 
kind gift from Benoit Viollet (Laderoute et al. 2006) 
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2.1.4 List of antibodies and conditions of use 
Table 2.1 Primary antibodies for immunoblotting 
Epitope Host Dilution Source 
Adiponectin Rabbit 1:1000 University of Glasgow 
(Clarke et al. 2006) 
Akt Mouse 1:1000 Cell signalling; #2920 
AMPKα1 Sheep 1:1500 University of Dundee (Woods et al. 1996) 
GAPDH Mouse 1:20,000 Abcam; #AM4300 
IκB Rabbit 1:1000 Cell signalling; #4812 
JNK Rabbit 1:1000 Cell signalling; #9252 
Lipocalin 2 (Ngal) Rabbit 1:1000 Millipore; #Ab2267 
Mineralocorticoid receptor Rabbit 1:500 Santa Cruz; #H300 
MCP-1 Rabbit 1:1000 Cell signalling; #2029 
NF-κB p65 Mouse 1:1000 Cell signalling; #6956 
p44/42 MAPK (Erk1/2) Rabbit 1:1000 Cell Signalling; #9102 
Phospho- p44/42 MAPK (Erk1/2) Mouse 1:2000 Cell Signalling; #9106 
Phospho-Acetyl-CoA Carboxylase (Ser79) Rabbit 1:1000 Cell Signalling; #3661 
Phospho-Akt (Ser473) Rabbit 1:1000 Cell signalling; #4058 
Phospho-AMPKα (Thr172) Rabbit 1:500 Cell Signalling; #2535 
Phospho-AS-160 (Thr642) Rabbit 1:1000 Cell signalling; #8881 
Phospho-IκB (Ser32) Mouse 1:1000 Cell signalling; #9246  
Phospho-JNK(Thr183, Tyr185) Rabbit 1:1000 Cell signalling; #4668 
Phospho -NF-κB p65 Rabbit 1:1000 Cell signalling; #3033 
Phospho-STAT3(Ser727) Mouse 1:1000 Cell signalling; #9136 
SGK1 Rabbit 1:500 Millipore; #04-1027 
STAT3 Rabbit 1:1000  Cell signalling; #4904 
 
 
 
 
 69 
Table 2.2 Secondary antibodies for immunoblotting 
Epitope Host species Conjugate Dilution Source 
Goat IgG (H+L) Donkey IRDye® 800CW 1:10,000 LI-COR; #926-32214 
Mouse IgG (H+L) Donkey IRDye® 800CW 1:10,000 LI-COR; #926-32212 
Rabbit IgG (H+L) Donkey IRDye® 800CW 1:10,000 LI-COR; #926-32213 
Rabbit IgG (H+L) Donkey IRDye® 680RD 1:10,000 LI-COR; #926-68023 
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2.1.5 List of Taqman® qPCR probes 
Table 2.3 Taqman® gene expression assays 
Target Assay ID (human) Assay ID (mouse) 
Angiotensin converting enzyme I Hs00174179_m1 Mm00802048_m1 
Angiotensin converting enzyme II Hs01085333_m1 Mm01159006_m1 
Angiotensin II type 1 receptor Hs00258938_m1 Mm01957722_s1 
Angiotensin II type 2 receptor Hs02621316_m1 Mm01341373_m1 
Angiotensinogen Hs01586213_m1 Mm00599662_m1 
CXCL-10 Hs01124251_g1 Mm00445235_m1 
Interleukin-1β  Mm00434228_m1 
Glucocorticoid receptor Hs00353740_m1 Mm00433832_m1 
Mas receptor Hs00267157_s1 Mm00434823_s1 
Mineralocorticoid receptor Hs01031809_m1 Mm01241596_m1 
SGK-1 Hs00985033_g1  
Steroid acute regulatory protein Hs00986559_g1 Mm00441558_m1 
TATA-box binding protein Hs00427620_m1 Mm01277042_m1 
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2.1.5 Standard solutions 
Bradford’s reagent 
35.0 mg/l coomassie brilliant blue 
5.0% (v/v) ethanol 
5.1% (v/v) orthophosphoric acid 
Bradford’s reagent was filtered and stored in the dark. 
 
Adipose tissue collection buffer 
130 mM NaCl 
20 mM HEPES-NaOH, pH 7.4 
4.8 mM KCl 
5 mM NaH2PO4 
3 mM glucose 
1.25 mM MgSO4 
1.25 mM CaCl2 
1% (w/v) BSA 
10 µM adenosine 
pH 7.4 at 37°C 
 
Immunoprecipitation (IP) buffer 
50mM Tris-HCl, pH 7.4 at 4°C 
150 mM NaCl 
50 mM NaF 
5 mM Na4P2O7 
1 mM EDTA 
1 mM EGTA 
1% (v/v) Triton-X-100 
1% (v/v) glycerol 
1mM DTT 
0.1 mM benzamidine 
0.1 mM PMSF 
5 µg/ml SBTI 
1 mM Na3VO4 
 
 72 
Krebs-Ringer HEPES (KRH) buffer 
119.0 mM NaCl 
20.0 mM HEPES-NaOH, pH 7.4 
5.0 mM NaHCO3 
10.0 mM glucose 
4.8 mM KCl 
2.5 mM CaCl2 
1.2 mM MgSO4  
1.2 mM NaH2PO4 
 
Krebs-Ringer phosphate (KRP) buffer 
130 mM NaCl 
4.8 mM KCl 
5 mM NaH2PO4, pH 7.4 
1.25 mM MgSO4 
1.25 mM CaCl2 
 
Lysis Buffer 
50mM Tris-HCl, pH 7.4 at 4°C 
50 mM NaF 
1 mM Na4P2O7 
1 mM EDTA 
1 mM EGTA 
1% (v/v) Triton-X-100 
1mM DTT 
1 mM Na3VO4 
0.1 mM benzamidine 
0.1 mM PMSF 
5 µg/ml SBTI 
 
Phosphate-buffered saline (PBS) (pH 7.2) 
85 mM NaCl 
1.7 mM KCl 
5 mM Na2HPO4 
0.9 mM KH2PO4 
 73 
Phosphate-buffered saline + Tween 20 (PBST) 
85 mM NaCl 
1.7 mM KCl 
5 mM Na2HPO4 
0.9 mM KH2PO4 
0.1% (v/v) Tween 20 
 
Ponceau S stain 
0.2% (w/v) ponceau S 
1% (v/v) acetic acid 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) Running buffer (pH 8.3) 
192 mM glycine 
25 mM Tris base 
0.1% (w/v) SDS 
 
4 X SDS PAGE sample buffer 
200 mM Tris-HCl, pH 6.8 
8% (w/v) SDS 
40% (v/v) glycerol 
0.4% (w/v) bromophenol blue 
200 mM DTT 
 
Transfer buffer (pH 8.3) 
192 mM glycine 
25 mM Tris base 
20% (v/v) ethanol 
 
Tris-buffered saline (TBS) 
20 mM Tris-HCl, pH 7.5 
137 mM NaCl 
 
Tris-buffered saline + Tween 20 (TBST) 
20 mM Tris-HCl, pH 7.5 
137 mM NaCl 
 74 
0.1% (v/v) Tween 20 
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2.2 Cell Culture Methods 
2.2.1 Growth of 3T3-L1 fibroblasts 
3T3-L1 cells were cultured at 37°C and 10% (v/v) CO2 in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10% (v/v) newborn calf serum (NCS) 
and antibiotics (0.1 mg/ml streptomycin and 100 U/ml penicillin (PS)).  Media 
was refreshed every 2-3 days (Torado and Green, 1963).  
 
2.2.1 Passage of 3T3-L1 fibroblasts 
When cells reached 80% confluence in Corning T75 flasks, they were washed 
with sterile PBS then incubated at 37°C with 3 ml of sterile trypsin until cells 
detached from the flask. DMEM growth medium was added in sufficient 
volume to seed cells into further Corning T75 flasks and Falcon cell culture 
plates (6- or 12-well) or dishes as required. 
 
2.2.2 Differentiation of 3T3-L1 adipocytes 
Two days post-confluence differentiation was induced using DMEM 
supplemented with 10% (v/v) foetal calf serum (FCS), PS and 0.25 µM 
dexamethasone, 0.5 mM IBMX, porcine insulin (1 µg/ml) and 5 µM troglitazone 
for 3 days, culture medium was then exchanged for DMEM containing 10% 
(v/v) FCS, PS, porcine insulin (1 µg/ml) and 5 µM troglitazone for 3 days at 
which time culture medium was maintained with DMEM, 10% (v/v) FCS and PS. 
Differentiation was complete at day 8 and experiments conducted between 
day 8 and day 12. 
 
2.2.3 Freezing of 3T3-L1 fibroblasts 
Cells were detached as per 2.2.1 then 12 ml of growth medium added and the 
cell suspension transferred to a 15 ml centrifuge tube. Following 
centrifugation at 350 x g for 5 minutes the trypsin/media was aspirated 
leaving the cell pellet. The pellet was resuspended with 3 ml freeze medium 
(FCS plus 10% (v/v) DMSO) then 1 ml aliquots transferred to 1.8 ml 
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polypropylene cryogenic tubes. The cryogenic tubes were stored overnight in 
a polycarbonate container at -80°C then transferred to liquid nitrogen 
container for long term storage. 
 
2.2.4 Growth of SW872 fibroblasts 
SW872 cells were cultured at 37°C and 5% (v/v) CO2 in DMEM supplemented 
with 10% (v/v) FCS and PS.  Media was refreshed every 2-3 days (Berg et al. 
1996, Guennoun et al. 2015).  
 
2.2.5 Passage of SW872 fibroblasts 
When cells reached 80% confluence in Corning T75 flasks, they were washed 
with sterile PBS then incubated with 3 ml of sterile trypsin until cells 
detached from the flask. DMEM growth medium was added in sufficient 
volume to seed cells into further Corning T75 flasks and Falcon cell culture 
plates (6- or 12-well) or dishes as required. 
 
2.2.6 Differentiation of SW872 adipocytes 
Once confluent, differentiation was induced using DMEM supplemented with 
10% (v/v) FCS, PS and 0.25 µM dexamethasone, 0.5 mM IBMX and 1 µM porcine 
insulin for 2 days, culture medium was then exchanged for DMEM containing 
10% (v/v) FCS, PS and 1µM porcine insulin for 2 days at which time culture 
medium was maintained with DMEM, 10% (v/v) FCS and PS.  
 
2.2.7 Freezing of SW872 adipocytes 
Freezing of SW872 adipocytes was carried out in the same manner as 3T3-L1 
adipocytes described in 2.2.3. 
 
2.2.8 Growth of mouse embryonic fibroblasts 
AMPKα1-/-AMPKα2-/- (Laderoute et al. 2006) and wild-type mouse embryonic 
fibroblasts (MEFs) were a kind gift from Dr. Benoit Viollet (Institut Cochin, 
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Paris, France) and cultured at 37°C and 5% (v/v) CO2 in DMEM supplemented 
with 10% (v/v) FCS and PS.  Media was refreshed every 2-3 days. 
 
2.2.9 Preparation of cell lysates 
Cells grown in 6 well Falcon cell culture dishes were serum deprived for at 
least 2 hours by replacing culture medium for serum-free medium for short 
incubations or 1% (v/v) NCS for incubations over 6 hours, then stimulated with 
test substances for different durations and maintained at 37°C. Following 
stimulation dishes were placed on ice and culture medium removed and 
stored at -20°C for ELISA. Cells were washed with ice-cold PBS then 0.1 ml of 
lysis buffer was added to each well. Each well was scraped and cell extracts 
were placed in a microcentrifuge tube, vortex mixed and placed on ice for 20 
min. Lysates were subsequently centrifuged (21,910 x g at 4°C for 3 min) and 
supernatants stored at -20°C in new microcentrifuge tubes.  
 
2.2.10 Oil Red O staining of 3T3-L1 and SW872 adipocytes 
Preadipocyte fibroblasts or differentiated adipocytes were washed with 10% 
(v/v) formalin for 5 min then incubated in 10% (v/v) formalin for 1 h at room 
temperature. Cells were subsequently washed with 60% (v/v) isopropanol and 
covered with 60% (v/v) Oil Red O for 5 minutes and washed 4 times with 
dH2O. Plates were allowed to dry then stored at 4°C prior to imaging.  
 
2.3 Analysis of Cellular Proteins 
2.3.1 Preparation of Bradford Reagent and protein assays 
Protein content was calculated using spectrophotometric analysis as per the 
Bradford method (Bradford 1976). Protein standards using duplicates of 2 µg, 
4 µg and 6 µg BSA were used as reference. Lysates were first diluted either 
1:5 or 1:10 then 5 µl added to 95 µl dH2O in disposable cuvettes. Bradford’s 
reagent (1 ml) was added to all samples and standards prior to immediate 
analysis of absorbance at 595 nm using a WPA S2000 spectrophotometer. Mean 
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protein concentration per sample duplicate was calculated by comparison to 
the mean A595/µg BSA from the linear portion of the standard reference curve. 
 
2.3.2 SDS-Polyacrylamide gel electrophoresis  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out with 1.5 mm thick vertical slab gels containing 8-15% acrylamide 
using the Bio-Rad mini-protein III system. The stacking gel comprised 5% (v/v) 
acrylamide/0.136% (v/v) bisacrylamide, 125 mM Tris-HCl (pH 6.8), 0.1% (w/v) 
SDS polymerized with 0.1% (w/v) ammonium persulphate and 0.05% (v/v) 
TEMED. Lysate samples were mixed with 4x sample buffer at a ratio of 3:1 
then heated at 95°C for 5 minutes. Once immersed in running buffer, broad 
range pre-stained molecular markers were added in at least one well as 
standard then lysates were loaded into wells. Gels were electrophoresed at 80 
V through the stacking gel then 170 V through the resolving gel until the 
tracking dye reached the bottom of the gel. 
 
2.3.3 Immunoblotting 
After protein separation, each gel was carefully removed from the plates and 
placed upon a pre-wetted equal sized piece of nitrocellulose (0.45 µm pore 
size) in a bath of transfer buffer then sandwiched between Whatmann 3MM 
filter paper and sponges within the gel holder cassette.  Proteins were 
transferred using a Bio-Rad mini Protean III trans-blot electrophoretic transfer 
cell at 60 V for 2.5 h or 40 mA overnight. 
 
2.3.4 Ponceau staining 
Protein transfer was checked by washing in Ponceau stain for several seconds 
and immunoblots de-stained by washing the membranes 3 times in PBS. 
 
2.3.5 Immunodetection of proteins 
Nitrocellulose membranes were blocked for non-specific protein binding with 
5 % (w/v) milk in PBS at room temperature for 30 min with gentle shaking. 
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Membranes were then washed (3 x 5 min) with PBST prior to incubation with 
primary antibody in PBST/50% (v/v) Odyssey® blocking buffer overnight at 
4°C. Then membranes were washed (3 x 5 min) with PBST and incubated with 
secondary antibody for 1 h at room temperature with the appropriate 
fluorescent IRDye®-conjugated secondary antibody in PBST/50% (v/v) 
Odyssey® blocking buffer. Membranes were then washed (4 x 5 min) with 
PBST and once with PBS (5 min). Imaging was carried out using the Li-cor 
ODYSSEY® infrared imaging system and immunoblots were quantified using 
Image J software. 
 
2.3.6 Aldosterone ELISA 
Conditioned culture medium (1 ml) from 3T3-L1 and SW872 cells was 
concentrated using a Thermo Scientific DNA 120 SpeedVac Concentrator 
overnight, the concentrate was resuspended in 200 µl of culture medium and 
stored in 50 µl aliquots at -20°C. Aldosterone ELISA was carried out using the 
Aldosterone EIA kit – Monoclonal from Cayman Chemical Company as per the 
manufacturer’s instructions. In brief, 50 µl of sample was combined with 
aldosterone acetylcholine esterase (AChE) tracer and monoclonal antibody for 
18 hours at 4°C. Wells were emptied and washed then 200 µl of Ellman’s 
solution and 5 µl of tracer were added and incubated shaking in the dark for 
90 minutes. The plate was read using using a FLUOstar OPTIMA microplate 
reader (BMG Labtech, Germany). Mean absorbance at 405 nm (ref 405-420) 
was determined from duplicate samples and concentration calculated by 
comparison to the standard curve using MyAssays. 
 
2.4 Gene Expression Analyses 
2.4.1 RNA extraction from cells 
Culture medium was removed from cells cultured in 6-well cell culture dishes 
and RNA extracted using an RNeasy kit (Qiagen) according to manufacturer’s 
instructions including the DNase step. In summary, cells were lysed using 
buffer RLT, scraped from plates then homogenised by passing 5 times through 
a sterile 21 gauge needle. Samples were then mixed with an equal volume of 
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70% (v/v) ethanol and placed onto a RNeasy mini column 700 µl at a time. 
Columns were centrifuged (13,226 x g) for 15 seconds and waste discarded. An 
on-column DNase digestion was performed using the DNase kit (Qiagen) as 
instructed with one wash using RW1 buffer then a 15 min incubation with 80 
µl of DNase I incubation mix (10 µl DNase I stock solution + 70 µl Buffer RDD) 
terminated with a wash with 350 µl RW1 then one further wash with 700 µl of 
RW1. Columns were further washed twice with 500 µl RPE buffer and 40 µl of 
RNase-free water added prior to centrifugation (13,226 x g, 1 min) to elute 
the RNA. Samples were kept on ice during whilst RNA concentration was 
determined using the NanoDrop (Thermo Scientific). Samples were stored at -
80°C.  
 
2.4.2 cDNA production from RNA 
RNA was reverse-transcribed using a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems) as per the manufacturer’s instructions. 
RNA (2 µg in 10 µl RNase-free water) was added to 10 µl of 2 x reverse 
transcription mastermix in RNase-free micro PCR tubes maintained at 4°C. 
Samples were mixed, briefly centrifuged and placed in a MJ Research PTC-225 
Peltier Thermal Cycler. Reverse transcription was performed using the 
following parameters: 10 min at 25°C, 120 min at 37°C then 85 min at 5°C. 
The resultant cDNA was diluted 1:10 and stored at -20°C until PCR performed. 
 
2.4.3 Quantitative real time polymerase chain reaction 
Real-time quantitative RT-PCR was performed with an ABI-PRISM 7900HT 
Sequence Detection System by mixing 2 µl cDNA, 1 µl Taqman® probe, 5 µl 
Taqman® Universal Mastermix II (no UNG) and 2 µl RNase free water per well 
of a 364-well plate using the following thermal cycling pattern: 2 min 50°C, 
10 min 95°C, then 40 cycles of 15 sec 95°C and 1 min 60°C. mRNA levels were 
normalized to TATA-box binding protein as control. All PCR experiments were 
carried out in duplicate. Results were analysed using the ΔΔCt method. 
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2.5 Radiolabelled activity assays 
2.5.1 2-deoxy-D-glucose uptake assay 
Differentiated adipocytes (3T3-L1 or SW872) grown in Falcon 12 well cell 
culture dishes were serum deprived for 2 h in serum-free DMEM then the 
media was removed, cells washed with PBS and placed in Krebs-Ringer 
Phosphate (KRP) buffer supplemented with 0.1% (w/v) BSA, at 37°C for 1 
hour. Plates were transferred to a 37°C hot plate prior to stimulation with 
insulin for 10 min at indicated concentrations; [3H]-2-deoxyglucose (final 
concentration 50 µM and 1 µCi/ml) was then added to cells for the times 
indicated and cytochalasin B (10 µM) was applied to control experiments. 
Transport assays were terminated by rapid washing of cells 3 times in ice cold 
PBS. Once air dried, 500 µl/well 1% (v/v) TX100 was added and plates 
incubated overnight. Solubilised cells were then added to 5 ml scintillation 
fluid and cell-associated radioactivity detected using a Beckman Multi-
Purpose scintillation counter. Method adapted from description by Gibbs et al. 
1988.  
 
2.5.2 AMPK activity assay 
Protein-G sepharose beads (10 µl 50% (v/v) slurry per immunprecipitation) 
were washed 3 times by the addition of 1 ml immunoprecipitation (IP) buffer 
then centrifuged at 17,500 x g at 4°C for 1 min.  Bead density was adjust to 
25% (v/v) then 1 µg each of AMPK α1 and α2 antibody (University of Dundee) 
per reaction added prior to rotating incubation for 1 h at 4°C. Antibody-bead 
complexes were then collected by centrifugation and 3 further washes in 1 ml 
IP buffer completed. Cell lysate (100 µg protein) was added to 5 µl of 
antibody-bead complex for each IP reaction then sample volumes equalised 
with IP buffer as required. Samples were incubated for 3 h at 4°C on a 
rotating platform to allow antibody-protein binding. Pellets were collected 
following centrifugation and 5 washes completed as follows: 2 x high salt IP 
buffer (1 M NaCl), 2 x IP buffer then 1 x HEPES-Brij-DTT (HBD) buffer (50 mM 
HEPES-NaOH (pH 7.4 at 4°C, 0.02 % (v/v) Brij-35, 1 mM DTT) and stored at -
20°C. Prior to kinase assay pellets were resuspended in 20 µl HBD then 
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combined with 5 µl HBD, 5 µl 1 mM AMP, 5 µl 1 mM SAMS peptide and 5 µl of 
0.2 µCi/µl [γ-32P]-ATP (prepared in HBD containing 1 mM ATP and 25 mM 
MgCl2). After 10 min incubating at 30°C on a vibrating platform 15 µl of 
sample was spotted onto a square of P-81 Whatman phosphocellulose paper 
then submerged in 500 ml of 0.1% (v/v) H3PO4. Paper squares were washed as 
follows: 2 x H2O, 1 x H3PO4 (5 min), 2 x H2O then added to 5 ml scintillation 
fluid once air dry and radioactivity detected using a Beckman Multi-Purpose 
scintillation counter. Samples were assayed in duplicate with an additional 
reaction lacking SAMS peptide. Total counts were measured in a 5 µl sample 
of 0.2 µCi/µl [γ-32P]-ATP. 
 
2.6 In vivo Methods 
2.6.1.1 Experimental animals 
Experimental animals were housed in the Central Research Facility at the 
University of Glasgow and experiments conducted under the United Kingdom 
Animals Scientific Procedures Act 1986. Wild type (WT) (SV129) mice were 
originally purchased from Harlan laboratories and AMPKα1 knock out (KO) 
mice were a kind gift from Benoit Viollet (Institut Cochin, Paris, France). KO 
mice were originally generated by the injection of positive embryonic stem 
cells into blastocysts from C57BL/6J mice (Jorgensen et al. 2004) and 
subsequent mating led to the present mixed C57BL6/SV129 background.  Mice 
were maintained at an ambient temperature with 12 h light and dark cycles. 
They had free access to food and water. Conditions and experiments were 
overseen by the following project licenses 70/8572, 60/4244 and 60/4526. 
 
2.6.1.2 Genotyping of experimental animals 
DNA was extracted from ear notches using 10 µl of DNAreleasy and performing 
PCR the following thermal cycling pattern: 5 min at 75°C, 2 min at 96°C then 
20°C indefinitely. Nuclease-free dH2O (90 µl) was added prior to RT-PCR using 
the Go Taq amplification system. The primer sequence is described in Table 
2.1. A mastermix containing Taq (Go) hot start mastermix, forward primer, 
reverse primer and NF-dH2O was added to the DNA sample then subjected to 
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the following thermal cycling pattern: 5 min 95°C, 40 x (30 sec 95°C, 40 sec 
58°C, 1 min 72°C), 10 min 72°C, then 4°C until electrophoresis performed. A 
2% (w/v) agarose/TAE gel was used to separate DNA products then 0.1% (v/v) 
ethidium bromide added to allow visualization by the Alpha Innotech digital 
imaging system, an example is shown in figure 2.1.  
 
Table 2.4 Primer sequences for genotyping 
Primer Type Sequence 
AMPKα1+/+ 
Forward AGCCGACTTTGGTAAAGGATG 
Reverse CCCACTTTCCATTTTCTCCA 
AMPKα1-/- 
Forward GGGCTGCAGGAATTCGATATCAAGC 
Reverse CCTTCCTGAAATGACTTCTG 
 
 
Figure 2.1 Genotyping of experimental animals.  
With reference to a 100 bp ladder (left) the absence of a band on the upper 
(WT DNA primer) or lower (KO DNA primer) row indicates presence of knock 
out or wild type mice respectively. Presence of both bands indicates 
heterozygote. 
 
2.6.2 High fat diet protocol 
Male WT and KO mice were allocated in pairs to either normal chow or high 
fat diet (42% fat) between 8 and 10 weeks of age for 12 weeks. At this point 
they were individually housed and had weight measured weekly and food 
intake estimated by weighing their food at the beginning and end of a 24 h 
period. Constituents of high fat diet in Appendix 1. 
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2.6.3 Glucose tolerance tests 
At the end of the 12 week diet intervention each mouse undertook a glucose 
tolerance test. Following a 16 h overnight fast mice were weighed and 
received an intraperitoneal injection of 1g/kg glucose. Tail vein blood 
sampling was performed at 0, 15, 30, 60, 90 and 120 min and glucose 
measured using a Freestyle glucose meter (Abbot Diabetes Care). Animals 
were then given free access to their allocated diet. 
 
2.6.4 Serum measurements 
Mice were fasted overnight then sacrificed by CO2 narcosis prior to blood 
sampling by cardiac puncture using a 1 ml syringe and heparinised 23 gauge 
needle. Blood was transferred to a chilled centrifuge tube and kept on ice for 
at least 30 min. Samples were centrifuged for 10 min at 720 x g at 4°C then 
serum collected into 50 µl aliquots and stored at -80°C. 
 
2.6.4.1 Insulin ELISA 
Insulin concentration was determined using a Rat/Mouse insulin ELISA kit 
(Millipore) according to the manufacturer’s instructions. In brief, using the 
microplate and strips provided, 10 µl of sample was added to 10 µl of assay 
buffer then 80 µl of detection antibody combined prior to incubating for 2 h 
at room temperature on a shaking platform at 500 rpm. The wells were 
emptied, washed and incubated with 100 µl of enzyme solution for 30 min, 
then emptied and washed again, incubated with substrate solution for 15 min 
then stop solution added and the absorbance at 485 nm determined using a 
FLUOstar OPTIMA microplate reader (BMG Labtech, Germany). Mean 
absorbance was determined from duplicate samples and concentration 
calculated by comparison to the standard curve. 
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2.6.4.2 RAAS analysis 
Serum samples were sent to the Attoquant Diagnostics lab (Austria) for 
analysis of aldosterone, angiotensin I, angiotensin II, angiotensin 1-7 and 
angiotensin I formation rate by mass spectrometry. 
 
2.6.5.1 Liver histology 
Livers were isolated and weighed then collected into 10% zinc formalin for 24 
hours then stored in ethanol until paraffin embedding. Using a Citadel 1000 
tissue processor liver samples were passed through different ethanol 
concentrations (70% (v/v), 85% (v/v), 90% (v/v), 100% (v/v)), followed by 
histoclear then paraffin prior to embedding in paraffin wax blocks using a 
Shandon Histocentre 3 embedding centre. Blocks were cut into 5 µm slices 
using a Leica Finesse 325 microtome, slices placed onto glass plates prior yo 
haematoxylin and eosin staining. Paraffin was removed by immersion of plates 
into xylene then slides rehydrated through an ethanol gradient (100% (v/v), 
90% (v/v), 70% (v/v) for 5 min each then washed in running water for 5 min. 
Sections were stained with Harris haematoxylin for 4 min then washed in 
running water prior to placement in 1% (v/v) HCl in ethanol for 30 sec. Slides 
were then washed in water for 1 min then placed in 1% (v/v) eosin for 2 min 
prior to further 5 min wash in deionised water. Sections were then 
dehydrated by ethanol immersions (70% (v/v), 90% (v/v), 100% (v/v)) followed 
by 10 min in Histoclear. The cover slips were fixed over the section using DPX 
mounting medium.  
 
2.6.5.2 Liver triglyceride assay 
Liver (25mg) was homogenised in 1 ml 5% (v/v) NP-40 in a Dounce 
homogeniser (15 passes), heated to 100°C for 5 min then cooled to room 
temperature.  Homogenates were heated to 100°C again for 5 min, cooled to 
room temperature and centrifuged (21,910 x g, 3 min). Supernatants were 
diluted in 9 vol of H2O and 25 µl assayed using an Abcam Triglyceride 
Quantification Assay Kit (ab65336), measuring absorbance at 570 nm. 
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2.6.6 Adipose measurements 
Adipose tissue was isolated from subcutaneous (inguinal, excluding lymph 
node), epididymal, mesenteric, perinephric and interscapular (brown adipose 
tissue) regions and weighed. Samples were then snap frozen for protein or 
RNA analysis. 
 
2.6.6.1 Adipose tissue protein extraction 
Tissue samples were weighed then homogenised with 4 vol of lysis buffer by 
10 passes with a Dounce homogeniser. Homogenates were transferred to a 
microcentrifuge tube, vortex mixed and placed on ice for 20 min. 
Homogenates were subsequently centrifuged (21,910 x g, 4°C, 10 min). 
Supernatants were stored at -80°C. Protein lysates were separated by SDS-
PAGE and immunoblotting was used to analyse proteins of interest. 
 
2.6.6.2 Adipose tissue RNA extraction 
Tissue samples were homogenised with 750 µl Qiazol using a Precellys bead 
beating homogeniser. Homogenates were combined with 200 µl chloroform 
and incubated at room temperature for 2 min. Homogenates were 
subsequently centrifuged (12,000 x g at 4°C for 15 min).  The upper aqueous 
phase (300 µl) was mixed with 500 µl of isopropanol and incubated at room 
temperature for 10 min. The mixture was then centrifuged (12,000 x g at 4°C 
for 10 min) and supernatant combined with 500 µl 75% (v/v) ethanol. Samples 
were further centrifuged (8,000 x g at 4°C for 5 min) then sample pellets 
were dried prior to the addition of 40 µl nuclease free water and kept on ice. 
After 1 h samples were incubated at 65°C for 5 min then returned to ice. The 
RNA concentration was measured using the NanoDrop then stored at -80°C. 
This protocol was performed by Carol Thomson, University of Glasgow. 
 
2.7 Statistical Analysis  
Results are expressed as mean ± standard error of the mean. Where multiple 
experimental conditions exist and experiments have been repeated, results 
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were compared to a designated control or maximally stimulated sample 
within each experiment.  Data were analysed using GraphPad Prism software 
(California, U.S.A.).  Normal distribution has been assumed throughout as 
sample numbers were insufficient to determine normal distribution. 
Statistical significance was determined by one-way or two-way ANOVA or t-
test depending on number of treatments being compared, p<0.05 is regarded 
as significant. Given that normal distribution was assumed, selected data 
have been re-analysed using non-parametric analytic methods as indicated in 
the figure legend to allow further interpretation to readers. 
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3 Chapter 3 – The evaluation of SW872 cells as a 
human adipocyte model for the study of AMPK 
activation and the local adipocyte RAAS. 
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3.1 Introduction 
3.1.1 Adipocyte models 
Obesity and its associated cardiometabolic disorders including diabetes are a 
major threat to the health of current and future populations. Although 
prevention is the simplest way to address these problems (Schellenberg et al. 
2013, Stevens et al. 2015), present measures have not been able to control 
this global epidemic estimated to affect over 650 million adults worldwide 
(WHO Obesity and overweight, 2017). Adipose tissue is a logical place for 
investigation and targeting therapeutics. Adipose tissue contains many 
constituent cell types, however the principal site of fat storage is the 
adipocyte. In addition to its metabolic functions reviewed in 1.2 it has a 
complex endocrine function and can secrete in excess of 600 adipocytokines 
(Lehr et al. 2012). Dysfunctional secretion of pro-inflammatory mediators is 
one of the proposed mechanisms leading to systemic metabolic dysfunction 
associated with obesity (Esser et al. 2014). In addition, demand for fat 
storage can exceed the capacity of adipose tissue and result in ectopic fat 
deposition in key metabolic organs such as the liver and pancreas impacting 
on insulin secretion and action (Sattar and Gill, 2014). 
 
The adipocyte is therefore a complex cell with dynamic functions which are of 
great interest in the study of obesity and diabetes.  The 3T3-L1 pre-adipocyte 
is the most widely studied cell line in adipose research with highly 
standardised culture and differentiation protocols (Ruiz-Ojeda et al. 2016). 
However, as the 3T3-L1 adipocyte is derived from a mouse it may therefore 
not necessarily mimic human adipocyte function. The SW872 cell line is 
derived from humans and is also able to be differentiated into a lipid storing 
cell. It is derived from a liposarcoma and therefore its behaviour as a mature 
human adipocyte may also differ from adipocytes in normal adipose depots. 
Both of these cells require differentiation using a cocktail of hormones to 
reach adipocyte status (as described in 2.2.2 and 2.2.6). 
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3.1.2 AMPK activity in adipocytes 
AMP-activated protein kinase is a ubiquitously expressed heterotrimeric 
kinase activated in low energy states. In adipocytes AMPK activation inhibits 
insulin-stimulated glucose uptake, lipogenesis, adipogenesis and stimulates 
fatty acid oxidation (Bijland et al. 2013). AMPK is also known to have anti-
inflammatory properties and can regulate the expression of adipocytokines 
(Bijland et al. 2013). It is activated by a wide range of substances including 
metformin, the first line medication for type 2 diabetes (Boyle et al. 2011). 
The experimental pharmacological AMPK activator AICAR has been widely 
used in the investigation of AMPK, it is metabolized to ZMP which acts as an 
AMP mimic which has given rise to some concerns regarding its specificity 
(Guigas et al. 2009). The small molecule A769662 was described as an AMPK 
activator in 2006, it binds directly to heterotrimers containing the β1 subunit 
of AMPK resulting in activation (Cool et al. 2006). ACC is a downstream AMPK 
signalling target and phosphorylation of ACC at Ser79 (rat ACC1 sequence) is 
an indicator of AMPK activation (Hardie, 1989).   
 
3.1.3 The local adipocyte RAAS 
The RAAS has been implicated in the pathogenesis of metabolic disorders 
associated with obesity (Underwood and Adler, 2013). The systemic 
upregulation of RAAS may be the predominant contributing factor however 
intriguingly there is now known to be a complete RAAS within adipocytes 
which must also be considered (Briones et al. 2012, Marcus et al. 2013). 
Indeed studies have linked the local adipose RAAS with systemic insulin 
resistance (Marcus et al. 2013).  
 
3.1.4 Aims 
This study set out to characterise insulin and AMPK signalling in the SW872 
cell line with comparison to 3T3-L1 as a benchmark for in vitro investigation 
of adipocytes.  In addition, the presence of RAAS components was examined 
in these two adipocyte models.  
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3.2 Results 
3.2.1 Differentiation of 3T3-L1 and SW872 adipocytes 
Lipid uptake and storage is the characteristic function of an adipocyte. To 
determine the effect of adipocyte differentiation in both 3T3-L1 and SW872 
cells, oil red O staining was carried out on cells cultured for the same 
duration treated with or without adipocyte differentiation media. In 3T3-L1 
cells there was no basal staining with oil red O (Fig. 3.1A) however a marked 
increase in staining was seen in cells which had been treated with the 
adipocyte differentiation protocol (Fig. 3.1B).  In SW872 cells a small amount 
of oil red O uptake was observed in cells which had not been treated with 
adipocyte differentiation media (Fig. 3.1C). There was a definite increase in 
oil red O staining observed following treatment with differentiation media 
(Fig. 3.1D) yet not to the extent seen in 3T3-L1 adipocytes. 
 
3.2.2.1 Insulin signalling in SW872 adipocytes 
Insulin signalling in adipocytes leads to translocation of GLUT4 to the cell 
membrane and influx of glucose. Insulin responsiveness has been established 
in 3T3-L1 adipocytes, a classic tool for studying insulin stimulated glucose 
transport (Salt et al. 2000, Ewart et al. 2005, Sadler et al. 2015). Studies in 
our laboratory have demonstrated that 10 nM insulin will stimulate a robust 
signalling response in 3T3-L1 adipocytes (Boyle et al. 2011). To examine the 
insulin responsiveness of SW872 adipocytes, cells were incubated in insulin (10 
nM) for various durations or at different concentrations for 10 min. Akt Ser473 
phosphorylation was used as a marker of insulin signalling.  Insulin increased 
Akt phosphorylation maximally at a concentration of 100 nM after 10 min (58% 
increase, p=0.0002). Lower concentrations of insulin tended to increase Akt 
Ser473 phosphorylation, yet this did not achieve statistical significance.  
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3.2.2.2 Insulin stimulated glucose transport in SW782 
adipocytes 
Given the muted insulin signalling response in SW872 adipocytes, a 2-deoxy-
[3H]-glucose uptake assay was performed. Insulin stimulation (10 nM) led to a 
22% increase in glucose uptake (p=0.0036)(Fig 3.3A) which although significant 
was a smaller increase than expected. Therefore, stimulation with different 
insulin concentrations (10 nM, 100 nM and 1 µM) and after different durations 
of incubation with 2-deoxy-[H3]-glucose (1, 3 and 6 min) was carried out (Fig 
3.3B). This experiment demonstrated that basal 2-Deoxy-[3H]-glucose 
increased with time in a linear fashion however increasing concentrations of 
insulin did not result in a robust increase in glucose uptake. In contrast to 
previous studies in our laboratory using 3T3-L1 adipocytes, there was only 
minimal stimulation of 2-deoxy-[3H]-glucose uptake in response to insulin in 
SW872 adipocytes. Further investigation of glucose transport was therefore 
conducted in 3T3-L1 adipocytes (5.2.3.4). 
 
3.2.2.3 Basal Akt phosphorylation in SW872 adipocytes 
compared to 3T3-L1 adipocytes 
In light of the lack of insulin responsiveness, a comparison was performed to 
identify differences in basal Akt phosphorylation between 3T3-L1 adipocytes 
and SW872 adipocytes. Basal phosphorylation of Akt was significantly higher in 
SW872 adipocytes when compared to 3T3-L1 adipocytes (0.29 vs 2.28 a.u., 
p=0.0001) which, assuming similar species avidity of the antibody, may be one 
explanation for the reduced response to insulin even at concentrations up to 1 
µM.  
 
  
 93 
 
 
Figure 3.1 Oil red O staining of 3T3-L1 and SW872 
adipocytes pre- and post-differentiation. 
3T3-L1 and SW872 cells were cultured until confluence prior to 
differentiation (as described in 2.2.2). A. Undifferentiated 3T3-L1 
fibroblasts, B. Differentiated 3T3-L1 adipocytes, C. SW872 cells without 
differentiation medium and D. SW872 cells with differentiation medium were 
stained with oil red O and images obtained. Representative images are shown 
from 2 independent experiments. Scale bars represent arbitrary distance to 
allow comparison within cell types. 
 
 
  
A B
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Figure 3.2 Insulin signalling in SW872 adipocytes 
SW872 adipocytes were incubated in serum free media for 2 h then 
stimulated with insulin (10 nM) for the durations indicated or at the 
concentrations indicated for 10 min. Cell lysates were prepared, proteins 
resolved by SDS-PAGE and immunoblotted for the indicated proteins (P-Akt, 
phospho-Akt Ser473; T-Akt, total Akt). A. & B. Representative immunoblots 
with the molecular masses of marker proteins (in kDa) shown. C. & D. 
Quantification of P-Akt levels relative to Akt. n=3, ***P<0.001, one-way 
ANOVA. 
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Figure 3.3 Glucose transport in SW872 adipocytes 
SW872 adipocytes were incubated in serum free media for 2 h then media 
changed to KRP for 1 h prior to stimulation with A. 10 nM insulin for 10 min 
prior to incubation with 2-deoxy-3H-glucose for 3 min or B. various 
concentrations of insulin as indicated for 10 min, prior to incubation with 2-
deoxy-3H-glucose for the times indicated. Cell-associated 3H was measured 
using a scintillation counter, all experiments were performed in duplicate. A. 
n=3, t-test **p<0.01. B. n=1. 
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Figure 3.4 Immunoblot analysis of basal Akt signalling in 
3T3-L1 and SW872 adipocytes 
3T3-L1 and SW872 adipocytes were incubated in serum free media for 2 h. 
Cell lysates were prepared, proteins resolved by SDS-PAGE and 
immunoblotted for the indicated proteins. A. Representative immunoblot. B. 
Quantification of P-Akt levels relative to Akt. n=3, t-test ***P<0.001. Mann 
Whitney test not significant. 
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3.2.3.1 The effects of AICAR and A769662 on AMPK signalling in 
SW872 adipocytes 
Our laboratory has previously demonstrated that both AICAR and A769662 
stimulate AMPK activity in 3T3-L1 adipocytes (Boyle et al. 2011, Mancini et al. 
2017), yet whether AICAR and A769662 activate AMPK in SW872 adipocytes 
remains uncharacterised. SW872 cells were therefore incubated with different 
concentrations of AICAR or A769662 for different durations to assess their 
effect on AMPK activity as measured by phosphorylation of ACC. Stimulation 
of SW872 adipocytes with 1 mM AICAR significantly stimulated ACC 
phosphorylation within 60 min, an effect sustained for at least a further 60 
min (Figs 3.5A & 3.5B). Lower concentrations of AICAR tended to increase ACC 
phosphorylation, yet this did not achieve statistical significance (Fig 3.5D). 
ACC phosphorylation was significantly increased within 30 min of the addition 
of 300 µM A769662, a response sustained for a further 30 min (Fig 3.6). An 
incremental response to concentration was observed however a statistically 
significant increase in ACC phosphorylation was only achieved with 300 µM of 
A769662 (Figs 3.6C & 3.6D). 
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Figure 3.5 Effects of AICAR on AMPK signalling in SW872 
adipocytes. 
SW872 adipocytes were incubated in serum free medium for 2 h prior to 
stimulation with 1 mM AICAR for the times indicated in A. and B. (min) and 
at concentrations indicated in C. and D. for 1 h. Cell lysates were prepared, 
proteins resolved by SDS-PAGE and immunoblotted for the indicated proteins 
(P-ACC; phospho-ACC Ser79). A. and C. Representative immunoblots with the 
molecular masses of marker proteins (in kDa) shown. B. and D. Quantification 
of P-ACC levels relative to ERK or GAPDH. n=3, t-test *p<0.05, ***p<0.001. 
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Figure 3.6 Effects of A769662 on AMPK signalling in 
SW872 adipocytes. 
SW872 adipocytes were incubated in serum free medium for 2 h prior to 
stimulation with 300 µM A769662 for the times indicated in A. and B. (min) 
and at concentrations indicated in C. and D. for 30 min. Cell lysates were 
prepared, proteins resolved by SDS-PAGE and immunoblotted for the 
indicated proteins. A. and C. Representative immunoblots are shown. B. and 
D. Quantification of P-ACC levels relative to ERK or GAPDH as indicated. n=3, 
one-way ANOVA *p<0.05, **p<0.01. 
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3.2.4 The effect of adipocyte differentiation on expression of 
components of the renin angiotensin aldosterone system in 
SW872 adipocytes 
Gene expression of components of the RAAS in SW872 cells before and after 
adipocyte differentiation was next examined. The change in expression was 
determined relative to differentiated cells. 
 
Differentiation of SW872 cells resulted in a significant increase in mRNA 
expression of angiotensinogen (3.6-fold, p=0.012), type 2 angiotensin II 
receptor (7.1-fold, p=0.021) and the mineralocorticoid receptor (1.9-fold, 
p=0.01)(Fig. 3.7). In contrast, there was no change in the mRNA expression of 
the glucocorticoid receptor. Taqman® qPCR was also performed for the 
angiotensin II type 1 receptor however the result was undetectable after 40 
amplification cycles. The same probe was used with duplicate samples of 
human adipose tissue cDNA yielding a result with a Ct value of 36. 
 
3.2.5 Expression of components of the renin angiotensin 
aldosterone system in cultured SW872 and 3T3-L1 adipocytes 
To determine the basal mRNA expression level of RAAS components in 3T3-L1 
and SW872 adipocytes the mean Ct values of untreated samples were 
determined and are reported here with the standard error of the mean (Table 
3.1). The mean Ct values were lowest, indicating higher gene expression, for 
angiotensinogen (mean Ct 21.58 in 3T3-L1 and 23.36 in SW872) and the 
glucocorticoid receptor (mean Ct 25.06 in 3T3-L1 and 21.78 in SW872) in both 
groups. The mineralocorticoid receptor (mean Ct 27.22 in 3T3-L1 and 30.83 in 
SW872) had the next highest expression level followed by angiotensin type 2 
receptor (mean Ct 29.17 in 3T3-L1 and 34.77 in SW872). The AT1 receptor was 
not detectable in either cell type under these conditions. When the murine 
probe for AT1 receptor was used in mouse adipose tissue the Ct value was 
detected at 25 cycles. 
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Figure 3.7 RAAS component gene expression pre- and 
post-differentiation in SW872 adipocytes. 
RNA was extracted from SW872 cells pre- and post-differentiation into 
adipocytes. Reverse transcription was carried out prior to Taqman qPCR 
assays for A. angiotensinogen (AGT), B. angiotensin II type 2 receptor (AT2R), 
C. mineralocorticoid receptor (MR) and D. glucocorticoid receptor (GR). All 
mRNA levels were normalised to TATA-box binding protein expression. A. and 
B. n=3, C. and D. n=4, t-test *p<0.05, **p<0.01.  
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 3T3-L1 (Mean Ct) S.E.M. SW872 (Mean Ct) S.E.M. 
AGT 21.58 0.7729 23.36 0.4156 
AT1R >40  >40  
AT2R 29.17 1.085 34.77 0.4058 
MR 27.22 0.9196 30.83 0.2945 
GR 25.06 0.9784 21.78 0.2013 
 
Table 3.1 Mean Ct value of RAAS genes in 3T3-L1 
adipocytes and SW872 adipocytes. 
RNA was extracted from 3T3-L1 adipocytes and SW872 adipocytes. Reverse 
transcription was carried out prior to Taqman qPCR assays for 
angiotensinogen (AGT), angiotensin II type 1 receptor (AT1R), angiotensin II 
type 2 receptor (AT2R), mineralocorticoid receptor (MR) and glucocorticoid 
receptor (GR), normalized to TATA-binding protein mRNA expression. n=11-
12. 
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3.3 Discussion 
In this study two adipocyte models have been used, the widely investigated 
3T3-L1 adipocyte and the less commonly studied SW872 adipocyte. In many 
cases studies related to human disorders are carried out in adipocytes of 
mouse, rat or human descent and may be performed in whole adipose tissue, 
isolated adipocytes or cell lines. This results in a somewhat mixed and 
conflicted literature. In this work we aim to perform studies in the human 
white adipocyte model SW872 but reflect on 3T3-L1 as the standard, albeit 
murine, model. 
 
Initial studies determined the effect of adipocyte differentiation on lipid 
storage. Here, a marked staining of oil red O was observed in 3T3-L1 
adipocytes compared to undifferentiated fibroblasts, consistent with previous 
reports (Ruiz-Ojeda et al. 2016). In SW872 adipocytes, there was again an 
increase in lipid storage observed by increased oil red O staining of cells 
treated with differentiation media compared to untreated, however there 
was a small amount of oil red O visible on the untreated cells. Within the 
literature it is noted that this cell line will take up lipid without any specific 
adipogenic stimulus (Wassef et al. 2004). Another human adipocyte model, 
SGBS, was recently compared to SW872, in this regard SGBS was found to 
express some markers consistent with a brown adipocyte phenotype. Whereas 
SGBS cells stained positively for UCP-1, this was not the case for SW872 
(Guennoun et al. 2015). The authors identified the SW872 cells took on a 
white adipocyte phenotype from day 7 of differentiation and this phenotype 
remained consistent over subsequent days of culture, suggesting they are a 
preferable human model for the study of white adipocytes (Guennoun et al. 
2015). It must be noted that oil red o staining was poor in comparison to 3T3-
L1 adipocytes. Another method to assess adipocyte status which would 
compliment this work would be to assess for the presence of differentiation 
markers including PPARΥ, adiponectin and leptin. 
 
Insulin stimulated glucose transport in skeletal muscle and adipose tissue is 
crucial for maintaining normoglycaemia. Insulin signalling via PI3 kinase and 
Akt leads to GLUT4 translocation and glucose influx (Summers et al. 2000). 
 104 
3T3-L1 adipocytes have been demonstrated to be insulin sensitive and are 
therefore useful tools for the study of adipose glucose metabolism. According 
to the published literature at the start of these studies, SW872 adipocytes had 
been used to study lipid transfer and production but not insulin signalling or 
glucose transport (Richardson et al. 1996, Vassiliou et al. 2001). In this study, 
insulin signalling was examined by time and concentration response in SW872 
adipocytes. At 10 nM, a concentration stimulating a robust response in 3T3-L1 
adipocytes, insulin was unable to significantly increase Akt phosphorylation at 
a range of time points up to 30 min. However, a significant increase in Akt 
phosphorylation was achieved with 100 nM insulin in SW872 adipocytes.  One 
previous study has reported that insulin reduced apoC-1 and apoE secretion 
from SW872 adipocytes, although this was only at a very high insulin 
concentrations (1 µM) and no effect on insulin signalling pathways was 
evaluated (Wassef et al. 2004).  
 
Given that Akt phosphorylation was increased with insulin at 100 nM, glucose 
transport was examined next. Glucose enters mature adipocytes via two 
glucose transporters: GLUT1 which is present basally and GLUT4 which is 
insulin dependent and restricted largely to adipose and skeletal muscle 
(Hoffman and Elmendorf, 2011). Initial findings here identified a statistically 
significant yet very small increase in 2-deoxy-[3H]-glucose uptake with 10 nM 
insulin.  Despite increasing concentrations of insulin up to 1 µM there 
remained a lack of robust increase in glucose uptake although a linear 
response to time exposed to 2-deoxy-[3H]-glucose was demonstrated. It is 
possible that this model lacks the vesicular trafficking machinery required to 
translocate GLUT4 to the cell membrane efficiently, or may lack GLUT4 
completely, though there are many plausible explanations. Indeed, a crude 
comparison between basal Akt phosphorylation in 3T3-L1 and SW872 
adipocytes revealed increased basal signalling in SW872 adipocytes. Perhaps 
this is because the cells are derived from liposarcoma and therefore may have 
a high level of mitogenicity. Another possible cause for elevated basal Akt 
signalling could be SV40 transformation (Skoczylas et al. 2004), however this 
cell line was not SV40 tranformend (direct communication, ATCC, LGC, 
Middlesex, UK). From these data in SW872 adipocytes it can be concluded that 
SW872 adipocytes are not a useful model to study insulin stimulated glucose 
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transport nor insulin signalling. Therefore, later studies investigating glucose 
transport will be conducted in 3T3-L1 adipocytes. 
 
Stimulation of SW872 adipocytes with both AICAR and A769662 led to 
significant increases in ACC phosphorylation in this study at concentrations 
that were also effective in 3T3-L1 adipocytes. Establishing the use of these 
AMPK activators in this human white adipocyte model will allow further 
studies exploring the role of AMPK in its regulation of inflammation and the 
RAAS in SW872 adipocytes. 
 
In order to study the influence of AMPK on the adipocyte RAAS expression of 
components was first identified. This study found that expression of 
angiotensinogen, the AT2 receptor and the mineralocorticoid receptor were 
significantly increased following SW872 adipocyte differentiation. The 
increase in expression of angiotensinogen is consistent with studies in both 
3T3-L1 (Saye et al. 1990) and human adipocytes (Janke et al. 2002; Wang et 
al. 2005). The increase in AT2 receptor expression following adipocyte 
differentiation has been reported in one study which found very low 
expression in pre-adipocytes which was slightly increased following 
differentiation (Janke et al. 2002). One recent study found that the AT2 
receptor may be anti-adipogenic as deletion of the AT2 receptor accelerated 
adipocyte differentiation in murine mesenchymal stem cells and decreased 
Wnt10b expression (Matsushita et al. 2016), a finding which somewhat 
opposes the data presented here where AT2R is induced upon differentiation.  
 
The MR is proposed to be a crucial player in obesity and cardiometabolic 
disorders. The data presented in this chapter found an increase in expression 
of the MR in differentiated SW872 adipocytes with no change in the expression 
of the GR. This is consistent with another report that the MR was induced with 
adipocyte differentiation in 3T3-L1 cells at both the level of mRNA and 
protein, with no change in GR (Caprio et al. 2007). The function of the MR in 
adipose is not fully understood but it does appear to have an important role in 
adipogenesis where it is likely to be activated by glucocorticoids (Caprio et al. 
2007). Knockdown of the MR but not the GR inhibited adipogenesis therefore 
suggesting a critical role for MR over the GR in adipogenesis (Caprio et al. 
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2007). Similarly, preadipocytes from mice with genetic knockout of the MR did 
not accumulate lipid, however those from GR knockout mice did accumulate 
lipid following adipogenic stimuli (Hoppmann et al. 2010). Conversely, in cells 
derived from human subcutaneous adipose tissue, stable knockdown of the GR 
not the MR impaired adipogenic responses to cortisol (Lee and Fried, 2014). 
Glucocorticoids are undoubtedly important in adipogenesis where they appear 
to mediate effects via either MR or GR, with studies in mice favouring MR and 
humans favouring GR as the key receptor mediating adipogenic effects (Caprio 
et al. 2007; Hoppmann et al. 2010; Lee and Fried 2014).  
 
In this study the AT1R was undetectable in both the SW872 and 3T3-L1 
adipocytes. This was an unexpected finding as there is a literature describing 
effects of angiotensin II in 3T3-L1 adipocytes being mediated through the 
AT1R (Asamizu et al. 2009, Than et al. 2012). The same probes were able to 
identify the AT1R in murine adipose tissue and human adipose tissue. Both of 
these samples contained other cell types than adipocytes, which may indicate 
AT1R is largely expressed by stromal-vascular cells in adipose tissue. 
Alternatively, the lack of AT1R in either cell line may be due to the 
differentiation process used or the conditions in our laboratory although 
standard protocols were followed. Multiple passaging or freeze-thaw cycles 
may also have led to poor expression of the AT1R. It is possible that the lack 
of AT1R altered the dynamics of the RAAS in these cells systems and may 
impact the findings in later chapters.  
 
In summary, the human-derived SW872 white adipocyte model was able to 
store lipid but not to the same degree as 3T3-L1. High concentrations of 
insulin were required to achieve Akt signalling in SW872 adipocytes which 
appear to be a poor model for the study of insulin-stimulated glucose uptake. 
However, AMPK signalling was evident with similar doses of AICAR and 
A769662 to 3T3-L1 adipocytes and the RAAS system was present and induced 
with adipocyte differentiation.  In the coming chapters the cross-talk between 
AMPK and the RAAS is explored in these two adipocyte models. 
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4 Chapter 4 – The effect of AMPK activators on 
the renin angiotensin aldosterone system in 
cultured adipocytes 
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4.1 Introduction 
4.1.1 Local adipose tissue RAAS and interactions with AMPK 
The principal RAAS hormones angiotensin II and aldosterone have been 
implicated in the development of adipose tissue inflammation and subsequent 
obesity-related metabolic disorders including insulin resistance (Underwood 
and Adler, 2013). Expression of the MR is elevated in adipose tissue of obese 
rodent models and individuals with increased BMI (Hirata et al. 2012) and MR 
blockade is associated with adipokine release and improved insulin sensitivity 
in rodent models (Hirata et al. 2009). Complete local RAASs have been 
identified in several tissues including adipose tissue generating interest into 
their physiological role (Briones et al. 2012).  
 
AMPK is an energy sensing kinase which is activated by cellular stressors such 
as low energy (AMP abundance) and hypoxia in order to liberate ATP by 
several methods including increased mitochondrial biogenesis (Hardie et al. 
2012). Within adipose tissue AMPK has a role in glucose and lipid metabolism 
and an increasingly well-characterised anti-inflammatory function (Bijland et 
al. 2013).  
 
As the RAAS appears to play a causative role in obesity-related metabolic 
complications and AMPK is known to have anti-obesogenic actions in adipose 
tissue, the interaction between these two components was of great interest. 
At the start of the studies described in this chapter, interactions between 
AMPK and the RAAS had been studied in renal and cardiovascular models but 
not adipose tissue or adipocyte models (Nagata et al. 2004, Stuck et al. 2008, 
Lee et al. 2013). One study had also provided evidence that adipose tissue 
AMPK and RAAS are associated, in which both decreased AMPK activity and 
increased angiotensinogen expression were observed in subcutaneous adipose 
tissue of insulin resistant, but not insulin sensitive, obese individuals (Xu et al. 
2012). 
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4.1.2 Aims 
As alterations in AMPK activity and RAAS have been reported in adipose tissue 
from insulin resistant, obese individuals, the current study set out to 
determine the expression of RAAS components in murine (3T3-L1) and human 
(SW782) adipocyte cultured cell models and subsequently assess the influence 
of pharmacological AMPK activators on their expression and function. 
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4.2 Results 
4.2.1 The effect of AICAR on expression of components of the 
renin angiotensin aldosterone system in 3T3-L1 adipocytes 
In previous studies, AICAR has been demonstrated to activate AMPK for up to 
24 h in 3T3-L1 adipocytes (Boyle et al. 2011). To determine whether AMPK 
activation influenced mRNA expression of RAAS components, differentiated 
3T3-L1 adipocytes were incubated with AICAR at a concentration of 1 mM for 
5, 9 or 25 h. Incubation with AICAR downregulated gene expression of the 
angiotensin II type 2 receptor by 94% (p<0.0001) and the mineralocorticoid 
receptor by 39% (p=0.0439) after 25 h, but no significant effect was seen with 
shorter durations of incubation (Fig. 4.1). AICAR had no significant effect on 
mRNA expression of angiotensinogen or the glucocorticoid receptor at any 
time point examined. 
 
4.2.2 The effect of AICAR on expression of components of the 
renin angiotensin aldosterone system in SW872 adipocytes 
In chapter 3, AICAR and A769662 were demonstrated to activate AMPK for up 
to 120 and 60 min respectively in SW872 adipocytes. To determine whether 
AMPK activation influenced mRNA expression of RAAS components in SW872 
adipocytes, cells were incubated with 1 mM AICAR for 9 or 25 h and RAAS 
gene expression analysed. Stimulation with AICAR resulted in significantly 
reduced mRNA expression of angiotensinogen by 44% after 9 h (p=0.0001) and 
40% after 25 h (p<0.0001) and the mineralocorticoid receptor by 53% after 9 h 
(p=0.01) and 59% after 25 h (p=0.0068) (Fig. 4.2) without significantly altering 
the mRNA levels of either the type 2 angiotensin II receptor or the 
glucocorticoid receptor. AMPK activity was present up to 24 h (Fig. 4.4C). 
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Figure 4.1 Effects of AICAR on gene expression of renin 
angiotensin aldosterone system components in 3T3-L1 
adipocytes. 
RNA was extracted from 3T3-L1 adipocytes incubated in the presence (filled 
bars) or absence (open bars) of AICAR (1 mM) for the indicated durations. 
Reverse transcription was carried out prior to Taqman qPCR assays for A. 
angiotensinogen (AGT), B. angiotensin II type 2 receptor (AT2R), C. 
mineralocorticoid receptor (MR) and D. glucocorticoid receptor (GR). Data 
are normalised to TATA-binding protein mRNA expression. n=4, unpaired t-
test, *p<0.05, ****p<0.0001. 
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Figure 4.2 Effects of AICAR on gene expression of 
components of the renin angiotensin aldosterone 
system in SW872 adipocytes. 
RNA was extracted from SW872 adipocytes incubated in the presence or 
absence of AICAR (1 mM) for the indicated durations. Reverse transcription 
was carried out prior to Taqman qPCR assays for A. angiotensinogen (AGT), B. 
angiotensin II type 2 receptor (AT2R), C. mineralocorticoid receptor (MR) and 
D. glucocorticoid receptor (GR). Data are normalised to TATA-binding protein 
mRNA expression. n=3 except for the 9 h time point in panels A. and B., 
where n=2. Unpaired t-test, *p<0.05, ****p<0.0001. 
  
Control 9h 25h
0.0
0.5
1.0
1.5
A
G
T 
m
R
N
A 
le
ve
ls
Control 9h 25h
0.0
0.5
1.0
1.5
M
R
 m
R
N
A 
le
ve
ls
Control 9h 25h
0
5
10
15
20
AT
2R
 m
R
N
A 
le
ve
ls
Control 9h 25h
0
1
2
3
G
R
 m
R
N
A 
le
ve
ls
****
****
*
A B
DC
 113 
4.2.3 The effect of A769662 on expression of components of 
the renin angiotensin aldosterone system in SW872 adipocytes  
Having determined the effects of AICAR on RAAS gene expression in SW872 
adipocytes, the effect of the direct AMPK-activator A769662 was examined. 
Incubation with A769662 decreased expression of angiotensinogen and the 
mineralocorticoid receptor without any significant effect on the type 2 
angiotensin II receptor or the glucocorticoid receptor (Fig. 4.3), similar to the 
effects of AICAR (Fig. 4.2). There was a 40% decrease in angiotensinogen at 24 
h (p=0.004) but no significant change at 8 h. Furthermore, A769662 inhibited 
mineralocorticoid receptor mRNA expression with a consistent decrease at 8 
(50% decrease, p=0.0008) and 24 h (49% decrease, p=0.0015).  
 
4.2.4 The effect of A769662 on protein expression of the 
mineralocorticoid receptor in SW872 adipocytes  
Given the common inhibitory effect of AICAR in both murine and human 
adipocyte models as well as A769662 in SW872 adipocytes on 
mineralocorticoid receptor gene expression, it was important to determine 
the effect on protein expression. In SW872 adipocytes A769662 significantly 
decreased protein expression of the mineralocorticoid receptor by 65% after 
24 h (p=0.02)(Fig. 4.4). There was no significant decrease observed with 
AICAR (Fig. 4.4C).  
 
4.2.5 The effect of AMPK activators on expression of alternative 
RAAS components in SW872 adipocytes 
As both AICAR and A769662 decreased angiotensinogen and MR expression in 
SW872 adipocytes, the alternative arm of the RAAS was investigated. 
Expression of the Mas receptor was not significantly affected by either AMPK 
activator used (Fig 4.5A). However, AICAR decreased expression of ACE (42% 
decrease, p=0.0369) but A769662 had no effect. In contrast, ACE 2 expression 
was increased by A769662 (40% increase, p=0.0119), but was not influenced 
by AICAR. When ACE2 was normalised to ACE the ratio was significantly 
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increased by AICAR (35% increase, p=0.032, Fig 4.5 D) suggesting a shift 
towards the alternative from the classical RAAS. 
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Figure 4.3 Effects of A769662 on gene expression of 
components of the renin angiotensin aldosterone 
system in SW872 adipocytes. 
RNA was extracted from SW872 adipocytes incubated in the presence or 
absence of A769662 (300 µM) for the indicated durations. Reverse 
transcription was carried out prior to Taqman qPCR assays for A. 
angiotensinogen (AGT), B. angiotensin II type 2 receptor (AT2R), C. 
mineralocorticoid receptor (MR) and D. glucocorticoid receptor (GR). Data 
are normalised to TATA-binding protein mRNA expression. n=4 control and 8 
h, n=3 24 h, unpaired t-test, **p<0.01, ***p<0.001. 
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Figure 4.4 Effects of A769662 on protein levels of the 
mineralocorticoid receptor in SW872 adipocytes. 
SW872 adipocytes were incubated in medium containing 1% (v/v) NCS 
overnight prior to stimulation with A., B. 300 µM A769662 for the times 
indicated or C., D. 1 mM AICAR for 24 h. Cell lysates were prepared, proteins 
resolved by SDS-PAGE and immunoblotted for the indicated proteins. A. and 
C. Representative immunoblots are shown, with the molecular masses of 
marker proteins (in kDa) indicated. In panel C. unrelated lanes have been 
removed for clarity. B. Quantification of MR levels relative to GAPDH for 
A769662 experiment, n=3. D. Quantification of MR levels relative to GAPDH 
for AICAR experiment, n=4. one-way ANOVA *p<0.05. P-ACC, phospho-ACC 
Ser79; MR, mineralocorticoid receptor. 
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Figure 4.5 The effect of AMPK activators on the 
expression of Mas, ACE and ACE 2 in SW872 adipocytes 
RNA was extracted from SW872 adipocytes incubated in the presence of 
AICAR 1 mM or A769662 300 µM for 7 h. Reverse transcription was carried out 
prior to Taqman qPCR assays for A. Mas, B. ACE and C. ACE 2. For A. – C. data 
are normalised to TATA-binding protein mRNA expression. For D. ACE 2 is 
normalised to ACE. n=3, unpaired t-test *p<0.05. 
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4.2.6 The effect of AMPK activators on release of aldosterone 
from cultured adipocytes 
In view of the actions of AMPK activators on RAAS gene expression, 
aldosterone secretion in response to AMPK activators was also assessed. Figure 
4.6 demonstrates that AICAR increased aldosterone secretion by 42.5% after 8 
h stimulation (p=0.0165) in 3T3-L1 adipocytes. In SW872 adipocytes, AICAR 
tended to increase aldosterone secretion, yet this did not achieve statistical 
significance, whereas A769662 increased aldosterone secretion into culture 
medium of SW872 adipocytes by an additional 135% compared to vehicle 
(p=0.0002) (Fig. 4.6). 
 
4.2.7 The effect of AMPK activators on StAR gene expression in 
cultured adipocytes. 
Steroid acute regulatory protein (StAR) is a crucial early component of 
steroidogenesis, regulating mitochondrial cholesterol transfer, and is 
therefore required for the production of aldosterone (Hattangady et al. 2012). 
Given the marked effect of AMPK activators on aldosterone secretion in 
cultured adipocytes, the effect of AMPK activation on the expression of StAR 
was therefore assessed. Figure 4.7 demonstrates that AICAR in 3T3-L1 
adipocytes tended to increase StAR mRNA by 99%, yet this did not achieve 
statistical significance (p=0.0528), whereas A769662 stimulated a significant 
34.8% increase in StAR mRNA expression in SW872 adipocytes (p=0.0052). 
 
  
 119 
 
 
Figure 4.6 Effects of AMPK activators on aldosterone 
secretion from cultured adipocytes. 
A. 3T3-L1 adipocytes or B. SW872 adipocytes were incubated in medium 
containing 1% (v/v) NCS overnight then stimulated with 1 mM AICAR or 300 
µM A769662 (A76, SW872 adipocytes only) for 8 h. Culture medium was 
collected and aldosterone quantified by ELISA. A. n=4, unpaired t-test, B. 
Control and A76 n=4, AICAR n=3, one-way ANOVA, *p<0.05, ***p<0.001. 
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Figure 4.7 The effect of AMPK activators on StAR gene 
expression in cultured adipocytes. 
RNA was extracted from A. 3T3-L1 and B. SW872 adipocytes incubated in the 
presence or absence of A. AICAR (1 mM) or B. A769662 (A76 300 µM) for 8 h. 
Reverse transcription was carried out prior to Taqman qPCR assays for StAR. 
Data are normalised to TATA-binding protein mRNA expression. n=4, unpaired 
t-test, **p<0.01.  
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4.2.8 The effect of A769662 on mineralocorticoid receptor 
signalling in SW872 adipocytes 
4.2.8.1 The effect of A769662 on down-stream target of the 
mineralocorticoid receptor – SGK1 in SW872 adipocytes 
Serum and glucocorticoid-regulated protein kinase (SGK1) is known to be a 
target of aldosterone induced mineralocorticoid receptor activation (Pearce, 
2001). Given that A769662 increases aldosterone secretion yet decreases 
mineralocorticoid receptor expression, the effect on the target protein SGK1 
was assessed. Stimulation of SW872 adipocytes with A769662 significantly 
increased SGK1 protein levels by 4.2 fold after 24 h (p=0.0099)(Fig. 4.8).  
 
4.2.8.2 The effect of compound C and eplerenone on A769662 
induced SGK1 in SW872 adipocytes 
The AMPK inhibitor, compound C, was used to determine whether the 
induction of SGK-1 identified in response to A769662 in SW872 adipocytes was 
likely to be AMPK-dependent. In addition, the MR antagonist eplerenone was 
used to assess the MR-dependence of the SGK1 induction. Adipocytes were 
pre-incubated with compound C or eplerenone prior to stimulation with 
A769662 for 8 h or 24 h. After 8 h stimulation with A769662 ACC 
phosphorylation was increased 2.4 fold (p=0.0487) (Fig. 4.9A), an effect 
prevented by compound C.  A769662 increased SGK1 6.3-fold (p=0.2270) 
whereas in the presence of compound C A769662 increased SGK1 ~60-fold 
compared to compound C alone (p=0.0007) and 3.1-fold compared to A769662 
alone (p=0.0045) (Fig. 4.9B). After 24 h stimulation with A769662, SGK1 was 
significantly increased (4.2-fold, p=0.0192) but neither compound C nor 
eplerenone altered this response (5.2-fold increase with A769662 in the 
presence of compound C, p=0.013; 6-fold increase with A769662 in the 
presence of eplerenone, p=0.0361) (Fig. 4.10).  
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Figure 4.8 The effect of A769662 on SGK1 levels in 
SW872 adipocytes. 
SW872 adipocytes were incubated in medium containing 1% (v/v) NCS 
overnight prior to stimulation with 300 µM A769662 for the times indicated. 
Cell lysates were prepared, proteins resolved by SDS-PAGE and 
immunoblotted for the indicated proteins. A. Representative immunoblots 
are shown with the molecular masses of marker proteins (in kDa) indicated. 
B. Quantification of SGK-1 levels relative to GAPDH. n=3, unpaired t-test 
**p<0.01.  
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Figure 4.9 The effect of compound C on A769662 (8 h)-
induced SGK1 levels in SW872 adipocytes. 
SW872 adipocytes were incubated in medium containing 1% (v/v) NCS 
overnight then preincubated in the presence or absence of 30 µM compound C 
(Myers et al. 2017) or 1 µM eplerenone (Hirata et al. 2012) prior to 
stimulation with 300 µM A769662 for 8 h. Cell lysates were prepared and 
proteins resolved by SDS-PAGE and immunoblotted for P-ACC, SGK1 and 
GAPDH. A. Representative immunoblots are shown, with the molecular 
masses of marker proteins (in kDa) indicated. B. quantification of 
SGK1:GAPDH levels. n=2, two-way ANOVA, **p<0.01, ***p<0.001. P-ACC S79: 
Phospho-ACC Ser79. 
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Figure 4.10 The effect of compound C on A769662 (24 
h)-induced SGK1 levels in SW872 adipocytes. 
SW872 adipocytes were incubated in medium containing 1% (v/v) NCS 
overnight then preincubated in the presence or absence of 30 µM compound C 
or 1 µM eplerenone prior to stimulation with 300 µM A769662 for 24 h. Cell 
lysates were prepared and proteins resolved by SDS-PAGE and immunoblotted 
for P-ACC, SGK1 and GAPDH. A. Representative immunoblots are shown, with 
the molecular masses of marker proteins (in kDa) indicated. B. Quantification 
of SGK1:GAPDH levels. n=4, *p<0.05, two-way ANOVA. P-ACC S79: Phospho-
ACC Ser79. 
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4.2.8.3 The effect of AMPK activators on SGK1 in wild type and 
AMPK knock out mouse embryonic fibroblasts 
Complete AMPK knockout is lethal in mice however mouse embryonic 
fibroblasts lacking either AMPKα catalytic subunit isoform have been 
generated (Laderoute et al. 2006). Therefore, these AMPK knock out mouse 
embryonic fibroblasts were used as a genetic tool lacking AMPK activity 
entirely, to further examine the AMPK-dependence of AICAR- and A769662-
stimulated SGK1 expression. Stimulation of wild type mouse embryonic 
fibroblasts with AICAR or A769662 for 24 h markedly stimulated ACC 
phosphorylation, whereas ACC phosphorylation was entirely lacking in AMPK 
knock out mouse embryonic fibroblasts. Unlike SW872 adipocytes, A769662 
had no effect on SGK1 levels. Furthermore, AICAR also had no effect on SGK1 
levels in wild type mouse embryonic fibroblasts. Intriguingly, AICAR, but not 
A769662 stimulated a significant 181% increase in SGK1 in the knock out 
fibroblasts (p=0.008)(Fig. 4.11). 
  
4.2.8.4 The effect of compound C and eplerenone on A769662 
effects on mineralocorticoid receptor expression in SW872 
adipocytes 
The results described suggest that decreasing AMPK activity using 
pharmacological or genetic tools leads to an exacerbation of the observed 
effects of AMPK activators on SGK1. Given A769662 markedly reduced 
mineralocorticoid receptor levels in SW872 adipocytes (Fig. 4.4), the effect of 
pre-incubation with compound C or eplerenone was examined on the 
reduction of MR levels after 24 h. After 24 h A769662 did not increase ACC 
phosphorylation whilst compound C decreased AMPK activity. Prior addition of 
compound C led to a further decrease of mineralocorticoid receptor protein 
expression in response to A769662 in SW872 adipocytes (A769662 decreased 
MR by 36% whereas compound C with A769662 decreased MR by 82% compared 
to compound C alone p=0.0074). Similarly, eplerenone had no independent 
effect on expression of the MR and rather than inhibit the effects of A769662, 
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they were more pronounced (88% reduction in MR compared to eplerenone 
alone, p=0.0042) (Fig. 4.12).  
 
4.2.9 The effect of A769662 on AMPK protein expression in 
SW872 adipocytes 
In view of these data, the effect of prolonged stimulation with A769662 on 
AMPK levels was examined. AMPKα1 is the predominant catalytic isoform in 
adipocytes in terms of activity in whole cell extracts (Bijland et al. 2013). 
After 8 h incubation with A769662, ACC phosphorylation was increased 2.5 
fold (p=0.0489) but after 24 h activity had returned to baseline. However, 
AMPK phosphorylation was unchanged from basal levels following 8 h 
incubation with A769662, yet after 24 h it had significantly reduced (P-
AMPK:GAPDH 71% reduction, p=0.0001; P-AMPK:AMPK 22% reduction, 
p=0.0244). Indeed, following 24 h of stimulation with A769662, total levels of 
AMPKα1 protein decreased by 60% (p=0.0007) (Fig. 4.13).  
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Figure 4.11 The effect of A769662 on SGK1 levels in 
mouse embryonic fibroblasts lacking AMPKα. 
Mouse embryonic fibroblasts containing (WT) or lacking (KO) AMPKα were 
incubated overnight in medium containing 1% (v/v) NCS then stimulated with 
AICAR (500 µM) or A769662 (30 µM) for 24 h. Cell lysates were prepared and 
proteins resolved by SDS-PAGE and immunoblotted for the indicated proteins. 
A. Representative immunoblots are shown, with the molecular masses of 
marker proteins (in kDa) indicated. B. Quantification of SGK-1 levels relative 
to GAPDH. n=3, two-way ANOVA **p<0.01.P-ACC S79: Phospho-ACC Ser79. 
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Figure 4.12 The effect of compound C on A769662 
mediated mineralocorticoid receptor downregulation 
SW872 adipocytes were incubated in medium containing 1% (v/v) NCS 
overnight then preincubated in the presence or absence of 30 µM compound C 
or 1 µM eplerenone prior to stimulation with 300 µM A769662 for 24 h. Cell 
lysates were prepared and proteins resolved by SDS-PAGE and immunoblotted 
for indicated proteins. A. Representative immunoblots are shown, with the 
molecular masses of marker proteins (in kDa) indicated. B. Quantification of 
MR levels relative to GAPDH n=3, two-way ANOVA **p<0.01. P-ACC S79: 
Phospho-ACC Ser79. 
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Figure 4.13 The effect of A769662 on AMPK protein 
expression in SW872 adipocytes. 
SW872 adipocytes were incubated in medium containing 1% (v/v) NCS 
overnight prior to stimulation with 300 µM A769662 for the times indicated. 
Cell lysates were prepared, proteins resolved by SDS-PAGE and 
immunoblotted for the indicated proteins. A. Representative immunoblots 
are shown, with the molecular masses of marker proteins (in kDa) indicated.  
B. Quantification of AMPK levels relative to GAPDH. n=3, one-way ANOVA 
***p<0.001. P-ACC S79, Phospho-ACC Ser79; P-AMPK T172, Phospho-
AMPKαThr172; T-AMPK, total AMPKα1. 
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4.2.10 The effect of aldosterone on AMPK activity in murine 
adipose tissue 
As shown in Figures 4.6 and 4.7, stimulation of adipocyte cell lines with AMPK 
activators stimulated aldosterone secretion, SGK protein levels and StAR 
mRNA expression. Whether aldosterone regulates AMPK in adipose tissue 
remains uncharacterised, however. To assess the effects of aldosterone on 
adipose tissue AMPK and inflammatory processes, phosphorylation of AMPKα 
and ACC was examined in whole epididymal adipose tissue lysates from mice 
treated with or without aldosterone infusion. Aldosterone infusion had no 
effect on ACC or AMPK phosphorylation in epididymal adipose tissue (Fig. 
4.14). However, there was a significant increase in SGK1 protein levels in 
adipose tissue of mice infused with aldosterone (3.5-fold increase, 
p=0.0013)(Fig. 4.15A and B). In addition, protein levels of MR, NGAL and MCP-
1 were not significantly affected by aldosterone infusion (Fig. 4.15A, C, D and 
E).  
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Figure 4.14 The effect of aldosterone on AMPK activity 
in murine adipose tissue 
Epididymal adipose tissue lysates were prepared from 12-week old wild type 
mice (C57/Bl6J/FV129) treated with saline or aldosterone infusion (600 
mcg/kg/d) for 28 days. Protein was resolved by SDS-PAGE and immunoblotted 
for the indicated proteins. A. Representative immunoblots with the 
molecular masses of marker proteins (in kDa) shown. Quantification of B. P-
ACC levels relative to GAPDH and C. P-AMPK levels relative to AMPK, n=7 in 
each group. 
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Figure 4.15 The effect of aldosterone on MR, SGK1 and 
pro-inflammatory protein levels in murine adipose 
tissue 
Epididymal adipose tissue lysates were prepared from 12-week old wild type 
mice (C57/Bl6J/FV129) treated with saline or aldosterone infusion (600 
mcg/kg/d) for 28 days. Protein was resolved by SDS-PAGE and immunoblotted 
for the indicated proteins. A. Representative immunoblots with the 
molecular masses of marker proteins (in kDa) shown. Quantification of B. MR 
levels, C. SGK1 levels, D. NGAL levels and E. MCP-1 levels relative to GAPDH. 
n=7 in each group, unpaired t-test **p<0.01. Mann Whitney test for C. 
p=0.0023.  
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4.3 Discussion 
Adipose tissue dysfunction is implicated early in the pathogenesis of 
metabolic disorders such as type 2 diabetes (Esser et al. 2014). Upregulation 
of the renin-angiotensin-aldosterone system (RAAS) has been proposed as a 
contributing factor to the disordered lipid storage and adipokine secretion 
which can occur in such conditions (Jing et al. 2013). Altering the activity of 
the local adipose tissue RAAS may therefore be a strategy for preventing 
metabolic disease processes. The energy regulator AMPK has been 
demonstrated to have anti-inflammatory (Bijland et al. 2013, Mancini et al. 
2017) and vasculo-protective properties (Salt and Hardie, 2017). At the 
beginning of this work a handful of studies, reviewed in 1.5, demonstrated 
that AMPK activation could inhibit RAAS effects, since then two recent studies 
have added to this literature. These studies showed that metformin, via 
AMPK, attenuates detrimental effects of angiotensin II in models of vascular 
endoplasmic reticulum stress (Duan et al. 2017) and cardiac fibrosis (Chen et 
al. 2018). 
 
This chapter examined the effects of AMPK activation on expression and 
secretion of components of the RAAS within the cultured adipocyte models 
3T3-L1 (murine) and SW872 (human). The key findings in this chapter were 
that activation of AMPK was associated with increased secretion of 
aldosterone and expression of the downstream MR target SGK1 in addition to 
decreased expression of the MR in SW872 adipocytes. 
 
The initial hypothesis was that AMPK activation would downregulate the 
classical RAAS in adipocytes. In 3T3-L1 adipocytes, prolonged AICAR exposure 
downregulated gene expression of the AT2R and the MR. In SW872 adipocytes, 
incubation with AICAR decreased expression of angiotensinogen and the MR 
after 9 and 25 h. These effects on angiotensinogen and the MR were 
replicated by incubation with A769662 in SW872 adipocytes. Focus is drawn to 
the effects on the MR which is consistent between species and with both 
AMPK activators. A significant decrease in MR protein was confirmed with 
A769662 in SW872 adipocytes. Knowing that there is an increase in adipose 
tissue MR in obesity (Hirata et al. 2012) and that MR blockade can have 
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metabolic benefits (Sindelka et al. 2000, Wada et al. 2010), it would be of 
great interest to evaluate the effect of AMPK activation on MR expression in 
human adipose tissue. 
 
Angiotensinogen is the initial precursor of the RAAS. In the human SW872 
adipocyte model both AICAR and A769662 significantly decreased gene 
expression of angiotensinogen. Rodent studies with adipose tissue specific 
angiotensinogen knockout mice have found resistance to high fat diet-induced 
glucose intolerance and blood pressure elevation despite unchanged weight 
gain (Yiannikouris et al. 2012, LeMieux et al. 2016). Similarly, overexpression 
of angiotensinogen in adipose tissue was associated with increased adiposity, 
insulin resistance and adipose tissue inflammation (Kalupahana et al. 2012). 
Adipose tissue angiotensinogen also appears to be regulated by weight and 
insulin in humans. In obese individuals a 5% weight loss decreased both 
adipose tissue angiotensinogen and circulating angiotensinogen (Engeli et al. 
2005). Subcutaneous adipocytes exposed to insulin ex vivo showed an 
incremental increase in angiotensinogen protein expression with increasing 
concentrations of insulin (Harte et al. 2003), which is consistent with 
hyperinsulinaemia having an important early role in metabolic syndrome. 
These studies highlight the potential impact of the local adipose tissue RAAS 
on systemic blood pressure and metabolic function. The finding that AMPK 
activators downregulate angiotensinogen in the human adipocyte model used 
here may be linked to the association between decreased AMPK and increased 
angiotensinogen identified in obese insulin resistant individuals by Xu et al 
(2012) highlighted in 4.1.1. However, in 3T3-L1 adipocytes gene expression of 
angiotensinogen was not affected by AICAR at a concentration which 
activated AMPK, such that this may alternatively therefore be a species-
specific effect of AMPK. 
 
The finding that angiotensinogen and the MR may be negatively regulated by 
AMPK activation is consistent with the beneficial known metabolic effects of 
AMPK. The alternative arm of the RAAS which has been identified as 
counteracting many of the traditional actions of angiotensin II was therefore 
of interest. This study has identified that AMPK may regulate the alternative 
RAAS as well as the classical RAAS in adipocytes. The expression of ACE was 
 135 
decreased following AICAR exposure and ACE 2 was increased with A769662. 
Although the two AMPK activators have had different effects they both drive 
the system towards the alternative RAAS with AICAR significantly increasing 
the ACE 2:ACE ratio. Indeed the widely prescribed ACE inhibitors, discussed in 
detail in chapter 1, are known to prevent new onset diabetes and have been 
shown to activate AMPK (Scheen 2004, Tian et al. 2014). It would be of 
interest to study the effect of AMPK activators on ACE and ACE 2 activity in 
adipocytes in addition to expression. 
 
The secretion of aldosterone from adipocytes was first identified in 2012 and 
may regulate local vascular tone in adipose tissue and in vessels within 
perivascular adipose tissue (Briones et al. 2012). Another key finding reported 
here is the increase in aldosterone secretion from adipocyte models in 
response to AMPK activators and a corresponding increase in StAR. This is an 
interesting finding considering the downregulation of the RAAS precursor 
angiotensinogen, however there are stimuli of aldosterone secretion other 
than angiotensin II. One possible explanation for this finding is that in 
response to cellular stress or low energy states, AMPK is activated and 
aldosterone is secreted in order to increase vascular tone and decrease blood 
(and nutrient) delivery to adipose tissue as storage is not required. It may also 
be worth considering that the mitochondria are the site of steroidogenesis, 
and mitochondrial biosynthesis is increased by AMPK (Hardie et al. 2012). It 
may purely be an increase in number of mitochondria leading to increased 
aldosterone production. The effects of AMPK activation on steroidogenesis 
have previously been studied in the adrenal gland and the gonads but not in 
adipose tissue. AMPK signalling was required for the adiponectin-mediated 
increase in cortisol production from the adrenocortical cell line H295R 
(Ramanjaneya et al. 2011). However, AICAR inhibited hCG- and forskolin-
induced steroidogenesis in leydig cells and had no autonomous effect on 
hormone release (Abdou et al. 2014). These cell-based studies suggest a role 
for AMPK in steroidogenesis in adrenal but not testicular steroidogenesis. At a 
systemic level, it has been reported that the AMPK activating diabetes 
medications metformin and pioglitazone are associated with decreased 
circulating aldosterone levels (Eguchi et al. 2007), this discrepancy from the 
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current study could be due to direct effects on the adrenal gland or 
potentially more long term effects of AMPK activation.  
 
Effects of AMPK activation on serum and glucocorticoid inducible protein 
kinase 1 (SGK1), a downstream target of the MR, were next examined (Terada 
et al. 2012). SGK1 has been identified in adipocytes where it is induced by 
aldosterone and dexamethasone and it is increased in adipose tissue from 
individuals with obesity and diabetes compared to healthy lean individuals (Li 
et al. 2013). In SW872 adipocytes, A769662 induced SGK1 protein expression. 
Prior addition of the AMPK inhibitor compound C did not inhibit this effect of 
A769662, rather unexpectedly it exacerbated the initial rise in SGK1 (at 8 h) 
although this effect was lost by 24 h. Similarly, eplerenone, the MR 
antagonist, did not alter this response. This suggests that the A769662-
stimulated increase in SGK1 levels is neither AMPK- nor MR-dependent. 
Indeed, in wild type MEFs AICAR and A769662 did not induce SGK1, whereas it 
was induced by AICAR in AMPK knockout MEFs. However, following 24 h of 
A769662 exposure in SW872 adipocytes there was a significant downregulation 
of total AMPK protein and markedly reduced ACC phosphorylation, indicative 
of reduced AMPK activity. The impact of 24 h exposure may mimic extreme 
circumstances, such as hypoxia or hypoperfusion, which then become toxic to 
the cell resulting in altered processes including mitochondrial function.  One 
article has examined the effect of AICAR on dexamethasone induced SGK1 and 
found no significant effect, however they did show that as SGK1 increased in 
response to dexamethasone, the tumour suppressor LKB1 was downregulated 
(Lützner et al. 2012). Knowing that LKB1 is one of two upstream AMPK kinases 
(Shaw et al. 2004) raises the question as to whether the observations in this 
report have identified a negative feedback process regulating AMPK activity 
involving aldosterone, the MR, SGK1, LKB1 and AMPK (Fig 4.16).  However, it 
must be taken into consideration that in adipose tissue from mice infused 
with aldosterone, whilst SGK1 was increased, there was no significant effect 
on AMPK activity.  
 
Despite the common effects on angiotensinogen, the MR, aldosterone 
secretion and SGK1 of the AMPK activators used in this study there are some 
discrepancies which should not be overlooked. The possibility of a species 
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specific effect is one potential explanation why AICAR induces effects in 
murine cells whereas A769662 does in human cells but AICAR does not. For 
example, A769662 but not AICAR increased aldosterone secretion in the 
human adipocyte model, whereas AICAR induced SGK1 in KO MEFs but 
A769662 did not. Indeed AICAR and A769662 have different modes of action 
leading to possible non-AMPK mediated effects. AICAR has been widely 
studied as an AMPK activator yet as an AMP mimetic it can affect other 
enzymes that are regulated by or require AMP (Guigas et al. 2009). In 
addition, although A769662 is a highly selective AMPK activator it also has off 
target effects and was shown to inhibit Na+-K+-ATPase in L6 myotubes 
(Benziane et al. 2009). 
 
Figure 4.16 Proposed feedback mechanism regulating 
AMPK-induced aldosterone secretion. 
A769662 activates AMPK which phosphorylates ACC. AMPK activation is known 
to increase number of mitochondria, the site of steroidogenesis. This may 
lead to increased StAR and aldosterone secretion which increases SGK1 via 
the MR. SGK1 may decrease LKB1 and subsequently negatively regulate AMPK. 
Full arrow = positive association, incomplete arrow = negative association.  
 
AMPK% P&ACC%
Mitochondrial%
biogenesis%
StAR%
Aldosterone%
SGK1%
!
MR%
?%LKB1%
A769662%
 138 
In summary, this study has identified that two structurally-unrelated AMPK 
activators, AICAR and A769662, that activate AMPK by different mechanisms, 
negatively regulate classical RAAS components including the mineralocorticoid 
receptor whilst increasing aldosterone secretion in adipocyte models. These 
findings may represent a response to cellular stress where adipocytes play a 
crucial role in regulating nutrient delivery to adipose tissue by increasing 
vascular tone with aldosterone and preventing further (MR-dependent) 
adipogenesis. 
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5 Chapter 5 – The effect of angiotensin II and 
angiotensin 1-7 on AMPK activity in adipocytes 
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5.1 Introduction 
5.1.1 The effects of RAAS components on adipose tissue 
Angiotensin II has been reported to increase the production of pro-
inflammatory adipocytokines from adipose tissue in both humans and rodents, 
suggesting an effect on adipocytes, as well as likely effects on other 
constituent cells of adipose tissue including stromal vascular cells 
(Kalupahana and Moustaid-Moussa, 2012). Mechanistically, angiotensin II-
induced MCP-1 secretion from 3T3-L1 adipocytes was prevented by the NF-κB 
inhibitor BAY-11-7082 and NOX inhibitor apocynin suggesting that the pro-
inflammatory effects of angiotensin II are mediated by NF-κB and NOXs 
(Kalupahana et al. 2012).  Although angiotensin receptor blockers and ACE 
inhibitors have metabolic benefits and can reduce the incidence of type 2 
diabetes, angiotensin II was reported to enhance insulin signalling and glucose 
uptake in rat adipocytes ex vivo (Juan et al. 2005).  
 
Angiotensin II can be converted to ang 1-7 by ACE 2 (Patel et al. 2016). Ang 1-
7 acts via the Mas receptor and has predominantly been studied in the 
cardiovascular system where it opposes angiotensin II effects and is therefore 
regarded as part of the ‘alternative RAS’ (Patel et al. 2016). In adipocytes, 
ang 1-7 also appears to have metabolic benefits. Ang1-7 enhanced basal and 
insulin stimulated glucose uptake in isolated C57 mouse epidydimal 
adipocytes and reduced ROS whilst increasing adiponectin expression in 3T3-
L1 adipocytes (Liu et al. 2011). These actions were blocked by the Mas 
receptor antagonist A779 (Liu et al 2011). In transgenic rats secreting 
supraphysiological levels of ang 1-7, insulin sensitivity improved and body 
weight reduced compared to Sprague Dawley rats. Furthermore, there was an 
associated increase in circulating adiponectin suggesting an influence on 
adipose tissue (Santos et al. 2010). In addition, there was a decrease in 
angiotensinogen expression yet no change in expression of TNF-α or TGF-β 
was detected in adipose tissue of the transgenic rats (Santos et al. 2010). 
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There are therefore opposing potential metabolic actions of the classical and 
alternative RAS in adipose tissue which may become polarised towards the 
classical RAS in obesity. Rebalancing this system appears to have therapeutic 
potential in the context of obesity and diabetes and better understanding of 
the underlying mechanisms is therefore crucial in the search for preventative 
strategies. 
 
5.1.2 The effect of RAAS components on AMPK activity 
There is a small literature available regarding the cross-talk between AMPK 
and RAAS in cells relevant to cardiovascular and renal systems. In vascular 
smooth muscle cells (VSMCs) angiotensin II activated AMPK in an AT1 receptor-
dependent manner (Nagata et al. 2004). However, in primary rat neonatal 
cardiomyocytes angiotensin II reduced AMPK activity (Stuck et al. 2008). 
Consistent with this AMPK activity was also reduced by angiotensin II in a 
renal model of fibrosis using HK2 tubular epithelial cells (Lee et al. 2013).  
The effect of angiotensin II on AMPK activity therefore varies in different 
cardiovascular cell types. The RAAS is now known to be an important factor in 
the pathogenesis of metabolic disorders yet the effect of angiotensin II on 
AMPK in metabolic cells and tissues such as adipocytes remains unknown.  
 
5.1.3 Aims 
Given the lack of published studies investigating the actions of the classical 
and alternative RAS in adipocytes, the effects of angiotensin II and ang 1-7 on 
AMPK, inflammatory and insulin signalling pathways were examined in human 
and murine adipocyte models.  
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5.2 Results 
5.2.1 The effects of angiotensin II in SW872 adipocytes 
5.2.1.1 Angiotensin II signalling in SW872 adipocytes 
Angiotensin II has previously been reported to have pro-inflammatory effects 
in cultured adipocytes (Kalupahana et al. 2012). The effect of angiotensin II 
on proinflammatory and AMPK signalling in SW872 adipocytes was therefore 
examined. IL-1β (10 ng/ml, 5 and 15 min) and AICAR (1 mM, 1 h) were used as 
positive controls.  Angiotensin II (5 min) and AICAR both significantly 
increased ACC phosphorylation, however the level of phosphorylation was far 
greater with AICAR (Ang II 29% increase at 5 min, p=0.0084; AICAR 197% 
increase, p=0.0186)(Fig. 5.1B). IL-1β had no significant effect on ACC 
phosphorylation. Given that the angiotensin II-induced ACC phosphorylation 
was small an AMPK activity assay was carried out. Angiotensin II did not 
significantly increase AMPK activity (p=0.089) (Fig. 5.5B). 
 
The ERK signalling pathway is known to mediate effects of angiotensin II via 
the AT1R (Turner et al. 2001). In this study, activating ERK phosphorylation 
was not significantly affected by angiotensin II or IL-1β (Fig. 5.1C). 
Phosphorylation of NF-κB was significantly increased by IL-1β at both 5 and 15 
min (2.27 fold increase at 5 min, 2.07 fold increase at 15 min, p=0.0001) 
whilst neither angiotensin II nor AICAR had any effect (Fig. 5.1D). 
 
5.2.1.2 The mechanism of angiotensin II mediated AMPK 
signalling in SW872 adipocytes 
As angiotensin II activated AMPK activity, as assessed by ACC phosphorylation 
in SW872 adipocytes, further experiments were performed to explore the 
mechanism. As these cells had low transcript levels for the AT1R, it was likely 
that the AMPK activation was mediated by the AT2R. Therefore cells were 
preincubated with the AT2R antagonist PD123319 prior to stimulation with 
different concentrations of angiotensin II for 5 min (Fig. 5.2A).  Angiotensin II 
(100 nM) significantly increased ACC phosphorylation (p=0.012) yet at higher 
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concentrations no significant effect was observed. However, ACC 
phosphorylation tended to be increased in the presence of PD123319, whilst 
additional incubation with angiotensin II did not increase ACC phosphorylation 
at any concentration (Fig. 5.2B).  Again, a small effect of angiotensin II was 
seen and the previously significant increase seen with 10 µM was no longer 
present.  
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Figure 5.1 The effect of angiotensin II on AMPK and 
inflammatory signalling in SW872 adipocytes 
SW872 adipocytes were incubated in serum free media for 2 h then 
stimulated with angiotensin II (10 µM) or IL-1β (10 ng/ml) for 5 or 15 min as 
indicated or AICAR (1 mM) for 1 h. Cell lysates were prepared, proteins 
resolved by SDS-PAGE and immunoblotted for the indicated proteins. A. 
Representative immunoblot with the molecular masses of marker proteins (in 
kDa) shown. Quantification of B. (P-, phospho-) P-ACC levels relative to ERK1, 
C. P-ERK1 levels relative to ERK1 and D. P-NFκB levels relative to NFκB. n=3, 
B. unpaired t-test, D. one-way ANOVA, *p<0.05, **p<0.01, ****p<0.0001. 
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Figure 5.2 The effect of angiotensin II on AMPK 
signalling in SW872 adipocytes 
SW872 adipocytes were incubated in 1% NCS (v/v) overnight then stimulated 
with angiotensin II at concentrations indicated for 5 min after preincubation 
for 1 h in the presence or absence of 10 µM PD123319 (Mabrouk et al. 2001). 
Cell lysates were prepared, proteins resolved by SDS-PAGE and 
immunoblotted for the indicated proteins. A. Representative immunoblot 
with the molecular masses of marker proteins (in kDa) shown. B. 
Quantification of phospho-ACC (P-ACC) levels relative to ERK1. n=3, unpaired 
t-test *p<0.05. 
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5.2.2 The effect of ang 1-7 in SW872 adipocytes 
5.2.2.1 The effect of ang 1-7 on AMPK activity in SW872 
adipocytes 
Subsequent experiments focused on ang 1-7 to further explore the effect of 
the alternative RAS on AMPK activity.  Ang 1-7 (1 µM) was applied to SW872 
adipocytes for different durations or at different concentrations for 10 min. 
After 2 min, 1 µM ang 1-7 significantly increased phosphorylation of ACC (35% 
increase, p=0.0161) (Fig. 5.3B) whilst AMPK phosphorylation was significantly 
increased at 30 and 60 min (30 min 59% increase, p=0.004; 60 min 58% 
increase, p=0.0087) (Fig. 5.3C).  After 10 min, AMPK phosphorylation was 
increased by ang 1-7 at concentrations of 30 nM (55% increase, p<0.0001), 100 
nM (47% increase, p=0.0002), and 1 µM (42% increase, p=0.0276) (Fig 5.4C), 
whilst ACC phosphorylation was significantly increased by 30 nM ang 1-7 (89% 
increase, p=0.0087) but not higher concentrations (Fig. 5.4B). This increase in 
AMPK and ACC phosphorylation was associated with increased AMPK activity, 
assessed in AMPK immunoprecipitates. A 94% increase in AMPK activity was 
detected in SW872 adipocytes following exposure to ang 1-7 for 2 min 
(p=0.0167) (Fig. 5.5A). 
 
5.2.2.2 The mechanism of ang 1-7 induced AMPK signalling in 
SW872 adipocytes 
In order to determine the mechanism of AMPK activation by ang 1-7, SW872 
adipocytes were pretreated with selective inhibitors of Mas (A779), AT2R 
(PD123319) and the AMPK Thr172 kinase, CaMKK (STO-609) prior to the 
application of ang 1-7 or AICAR. Compared to control ang 1-7 tended to 
modestly increase ACC phosphorylation (p=0.066) whilst AICAR led to a much 
greater increase in ACC phosphorylation (p=0.0002)(Fig. 5.6B). When 
compared to STO-609, A779 and PD123319 the tendency for angiotensin 1-7 to 
increase ACC phosphorylation was lost whilst AICAR still increased ACC 
phosphorylation (Fig 5.6A). 
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Figure 5.3 The effect of ang 1-7 on AMPK signalling in 
SW872 adipocytes 
SW872 adipocytes were incubated in 1% NCS (v/v) overnight then stimulated 
with ang 1-7 (1 µM) for durations indicated. Cell lysates were prepared, 
proteins resolved by SDS-PAGE and immunoblotted for the indicated proteins. 
A. Representative immunoblot with the molecular masses of marker proteins 
(in kDa) shown. B. Quantification of phospho-ACC (P-ACC) levels relative to 
GAPDH. C. Quantification of P-AMPK levels relative to AMPK. n=4, unpaired t-
test *p<0.05, **p<0.01. 
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Figure 5.4 The effect of ang 1-7 on AMPK signalling in 
SW872 adipocytes 
SW872 adipocytes were incubated in 1% NCS (v/v) overnight then stimulated 
with ang 1-7 at concentrations indicated for 10 min. Cell lysates were 
prepared, proteins resolved by SDS-PAGE and immunoblotted for the 
indicated proteins. A. Representative immunoblot with the molecular masses 
of marker proteins (in kDa) shown. B. Quantification of phospho-ACC (P-ACC) 
levels relative to GAPDH. C. Quantification of P-AMPK levels relative to 
AMPK. n=3, unpaired t-test *p<0.05, ***p<0.001, ****p<0.0001. 
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Figure 5.5 Effect of ang 1-7 and angiotensin II on AMPK 
kinase activity 
SW872 adipocytes were incubated in 1% NCS (v/v) overnight then stimulated 
with A. ang 1-7 (1 µM) for 2 min or B. angiotensin II (10 µM) for 5 min. Cell 
lysates were prepared, AMPK immunoprecipitated and AMPK activity assayed 
in duplicate. n=3, unpaired t-test *p<0.05. 
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Figure 5.6 The mechanism of ang 1-7 induced AMPK 
signalling in SW872 adipocytes 
SW872 adipocytes were incubated in 1% NCS (v/v) overnight then 
preincubated in the presence or absence of STO-609 (10 µM) (Nguyen et al. 
2016), A779 (1 µM) (Liu et al. 2012) or PD123319 (10 µM) for 1 h prior to 
stimulation with ang 1-7 (100 nM) for 2 min or AICAR (1 mM) for 1 h. Cell 
lysates were prepared, proteins resolved by SDS-PAGE and immunoblotted for 
the indicated proteins. A. Representative immunoblot with the molecular 
masses of marker proteins (in kDa) shown. B. Quantification of phospho-ACC 
(P-ACC) levels relative to GAPDH. n=3, unpaired t-test, *p<0.05, ***p<0.001. 
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5.2.2.3 The effect of AMPK activators and ang 1-7 on CXCL-10 
expression and secretion from SW872 adipocytes 
During the course of this study, work in our laboratory demonstrated that 
AMPK has anti-inflammatory actions in cultured 3T3-L1 adipocytes, 
significantly inhibiting IL-1β-stimulated secretion of the chemokine CXCL-10 
(Mancini et al. 2017).  The impact of AMPK activators AICAR and A769662 as 
well as ang 1-7 on IL-1β-stimulated CXCL-10 mRNA expression was therefore 
assessed in SW872 adipocytes. Figure 5.7 demonstrates that IL-1β (10 ng/ml 
for 6 h) significantly increased CXCL-10 mRNA levels in SW872 adipocytes 
(p=0.0004) and that this effect was attenuated by pre-incubation with AICAR 
(p=0.001) or A769662 (p=0.02).  
 
To assess the functional impact of the ang 1-7-mediated AMPK activation on 
IL-1β stimulated CXCL-10 mRNA levels and protein secretion, SW872 
adipocytes were stimulated with ang 1-7 for 30 min prior to incubation with 
IL-1β (10 ng/ml for 8 h) (Fig. 5.8). Again, IL-1β significantly increased CXCL-10 
mRNA levels and also increased CXCL-10 secretion into the culture medium. 
However, pre-incubation with ang 1-7 did not affect IL-1β-stimulated CXCL-10 
mRNA levels (Fig. 5.8A) or CXCL-10 secretion (Fig. 5.8B). 
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Figure 5.7 The effects of AMPK activators on CXCL-10 
expression in SW872 adipocytes 
RNA was extracted from SW872 adipocytes incubated in the presence or 
absence of IL-1β (10 ng/ml) for 6 h with or without the 1 h prior addition of 
AICAR (1 mM) or the 30 min prior addition of A769662 (300 µM). Reverse 
transcription was carried out prior to Taqman qPCR assays for CXCL-10. Data 
are normalised to TATA-binding protein mRNA expression. n=3, two-way 
ANOVA, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.8 The effects of ang 1-7 on CXCL-10 expression 
and secretion in SW872 adipocytes 
RNA was extracted and ELISA performed on culture medium from SW872 
adipocytes incubated in the presence or absence of ang 1-7 (100 nM) for 30 
min prior to stimulation in the presence or absence of IL-1β (10 ng/ml) for 8 
h. A. Reverse transcription was carried out prior to Taqman qPCR assays for 
CXCL-10. Data are normalised to TATA-binding protein mRNA expression. B. 
CXCL-10 ELISA was performed and data quantified. n=4, two-way ANOVA, 
**p<0.01, ****p<0.0001. 
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5.2.3 The effect of ang 1-7 in 3T3-L1 adipocytes 
5.2.3.1 The effect of ang 1-7 on AMPK signalling in 3T3-L1 
adipocytes 
Given the findings in SW872 adipocytes, the effect of ang 1-7 on AMPK in 3T3-
L1 adipocytes was assessed, in addition to its impact on insulin signalling and 
glucose transport. Stimulation of 3T3-L1 adipocytes with ang 1-7 significantly 
increased ACC phosphorylation within 5 min, an effect that was sustained at 
30 and 60 min (5 min 81% increase, p=0.0058; 30 min 134% increase, 
p=0.0018; 60 min 60% increase, p=0.0148)(Fig. 5.9B). 
 
5.2.3.2 The mechanism of ang 1-7 signalling in 3T3-L1 
adipocytes 
Similar experiments to those described in 5.2.2.2 were performed in 3T3-L1 
adipocytes to assess Mas-, AT2R- and CaMKK-dependence of ang 1-7-
stimulated ACC phosphorylation. ACC phosphorylation tended to be increased 
by ang 1-7 whilst AICAR increased it robustly (p=0.002). The small tendency to 
increase phosphorylated ACC by ang 1-7 was lost in the presence of STO-609 
and A779 yet maintained in the presence of PD123319 (Fig. 5.10B). However, 
as these effects were small and did not reach statistical significance the exact 
mechanism cannot be confirmed. 
 
5.2.3.3 The effect of ang 1-7 on insulin signalling in 3T3-L1 
adipocytes 
As previously described, 3T3-L1 adipocytes are an excellent tool for the 
assessment of insulin signalling and insulin-stimulated glucose transport. To 
determine whether ang 1-7 influenced insulin signalling in 3T3-L1 adipocytes, 
cells were preincubated with ang 1-7 or AICAR prior to insulin stimulation and 
the phosphorylation of ERK, Akt and the Akt substrate, AS160 assessed. Insulin 
markedly increased phosphorylation of ERK1/2, Akt and AS160 (p<0.0001), 
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whereas ang 1-7 had no effect on basal or insulin-stimulated phosphorylation 
of any of these proteins. Intriguingly, AICAR increased basal Akt and AS160 
phosphorylation without influencing insulin-stimulated phosphorylation of 
ERK1/2, Akt or AS160 (Fig 5.11). 
 
5.2.3.4 The effects of ang 1-7 on glucose uptake in 3T3-L1 
adipocytes 
To determine the effects of ang 1-7 on insulin stimulated glucose transport, 
3T3-L1 adipocytes were stimulated with insulin in the presence or absence of 
ang 1-7. Insulin stimulation increased glucose uptake 2.3-fold (p=0.0421) 
whilst ang 1-7 alone had no effect on basal or insulin stimulated glucose 
uptake (Fig. 5.12). 
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Figure 5.9 The effect of ang 1-7 on AMPK signalling in 
3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated in serum free media for 2 h then 
stimulated with ang 1-7 (1 µM) for durations indicated. Cell lysates were 
prepared, proteins resolved by SDS-PAGE and immunoblotted for the 
indicated proteins. A. Representative immunoblot with the molecular masses 
of marker proteins (in kDa) shown. B. Quantification of phospho-ACC (P-ACC) 
levels relative to GAPDH. n=3, unpaired t-test *p<0.05, **p<0.01. Repeat 
analysis using non-parametric test (Kruskal-Wallis) significant at 30 min, 
p=0.0366. 
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Figure 5.10 The mechanism of ang 1-7 signalling in 3T3-
L1 adipocytes 
3T3-L1 adipocytes were incubated in serum free media for 2 h then incubated 
in the presence or absence of STO-609 (10 µM), A779 (1 µM) or PD123319 (10 
µM) for 1 h prior to stimulation with ang 1-7 (1 µM) for 30 min or AICAR (1 
mM) for 1 h. Cell lysates were prepared, proteins resolved by SDS-PAGE and 
immunoblotted for the indicated proteins. A. Representative immunoblot 
with the molecular masses of marker proteins (in kDa) shown. B. 
Quantification of phospho-ACC (P-ACC) levels relative to GAPDH. n=3, 
unpaired t-test **p<0.01. 
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Figure 5.11 The effect of ang 1-7 and AICAR on insulin 
signalling in 3T3-L1 adipocytes 
3T3-L1 adipocytes were incubated in serum free media for 2 h then 
stimulated with ang 1-7 (1 µM) for 30 min or AICAR (1 mM) for 1 h prior to 
insulin (100 nM) for 15 min. Cell lysates were prepared, proteins resolved by 
SDS-PAGE and immunoblotted for the indicated proteins. A. Representative 
immunoblot with the molecular masses of marker proteins (in kDa) shown. B. 
Quantification of phospho-ERK1 (P-ERK) levels relative to ERK1, C. phospho-
Akt (P-Akt) levels relative to Akt and D. phospho-AS160 (P-AS160) levels 
relative to GAPDH. n=3, two-way ANOVA, *p<0.05, ****p<0.0001. 
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Figure 5.12 The effect of ang 1-7 on insulin-stimulated 
glucose transport in SW872 adipocytes 
3T3-L1 adipocytes were incubated for 2 h in serum free DMEM then media 
changed to KRP + 0.1% (w/v) BSA for 1 h. Cells were subsequently stimulated 
with ang 1-7 (1 µM) for 30 min before addition of insulin (100 nM) for 10 min.  
2-deoxy-3H-glucose uptake was then assessed over 3 min, n=3, unpaired t-test 
*p<0.05. 
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5.3 Discussion 
This chapter studied the effects of angiotensin hormones on AMPK signalling 
along with pro-inflammatory and insulin signalling pathways in cultured 
adipocytes. The initial finding that angiotensin II activated AMPK and this 
effect may be mediated by the AT2R led to investigation of the alternative 
RAAS focusing on angiotensin 1-7 which was also demonstrated to activate 
AMPK.  
 
Aside from increasing aldosterone, angiotensin II has direct effects which are 
implicated in the development of metabolic syndrome. Plasma angiotensin II 
levels are elevated in obesity and ACE inhibitors and AT1R antagonists have 
been shown to prevent new onset type 2 diabetes (Goossens, 2012; Abuissa et 
al. 2005). The pro-diabetic effects of angiotensin II are therefore likely 
mediated by the AT1R. As previously discussed, the other angiotensin II 
receptor, AT2R, can mediate opposing effects to the AT1R. In this study, 
angiotensin II did not increase ERK 1/2 or NF-κB signalling in SW872 
adipocytes. These pathways have previously been shown to mediate AT1R- 
mediated effects of angiotensin II (Than et al. 2012; Kalupahana et al. 2011) 
in adipocyte models.  What was demonstrated was a rapid, yet modest, 
increase in the AMPK signalling which may, therefore, be mediated by the 
AT2R. In SW872 adipocytes angiotensin II initially activated AMPK at 10 µM yet 
when the concentration dependence was assessed, the increase in AMPK 
activity was only demonstrated at 100 nM. This inconsistency is likely a result 
of the modest activation observed at 10 µM and the variability in response. 
Indeed, increased AMPK activity was not confirmed by kinase assay. 
Differential effects of angiotensin II have been reported on AMPK activity in 
different cell types as outlined in 5.1.2. The other cell type in which AMPK 
has previously been reported to be activated by angiotensin II are VSMCs. In 
that case the stimulation of AMPK was reported to be via the AT1R at a 
concentration of 100 nM (Nagata et al. 2004). Interestingly, one study of AT2R 
knock out mice found smaller adipocytes and a protection from high fat diet 
induced obesity and insulin resistance thus implicating the AT2R in metabolic 
syndrome (Yvan-Charvet et al. 2005) which somewhat opposes the large 
clinical data on AT1R blockade. The absence of the AT1R in SW872 adipocytes 
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likely renders this model somewhat unique as actions may be swayed towards 
the alternative RAS. For this reason this study went on to explore the effects 
of ang 1-7. 
 
This work demonstrated for the first time that ang 1-7 activates AMPK in 
human and murine derived adipocyte models.  The mechanism of activation is 
likely to be Ca2+- and MAS receptor- dependent. In keeping with this, the MAS 
receptor is a G-protein coupled receptor with Ca2+ considered a potential 
secondary messenger (Tirupula et al. 2014). One previous study identified 
AMPK activation in aortas from rats 10 min following an injection of ang 1-7 
(Karpe and Tikoo, 2014). This occurred along with Akt and eNOS 
phosphorylation and activation (Karpe and Tikoo, 2014). In the present study, 
AMPK activation was rapid in SW872 adipocytes yet more sustained in 3T3-L1 
adipocytes. Ang 1-7 did not increase Akt phosphorylation in 3T3-L1 
adipocytes. It is worth noting that when compared to AICAR-stimulated ACC 
phosphorylation ang 1-7 was a far less potent stimulus and when the 
concentration-dependence was assessed the response of ACC phosphorylation 
to ang 1-7 was quite variable. This may be related to the length of exposure 
as ACC phosphorylation peaked rapidly in SW872 adipocytes whereas the AMPK 
phosphorylation appeared more sustained, as the concentration-dependence 
was determined after 10 min. As a consequence, it may be that the ACC 
phosphorylation had diminished in this time frame. However, contrary to the 
response to angiotensin II, when kinase assay was performed it confirmed 
increased activity in response to ang 1-7. The functional impact of this AMPK 
activation in adipocytes was explored by studying processes which are known 
to be influenced by AMPK and important in the pathogenesis of obesity and 
diabetes – inflammation and glucose transport (Bijland et al. 2013).   
 
Ang 1-7 has previously been shown to increase production of the archetypal 
adipokines adiponectin and leptin (Santos et al. 2010, Uchiyama et al. 2017) 
and in 2013 it was reported to promote adipogenesis in cultured cells (Than et 
al. 2013). It has also been proposed to mediate the metabolic benefits of 
captopril as the decreased weight gain and adipose tissue mass associated 
with this ACE inhibitor were attenuated by A779, the mechanism was 
proposed to be related to phosphorylation of hormone sensitive lipase (Oh et 
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al. 2012). In this study, the AMPK activators AICAR and A769662 attenuated IL-
1β-induced increases in CXCL-10 mRNA levels. In contrast, when ang 1-7 was 
applied prior to the addition of IL-1β there was no significant affect on the 
induction of CXCL-10 at the level of gene expression or protein secretion. This 
may be due to the modest degree of AMPK activation compared with that in 
response to AICAR or A769662. Similarly, no significant effect on either 
glucose transport or insulin signalling were identified in this study, suggesting 
that the role of ang 1-7 in adipocytes is not to acutely regulate insulin 
signalling. Within the literature there is a report of ang 1-7 enhancing basal 
and insulin-stimulated glucose transport in primary epididymal adipocytes (Liu 
et al. 2012). In the study of Liu et al. 1 nM ang 1-7 was used which is a major 
difference from this study (Liu et al. 2012). Additionally, the insulin 
concentration used is not reported and does not appear to have increased 
glucose uptake significantly (Liu et al. 2012). 
 
When assessing the effects on insulin signalling it was demonstrated that 
AICAR increased both Akt Ser473 and AS160 Thr642 phosphorylation. AICAR 
was previously found by this lab to increase Akt Ser473 phosphorylation in 
human aortic endothelial cells (Morrow et al. 2003). Interestingly, the direct 
effect of AICAR on Akt activity was assessed by kinase assay in 3T3-L1 
adipocytes and no change in Akt activity was seen (Salt et al. 2000). Whilst 
another group found that AICAR increased Akt Ser473 phosphorylation in 
muscle in a manner proposed to be AMPK-dependent, again suggesting cell 
specific effects of AMPK activation (Chen and Mackintosh, 2009). Yet another 
study found that AICAR had no effect on Akt phosphorylation but decreased 
AS160 phosphorylation in rat adipocytes (Gaidhu et al. 2010). 
 
In summary, the major finding of this chapter was that AMPK is activated by 
the alternative RAS. Angiotensin II, likely via the AT2R, and ang 1-7, likely via 
the Mas receptor, both significantly increased AMPK activity. As AMPK is 
known to be a key energy regulator, this significantly contributes to our 
understanding of the metabolic benefits of ACE inhibitors and AT1R blockers 
previously identified. However, the underlying functional effects of this are 
yet to be identified and from this work do not appear to be related to 
inflammation or insulin signalling in adipocytes. Whilst this may be due to the 
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modest activation of AMPK observed, further studies of the metabolic effects 
of ang 1-7 would therefore be of great interest. 
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6 Chapter 6 – The impact of high fat diet on 
metabolism, adipose tissue inflammation and the 
RAAS in AMPKα1-/- mice 
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6.1 Introduction 
6.1.1 Role of adipose tissue in obesity related problems 
The consequences of high fat diet (HFD) on human populations are many and 
rodent models of this provide a useful tool in determining mechanisms of 
metabolic disease. Adipose tissue inflammation due to excess nutrition is 
associated with increased pro-inflammatory adipocytokine release which can 
decrease insulin signalling and reduce insulin sensitivity (Reilly and Saltiel, 
2017). Despite this, when treatments targeting inflammation, such as 
neutralising antibodies targeting TNF and IL-1β, have been trialled in humans 
to treat insulin resistance, results have been disappointing (Ofei et al. 1996; 
Sloan-Lancaster et al. 2013). It therefore remains crucial to identify key 
changes in obesity-induced adipose tissue inflammation which may be targets 
for diabetes therapies. 
 
6.1.2 AMPK knockout mice 
AMPKα1 is the predominant catalytic AMPK subunit in adipose tissue. Global 
AMPKα1-/- mice have reduced AMPK activity in adipose tissue yet no 
significant basal metabolic phenotype (Viollet et al. 2003). The AMPKα2-/- 
mouse however exhibits impaired glucose handling (Viollet. et al 2003). 
AMPKα2 is the predominant subunit in other key metabolic tissues including 
the liver and skeletal muscle. The AMPKα1-/- model therefore provides a 
useful tool to assess the importance of adipose AMPK in the sensitivity to 
metabolic stress and the development of metabolic disorders. Previous studies 
report small adipocyte size in AMPKα1-/- mice and an increase in both basal 
and stimulated lipolysis (Daval et al. 2005). In addition, AMPKα1 appears to be 
required for AICAR-induced aortic ring relaxation, which was absent in 
AMPKα1-/- mice but remained in AMPKα2-/- mice (Goirand et al. 2007).  
AMPKα1-/- mice also display a marked erythrocyte abnormality and anaemia 
with a marked compensatory splenomegaly (Foller et al. 2009).  
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6.1.3 Aims 
This study aimed to identify the role that AMPKα1 plays in the development of 
adipose tissue dysfunction in obesity. Using wild type (WT) and AMPKα1-/- 
(KO) mice fed HFD or a normal chow diet, the impact of dietary excess on 
systemic metabolic physiology and adipose tissue was assessed.  
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6.2 Results 
6.2.1 Weight gain during the 12-week dietary intervention 
Littermate pairs of male WT and KO mice were allocated to receive either 
standard chow or high fat diet (HFD) for 12 weeks from 8-10 weeks old. 
Weight was charted weekly throughout the 12-week period (Fig. 6.1A). Mean 
baseline weight was similar between groups (25.64 g for WT chow, 26.23 g for 
KO chow, 23.66 g for WT HFD and 22.22 g for KO HFD). Both chow fed groups 
gained similar amounts of weight (14.4 WT, 7% KO). The WT mice fed HFD 
gained the most weight with a 35.5% rise from baseline, whilst the KO mice on 
HFD increased their weight by 28.7%. Although the WT mice on HFD gained 
the most weight, there was no significant difference compared to weight gain 
in KO mice (Fig 6.1B).  
 
Food intake was also assessed weekly by measuring the mass change of hopper 
food in a 24 h period for each mouse. Both WT and KO mice on chow diet ate 
more food per day (WT 4.3g, KO 4.4g; mean over 12 weeks) than those eating 
the high fat diet (WT 3.2g, KO 3.1g; mean over 12 weeks)(Fig 6.2A&B). The 
mass of food consumed did not vary significantly over the course of the 
dietary intervention. The mean daily estimated KCal intake per day was 
similar between groups at 14.1 for WT chow, 14.5 for KO chow, 14.8 for WT 
HFD and 14.3 for KO HF. 
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Figure 6.1 Weight gain during 12-week high fat diet 
intervention 
Weight was measured weekly during the dietary intervention. A. Weekly 
weight gain as a percentage of initial body weight and B. Percent weight gain 
following the 12 week intervention. Two way ANOVA, *p<0.05. WT Chow n=5, 
WT HFD n=7, KO Chow n=3, KO HFD n=6. 
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Figure 6.2 Food consumption during 12-week high fat 
diet intervention 
Available food was measured before and after 24 h once per week throughout 
the 12-week dietary intervention. Values represented for A. WT and B. KO 
mice. Unpaired t-test, *p<0.05. WT Chow n=6, WT HFD n=7, KO Chow n=4, KO 
HFD n=6. 
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6.2.2 The effect of HFD on glucose tolerance and metabolic 
parameters in WT and KO mice 
Fasting lipids, glucose and insulin were measured at the end of the dietary 
intervention as an index of metabolic health. There was a significant increase 
in total cholesterol in WT mice on high fat diet compared to chow (HFD 5.3 vs 
chow 3.9 mM, p=0.03)(Fig. 6.3A), whereas in KO mice the increase in 
cholesterol was close to significant (HFD 4.4 vs. chow 3.2 mM, p=0.053).  
There were no significant differences between groups for triglyceride 
concentration whereas HDL had a tendency to be higher in the KO HFD group 
compared to KO chow (p=0.056)(Fig. 6.3 A & B).  
 
Fasting glucose was not significantly different between the groups however 
there was a tendency toward lower fasting glucose in the KO group on chow 
diet compared to HFD (Fasting glucose chow 4.3 mM vs. HFD 5.9 mM, 
p=0.076)(Fig. 6.4A). Fasting insulin levels were highest in the WT group on 
high fat diet however the difference was not statistically significant (HFD 0.91 
vs. chow 0.57 ng/ml, p=0.064)(Fig. 6.4B).  
 
Glucose tolerance testing was performed following a 16 h fast at the end of 
the intervention. Each group responded similarly to intraperitoneal glucose 
and there were no significant differences between the incremental area under 
the curve (Fig 6.5E). There was a significant difference between the 15 min 
glucose level in the KO HFD group compared to the KO chow group (KO HFD 
215% increase vs KO chow 330% increase, p=0.008)(Fig 6.5D). It is not clear 
why the incremental glucose was higher at 15 min in the chow group 
compared to the HFD group however it may be related to the lower baseline 
glucose. 
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Figure 6.3 Serum lipids following 12-week dietary 
intervention 
Whole blood was obtained at sacrifice by cardiac puncture. Serum lipids were 
analysed using a clinically validated automated platform (c311, Roche 
Diagnostics, Burgess Hill, UK). The analyser was calibrated and quality 
controlled using the manufacturers materials. Data for A. cholesterol, B. 
triglycerides and C. HDL are displayed as individual values with means with 
standard error.  WT Chow n=5, WT HFD n=7, KO Chow n=4, KO HFD n=6. 
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Figure 6.4 Fasting serum glucose and insulin following 
12-week dietary intervention 
A. Tail vein glucose was analysed following 16 h fast using a FreeStyle 
Optium glucometer. B. Whole blood was obtained at sacrifice by cardiac 
puncture. Serum insulin was analysed by ELISA. Data are displayed as 
individual values with means with standard error.  WT Chow n=6, WT HFD 
n=7, KO Chow n=4, KO HFD n=6. 
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Figure 6.5 Glucose tolerance test 
Glucose tolerance tests were performed 1-2 days prior to sacrifice following 
a 16 h fast. Tail vein blood glucose was measured before and after an 
intraperitoneal glucose injection. Free access to food was granted after the 
test. Changes from baseline glucose are represented by genotype A. WT and 
B. KO in mmol/l C. WT and D. KO as % change from baseline. E.  Mean 
Incremental area under the curve for grouped mice. Unpaired t-test, 
**p<0.001. WT Chow n=6, WT HFD n=7, KO Chow n=4, KO HFD n=6. 
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6.2.3 The effect of HFD on serum RAAS and electrolytes in WT 
and KO mice 
Serum aldosterone, angiotensin II, angiotensin I and renin concentration were 
measured following the intervention. Mean aldosterone concentration was 
similar between both WT chow (84.33 pg/ml) and HFD groups (90.13 pg/ml) 
and tended to be lower in the KO chow group (53.33 pg/ml) yet highest in the 
KO HFD group (250.46 pg/ml). Angiotensin II concentrations were again similar 
in the WT groups (chow 268.13 pg/ml, HFD 254.3 pg/ml) yet tended to be 
higher in the KO groups (chow 641.23 pg/ml, HFD 885 pg/ml). Angiotensin I 
levels were also highest in the KO HFD group although the difference was not 
statistically significant (WT chow 199.1 pg/ml, WT HFD 249.2 pg/ml, KO chow 
267.5 pg/ml, KO HFD 469.64 pg/ml). In keeping with these findings, renin 
concentration (measured by ang I formation rate) was also highest in the KO 
HFD group (WT chow 21.2, WT HFD 43.36, KO chow 33.6, KO HFD 54) (Fig. 
6.6). Serum sodium, potassium and chloride were not significantly different 
between the treatment groups (Fig. 6.7).  
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Figure 6.6 Serum RAAS measurements following 12-
week dietary intervention 
Whole blood was obtained at sacrifice by cardiac puncture. Serum RAAS 
components were analysed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) by Attoquant Diagnostics (Vienna, Austria). Data 
are displayed as individual values with means with standard error for A. 
angiotensin I, B. angiotensin II, C. angiotensin I formation rate and D. 
aldosterone. WT Chow n=3, WT HFD n=3, KO Chow n=3, KO HFD n=5. 
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Figure 6.7 Serum electrolytes at the end of the 12-week 
dietary intervention 
Whole blood was obtained at sacrifice by cardiac puncture. Serum 
electrolytes were analysed using a clinically validated automated platform 
(c311, Roche Diagnostics, Burgess Hill, UK). The analyser was calibrated and 
quality controlled using the manufacturers materials. Data for A. sodium, B. 
potassium and C. chloride are displayed as individual values with means with 
standard error.  WT Chow n=5, WT HFD n=7, KO Chow n=4, KO HFD n=6. 
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6.2.4 The effect of HFD on organ weights in WT and KO mice 
High fat diet increased liver weight in both WT and KO mice. WT liver weight 
increased following HFD from a mean weight of 838 mg to 1106 mg (p=0.008). 
A similar increase was observed in KO mice (mean chow liver weight 842 mg 
vs mean HFD liver weight 1120 mg) (p=0.048) (Fig 6.8A). Spleen weights were 
significantly increased in KO mice and spleen weight was not affected by 
dietary intake (mean spleen weight WT chow 58 mg, KO chow 230 mg, 
p<0.0001) (Fig. 6.8B). HFD had no significant effect on heart or kidney 
weight.  When corrected for body weight, the significance of the increased 
liver mass was lost, but the spleen mass remained significantly increased in 
the KO mice on either diet.  Both WT and KO mice on chow diet displayed 
normal liver architecture with evidence of normal sinusoids. Following high 
fat diet liver architecture was altered and fat droplets were evident in both 
WT and KO liver samples (Fig. 6.9). Mean liver triglyceride content was not 
significantly different between genotype at baseline. Following HFD liver 
triglyceride significantly increased in both genotypes (WT chow 11.44 vs WT 
HFD 30.51 nmol/mg, p=0.049) (KO chow 7.78 vs KO HFD 21.39 nmol/mg, 
p=0.038) (Fig 6.10). There was no significant difference in liver triglyceride 
content between genotype following HFD. 
 178 
 
 
Figure 6.8 Organ weights  
A. liver, B. spleen, C. heart and D. kidneys were collected and weighed at 
the time of sacrifice. E. liver and F. spleen weights have been corrected to 
body weight. T-test, *p<0.05, **p<0.01, ****p<0.0001. WT Chow n=6, WT HFD 
n=7, KO Chow n=4, KO HFD n=6. 
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Figure 6.9 Liver histology 
Representative micropictographs of liver sections stained with haemotoxylin 
and eosin from experimental mice. Images (40 x magnification) were 
generated by Omar Katwan (University of Glasgow). 
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Figure 6.10 Liver triglyceride content 
Triglyceride content of liver homogenates was assayed using an Abcam 
Triglyceride Quantification Assay Kit. T-test *p<0.05. Data shown is from four 
chow-fed animals of each genotype and five animals of each genotype fed 
high fat diet (HFD). Assay conducted by Dr Ian Salt (University of Glasgow). 
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6.2.5 The effect of HFD on adipose tissue in WT and KO mice 
6.2.5.1 Adipose tissue mass 
Subcutaneous (SCUT) and epididymal (EVAT) adipose tissue depot weights at 
the time of sacrifice were corrected to final body weight. High fat diet 
significantly increased EVAT weight in WT and KO mice (Fig 6.10B). However, 
SCUT weight increased significantly only in the WT group (Fig. 6.11). 
 
6.2.5.2 AMPK phosphorylation in adipose tissue  
AMPK Thr172 phosphorylation was significantly lower in SCUT and EVAT of KO 
mice compared to WT mice (Fig. 6.12). As the antibody used recognizes 
activating phosphorylation sites in both AMPKα1 and AMPKα2, the remaining 
immunoreactivity in KO mice reflects phospho-AMPKα2 levels.  
 
6.2.5.3 STAT3 phosphorylation in adipose tissue 
STAT3 is a transcription factor with a crucial role in IL-6 mediated JAK-STAT 
signalling and the induction of chemokines such as MCP-1 (Fasshauer et al. 
2004) but also mediates anti-inflammatory effects of IL-10 (MacPherson et al. 
2015). This group previously identified an increase in STAT3 phosphorylation 
in gonadal and SCUT adipose tissue from female KO mice compared to WT 
(Mancini et al. 2017). To determine the effect of HFD on adipose STAT3 
phosphorylation western blotting was performed on adipose tissue lysates. In 
SCUT, STAT3 phosphorylation was significantly reduced in KO mice fed a HFD, 
compared to those fed chow diet (p=0.0004), a similar tendency was observed 
in WT mice although this difference was not statistically significant (Fig. 
6.13A). In EVAT, STAT3 phosphorylation was significantly increased in KO mice 
compared to wild type mice fed chow diet. Interestingly, STAT3 
phosphorylation in KO mice fed HFD was significantly reduced compared to 
chow-fed KO mice, yet diet had no effect on WT mice (Fig. 6.13B).  
 182 
6.2.5.4 JNK phosphorylation in adipose tissue 
Another pro-inflammatory signalling pathway which can be attenuated by 
AMPK is the JNK signalling pathway (Mancini et al. 2017). In SCUT from WT 
mice JNK phosphorylation increased in response to HFD (p=0.02)(Fig. 6.14A & 
B). In SCUT from KO mice, however, JNK phosphorylation was not changed by 
HFD. In EVAT from WT mice there was a tendency for HFD to increase JNK 
phosphorylation whilst in KO mice JNK phosphorylation was unchanged by diet 
(Fig 6.14C & D). Therefore, KO mice appear resistant to the effect of HFD on 
JNK phosphorylation. 
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Figure 6.11 Adipose tissue weights 
Inguinal subcutaneous (SCUT) and epididymal (EVAT) fat pads were collected 
and weighed following sacrifice. Weights corrected to body weight are 
presented for A. subcutaneous and B. epididymal adipose tissue depots. Two-
way ANOVA, *p<0.05, **p<0.01, ***p<0.001. WT Chow n=6, WT HFD n=7, KO 
Chow n=4, KO HFD n=6. 
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Figure 6.12 AMPK phosphorylation in adipose tissue 
following 12-week dietary intervention  
SCUT (A. and B.) or EVAT (C. and D.) lysate proteins were resolved by SDS-
PAGE and immunoblotted for the indicated proteins. A. and C. 
Representative immunoblots with the molecular masses of marker proteins 
(in kDa) shown. Quantification of P-AMPK relative to GAPDH for B. SCUT and 
D. EVAT.  Two-way ANOVA, **p<0.01. WT Chow (WC) n=6, WT HFD (WH) n=6 
(SCUT) or 7 (EVAT), KO Chow (KC) n=4, KO HFD (KH) n=6. 
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Figure 6.13 STAT3 phosphorylation in adipose tissue 
following 12-week dietary intervention 
SCUT (A. and B.) or EVAT (C. and D.) lysate proteins were resolved by SDS-
PAGE and immunoblotted for the indicated proteins. A. and C. 
Representative immunoblots with the molecular masses of marker proteins 
(in kDa) shown. Quantification of P-STAT3 relative to STAT3 for B. SCUT and 
D. EVAT.  Two-way ANOVA, *p<0.05, ***p<0.001. WT Chow (WC) n=6, WT HFD 
(WH) n=3 (SCUT) or 7 (EVAT), KO Chow (KC) n=4, KO HFD (KH) n=6. 
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Figure 6.14 JNK phosphorylation in adipose tissue 
following 12-week dietary intervention 
SCUT (A. and B.) or EVAT (C. and D.) lysate proteins were resolved by SDS-
PAGE and immunoblotted for the indicated proteins. A. and C. 
Representative immunoblots with the molecular masses of marker proteins 
(in kDa) shown. Quantification of P-JNK 54 relative to JNK 54 for B. SCUT and 
D. EVAT.  Two-way ANOVA, *p<0.05. WT Chow (WC) n=6, WT HFD (WH) n=6 
(SCUT) or 7 (EVAT), KO Chow (KC) n=4, KO HFD (KH) n=6. 
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6.2.5.5 MR expression in adipose tissue 
Previous reports have identified increased adipose tissue MR expression in 
obesity (Urbanet et al. 2015). MR protein levels were not significantly altered 
by genotype nor by dietary intake (Fig. 6.15) in this study however there was 
a trend towards increase with HFD.  
 
6.2.5.6 Adiponectin expression in adipose tissue 
Circulating levels of the insulin-sensitising adipokine adiponectin usually 
decrease with increased adiposity (Lara-Castro et al. 2007). As shown in figure 
6.16, adipose tissue adiponectin protein levels tended to be higher in the HFD 
groups, particularly in SCUT of KO mice (p=0.055 vs chow).  
 
6.2.5.7 MCP-1 expression in adipose tissue 
Lastly, protein levels of the chemokine MCP-1 were determined in SCUT and 
EVAT. MCP-1 levels in SCUT were unchanged between the groups (Fig 6.17A). 
In EVAT however, MCP-1 levels were increased with HFD, a change which was 
more prominent in the WT mice (p=0.035) and did not reach statistical 
significance in KO mice (Fig. 6.17B). 
 
 188 
 
Figure 6.15 Expression of MR in adipose tissue following 
12-week dietary intervention 
EVAT lysate proteins were resolved by SDS-PAGE and immunoblotted for the 
indicated proteins. A. Representative immunoblots with the molecular 
masses of marker proteins (in kDa) shown. B. Quantification of MR relative to 
GAPDH. WT Chow (WC) n=6, WT HFD (WH) n= 7, KO Chow (KC) n=4, KO HFD 
(KH) n=6. 
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Figure 6.16 Expression of adiponectin in adipose tissue 
following 12-week dietary intervention 
SCUT (A. and B.) or EVAT (C. and D.) lysate proteins were resolved by SDS-
PAGE and immunoblotted for the indicated proteins. A. and C. 
Representative immunoblots with the molecular masses of marker proteins 
(in kDa) shown. Quantification of adiponectin relative to GAPDH for B. SCUT 
and D. EVAT. WT Chow (WC) n=6, WT HFD (WH) n=6 (SCUT) or 7 (EVAT), KO 
Chow (KC) n=4, KO HFD (KH) n=6. 
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Figure 6.17 Expression of MCP-1 in adipose tissue 
following 12-week dietary intervention 
SCUT (A. and B.) or EVAT (C. and D.) lysate proteins were resolved by SDS-
PAGE and immunoblotted for the indicated proteins. A. and C. 
Representative immunoblots with the molecular masses of marker proteins 
(in kDa) shown. Quantification of MCP-1 relative to GAPDH for B. SCUT and D. 
EVAT. T-test, *p<0.05. WT Chow (WC) n=6, WT HFD (WH) n=6 (SCUT) or 7 
(EVAT), KO Chow (KC) n=4, KO HFD (KH) n=6. Repeat analysis with non-
parametric test (Mann-Whitney) D. WC vs. WH p=0.0734. 
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6.2.5.8 CXCL-10 gene expression in adipose tissue 
As demonstrated in 5.2.2.3, CXCL-10 is secreted from adipocytes in response 
to pro-inflammatory stimuli such as IL-1β. In this study, CXCL-10 mRNA levels 
in SCUT were not changed between genotype or dietary intervention (Fig. 
6.18A). However, in EVAT it tended to increase with HFD in WT mice. There 
was also a trend for CXCL-10 mRNA levels to be higher in KO animals however 
when they were exposed to HFD the CXCL-10 mRNA levels decreased although 
RNA from only two KO mice fed HFD were analysed (Fig. 6.18B).  
 
6.2.5.9 IL-1β gene expression in adipose tissue 
IL-1β mRNA levels were determined in EVAT samples.  Basal IL-1β mRNA levels 
were increased in KO compared to WT mice (p=0.017) and there was a 
tendency for HFD to increase levels in WT EVAT (p=0.07) but not in KO mice 
where levels were unchanged (Fig 6.19).  
 
6.2.5.10 Angiotensinogen gene expression in adipose tissue 
The RAAS precursor angiotensinogen was increased in adipose tissue from 
insulin resistance obese individuals when compared to non-insulin resistant 
obese individuals (Xu et al. 2012). In this study however, there was a 
tendency for HFD to decrease SCUT angiotensinogen expression. This finding 
was most pronounced in KO mice yet the change did not reach statistical 
significance (p=0.08) (Fig 6.20). 
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Figure 6.18 mRNA expression of CXCL-10 in adipose 
tissue following 12-week dietary intervention 
RNA was extracted from A. SCUT or B. EVAT. Reverse transcription was 
carried out prior to Taqman qPCR assays for CXCL-10. Data are normalised to 
TATA-binding protein mRNA expression. A. SCUT: WT Chow n=6, WT HFD n=4 
KO Chow n=4, KO HFD n=2. B. EVAT: WT Chow n=3, WT HFD n=6, KO Chow 
n=3, KO HFD n=6. 
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Figure 6.19 Expression of IL-1β in adipose tissue 
following 12-week dietary intervention 
RNA was extracted from EVAT samples. Reverse transcription was carried out 
prior to Taqman qPCR assays for IL-1β. Data are normalised to TATA-binding 
protein mRNA expression. T-test *p<0.05. WT Chow n=6, WT HFD n=4 KO 
Chow n=4, KO HFD n=3. 
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Figure 6.20 Expression of angiotensinogen in adipose 
tissue following 12-week dietary intervention 
RNA was extracted from SCUT samples. Reverse transcription was carried out 
prior to Taqman qPCR assays for angiotensinogen. Data are normalised to 
TATA-binding protein mRNA expression. WT Chow n=6, WT HFD n=7, KO Chow 
n=4, KO HFD n=6. 
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6.3 Discussion 
This chapter sought to identify the impact of HFD on mice with decreased 
AMPK activity in adipose tissue. The effects on systemic and adipose tissue 
specific parameters were examined in chow- and HFD-fed WT and AMPKα1 KO 
mice with a focus on inflammation and the RAAS. 
 
In this study, WT and KO mice on HFD gained a similar percentage of body 
weight which was significantly more than those on chow diet. A tendency for 
the WT to gain more weight was observed and consistent with this the 
increased weight of EVAT and SCUT depots in WT reached higher degrees of 
significance than in KO mice where the SCUT depot did not significantly 
increase in weight.  
 
Despite gaining weight and significantly expanding adipose tissue depots, no 
major glycaemic dysregulation was detected as a result of HFD. 
Intraperitoneal glucose tolerance testing showed similar glucose dynamics 
between the groups. At 15 minutes there was a significant decrease in the % 
glucose rise from baseline in the KO HFD group compared to the KO chow 
group. Suggesting a benefit of the high fat diet in the KO mice. Consistent 
with these findings, fasting blood glucose was lowest in the KO chow group 
and insulin was highest in the WT HFD group leading to a tendency for HOMA-
IR to be highest in the WT HFD group.  It certainly would have been 
anticipated that HFD would lead to impaired glucose tolerance however 
several factors can influence this response (Kleinert et al. 2018). It may be a 
consequence of the length of this study where longer exposure to the HFD 
would result in metabolic dysregulation. In addition, the Sv129 strain is known 
to be more resistant than others to diet-induced obesity and may explain the 
lack of response. (Xiao et al. 2017). It should be noted that it was not possible 
to integrate the C57/Bl6 background into the KO mice (Benoit Viollet, Institut 
Cochin, personal communication). 
 
Fatty liver is an important metabolic consequence of obesity and can result in 
cirrhosis (Tilg & Hotamisligil, 2006). In this study, liver weight and triglyceride 
content increased in both HFD groups however there was no difference 
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between genotypes at baseline or following dietary intervention. Similarly, 
there was evidence of ectopic lipid deposition in both groups when liver 
section examined by H&E staining. The liver plays a key role in cholesterol 
synthesis. Here, the WT HFD group had a significantly higher serum 
cholesterol concentration than the chow-fed WT mice whilst the KO HFD mice 
did have a rise in cholesterol it did not reach statistical significance. Indeed it 
is very well described that in metabolic disorders when human adipose 
capacity becomes overwhelmed fatty liver can develop (Bertot et al. 2017). 
Given the known anti-steatotic effect of AMPK, it is interesting that there was 
not more steatosis evident in the KO mice, however as the liver would have 
normal functioning AMPKα2 this may well compensate for the lack of α1 
(Smith et al. 2016, Woods et al. 2017). 
 
This group and others have shown that activators of AMPK have anti-
inflammatory properties in adipocytes (Shibata et al. 2013, Mancini et al. 
2017). Here the effect of HFD on inflammatory mediators was examined in 
SCUT and EVAT depots which contain many cells types including adipocytes. 
Immunoblotting for phosphorylation of AMPK at Thr 172 found significantly 
less AMPK activity in KO mice, confirming the key role of AMPKα1 in adipose 
tissue where it is known to be the predominant catalytic isoform (Lihn et al. 
2004, Daval et al. 2005). There was no difference in AMPK phosphorylation 
following HFD in SCUT or EVAT in WT mice, however we have shown that HFD 
decreased AMPK activity in perivascular adipose tissue from WT mice 
(Almabrouk et al. 2018). In WT mice HFD led to significant increases in 
adipose tissue JNK phosphorylation and MCP-1 protein whilst there was a 
tendency for increased IL-1β gene expression. These findings have previously 
been identified and are consistent with the pro-inflammatory effects of HFD 
and obesity (Cranford et al. 2016). Interestingly, STAT3 signalling was not 
increased with HFD in WT mice, but was increased in EVAT of KO chow mice 
compared to WT and most strikingly, this was decreased in response to HFD. 
In agreement with this, STAT3 signalling was increased in female gonadal and 
SCUT adipose tissue from KO mice compared to WT (Mancini et al. 2017). 
Similarly, JNK phosphorylation did not increase in response to HFD in KO 
mice. However, there was no difference between chow WT and KO adipose 
JNK phosphorylation, a difference which was observed in the gonadal adipose 
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of the female cohort (Mancini et al. 2017), this could be a gender difference. 
In a report of nicotine induced insulin resistance examining adipose specific 
AMPKα1 and AMPKα2 deletion, no difference was seen in basal JNK 
phosphorylation in white adipose tissue (Wu et al. 2015). In the present study 
there was a trend towards increased MCP-1 expression in KO chow compared 
to WT and again this tended to decrease with HFD. Considering the only 
difference in glucose tolerance observed was a decrease in 15 min 
incremental glucose in KO HFD compared to KO chow mice, the data suggest 
that KO mice fed a chow diet have a pro-inflammatory adipose tissue, when 
compared to WT mice, yet this is in some way improved in response to high 
fat diet. This finding is certainly intriguing if not confusing. This may explain 
the finding that adiponectin protein expression was highest in the KO mice on 
high fat diet, whereas others have reported lower adipose expression of 
adiponectin following this dietary intervention (Barnea et al. 2006). 
Adiponectin secretion from PVAT was decreased by HFD and decreased in KO 
mice despite no significant change in mRNA expression (Almabrouk et al. 
2018). It may be that release of adiponectin, rather than production or 
storage, is the main alteration in response to HFD.  
 
Upregulation of adipose RAAS in obesity is one potential mechanism 
underlying the pro-inflammatory changes in obesity giving rise to 
cardiometabolic disorders. In this study, the systemic RAAS was not 
significantly affected by HFD in WT mice. However, KO mice tended to have 
higher basal angiotensin II levels, and when exposed to HFD, KO mice had the 
highest levels of angiotensin I and II, aldosterone and renin activity. Although 
these findings were not statistically significant, likely due to low number of 
samples, there was a clear trend which suggests a relationship between 
decreased AMPK and increased RAAS. Certainly this would be consistent with 
findings in chapter 4 of this thesis. No significant changes in adipose tissue MR 
protein or angiotensinogen mRNA levels were identified between the groups 
studied here. Previous reports have shown that adipose MR is increased in 
obesity (Urbanet et al. 2015). Whilst angiotensinogen mRNA levels were 
increased in adipose tissue from insulin resistant obese individuals but not 
those who were insulin sensitive (Xu et al. 2012).  
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Whilst considering these findings it is important to note that rodent HFD 
studies can differ considerably in nature between constituent diet and 
duration of intervention. In this study a 42% calories from fat diet was used 
which may be considered as a modest % of fat, closer to the 30% fat intake of 
humans. Certainly studies commonly use 60% calories from fat or even higher 
(Kleinert et al. 2018). Additionally, some diets use a combination of fat and 
sugars to try and replicate diabetes more closely. Or employ an injection of 
streptozotocin to injure the pancreatic beta cells and make diabetes more 
likely (Kleinert et al. 2018). Longer duration of HFD is likely to induce a more 
marked metabolic injury and could be utilised to further study some of the 
changes identified in this cohort of mice.  One must also be mindful of the 
global AMPKα1 knockout in these mice, there have been recent reports from 
mice with adipose specific knock down of different AMPK subunits including 
α1 which would be of interest to this work (Wu et al. 2015). 
 
In conclusion, AMPKα1 deficient mice had no significant metabolic features 
basally, or when exposed to HFD. There was evidence of pro-inflammatory 
changes in the KO adipose tissue basally which intriguingly improved with 
HFD. However, the systemic RAAS appeared to be upregulated in the KO HFD 
group. Overall this draws more interest to the role of AMPK in adipose tissue 
and the development of metabolic disorders. Certainly, the paradoxical effect 
of improvements with HFD in the KO mice requires further exploration.  
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7 Chapter 7 – Discussion and summary 
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7.1 Discussion 
Obesity is a major threat to the health of current and future generations with 
projected global rates of 18% in men and 21% in women by 2025 (NCD risk 
factor collaboration, 2016). Adipose tissue inflammation appears to be an 
important factor in the development of obesity-related insulin resistance 
which may lead to type 2 diabetes if not addressed. This work sought to 
identify a mechanism whereby a known metabolically active kinase, AMPK, 
could regulate the local RAAS in adipocytes/adipose tissue and determine the 
effects of RAAS on AMPK activity.  
 
7.1.1 The effects of AMPK on adipocyte RAAS, inflammation and 
metabolism 
One of the major findings in this study was downregulation of the adipocyte 
MR by AMPK activators.  As the MR mediates metabolic effects of both 
mineralocorticoids and glucocorticoids in adipocytes and is reportedly 
increased in obese adipose tissue, the negative regulation by AMPK is an 
important and relevant new finding (Caprio et al. 2007, Hoppmann et al. 
2010, Hirata et al. 2012, Lee and Fried 2014). It would be of interest to 
determine if similar effects were seen in other cell types including those 
relevant to renal and vascular tissues. Previous reports demonstrate that 
AMPK activation attenuates the pro-fibrotic effects of aldosterone however, 
do not assess the effect of AMPK on MR expression (Lee et al. 2013, Mummidi 
et al. 2016). Interestingly, the current work was not able to implicate 
aldosterone in metabolic dysfunction. Determining the effect of AMPK 
activation on MR expression in primary human adipocytes would strengthen 
this study. In keeping with the original hypothesis, this work also 
demonstrated that AICAR and A769662 affected expression of the angiotensin 
converting enzymes. AICAR decreased ACE gene expression and increased the 
ACE2:ACE ratio whilst A769662 increased ACE2 expression. However, it must 
also be considered that further investigation revealed that aldosterone 
secretion from adipocytes was increased by AICAR in 3T3-L1 adipocytes and 
A769662 in SW872 adipocytes. Adipose-derived aldosterone may have a role in 
the regulation of local vascular function which is of particular relevance for 
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nutrient delivery (Briones et al. 2012, Nguyen et al. 2018). However, when 
systemic RAAS was assessed in vivo there was a tendency for an increase in 
the AMPK KO mice, and in fact AMPK was downregulated in the context of 
prolonged AMPK activation in adipocytes which leads to the hypothesis that 
aldosterone secretion may be acting to negatively regulate AMPK levels within 
adipocytes, potentially via SGK1 and LKB1. Given the paucity of published 
data in relation to this area it is difficult to compare these findings to those 
previously reported. Indeed, the regulation of adipose MR is not well 
understood but it has been established that blockade of the MR improves 
metabolic function and cardiovascular outcomes for people with diabetes and 
therefore downregulation of the MR by AMPK activation is highly likely to be a 
beneficial thing.  
 
There are now more specific AMPK activators available which have recently 
been used in vivo in primate and rodent models. PF-739 (non-selective) and 
PF-249 (β1 activator) were compared to assess the impact on glycaemia in 
cynomolgus monkeys, with only the non-selective activator able to reduce 
glucose levels, through skeletal muscle dispersal, due to the predominance of 
β2 in skeletal muscle compared to β1 (Cokorinos et al. 2017). This study goes 
some way towards confirming the importance for skeletal muscle over the 
liver in glucose homeostasis. Another group assessed MK-8722, which activates 
all AMPK complexes, assessing its effect on diabetes in rhesus monkeys, it 
reduced HbA1c in 10 monkeys but increased it in 3 monkeys, these 3 monkeys 
exhibited the more severe glycaemic disturbance at baseline (Myers et al. 
2017). In addition, they found that MK-8722 increased cardiac hypertrophy 
and glycogen storage in the heart which may have clinical implications if 
translated to humans (Myers et al. 2017). The most recent report, of PF-
06409577 (B1 activator), found benefits in rodents with hepatic steatosis and 
fibrosis and reported a decrease in cholesterol after 6 weeks treatment in 
monkeys. However, again as the β1 expression is low in skeletal muscle in 
humans and primates this may explain the lack of glucose lowering effect 
(Esquejo et al. 2018). It would be of major interest to utilise these agents to 
assess the effect on adipose RAAS and inflammation in addition to glycaemic 
control in the context of obesity and diabetes. Ultimately, due to the 
ubiquitous expression of AMPK, tissue or cell targeted therapies would be the 
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optimal method of targeting adipose AMPK with the avoidance of potential 
adverse effects in the heart and hypothalamus. Certainly the use of adipose 
AMPK KO mice is beneficial for the characterisation of adipose-specific 
effects.  
 
In this study, AMPKα1-/- mice did not exhibit any major metabolic phenotype, 
consistent with previous reports of AMPKα1-/- mice (Viollet et al. 2003). In 
the current work AMPKα1-/- mice exposed to HFD responded similarly to WT 
mice in terms of metabolic dysfunction and in fact were protected against 
some of the increases in markers of adipose inflammation seen in WT mice. 
However, there was a trend toward an increase in circulating RAAS in the 
AMPKα1-/- mice on HFD suggesting that despite a lack of metabolic 
disturbance, the RAAS was still upregulated. However, no change was seen in 
adipose tissue MR although isolated adipocytes were not examined and 
angiotensinogen expression tended to be reduced by HFD. It is possible that 
the background genotype of mouse or the length of dietary intervention may 
have influenced the outcomes of this work. Interestingly, data from adipose 
specific KO mice has recently revealed the role of adipose AMPK. Wu et al. 
demonstrated nicotine-induced insulin resistance and increased lipolysis in WT 
and adipose-specific α1 KO but not α2 KO mice. Suggesting that, although less 
abundant, the α2 subunit in adipose tissue is required for the pro-
inflammatory effects of nicotine. This study also identified glucose 
intolerance in response to nicotine in WT and α1 KO but not α2 KO mice (Wu 
et al. 2015). In the current study the α1 deletion was global and therefore the 
systemic effects on metabolic processes must be considered relevant. This 
work would certainly be enhanced by the use of adipose specific AMPK KO 
mice with HFD to determine the effect on adipose RAAS, inflammation and 
systemic metabolism. In 2016, an inducible adipose specific AMPK KO of β1 
and β2 deletion (adiponectin promoter) was found to have a major influence 
in brown adipose tissue function leading to cold intolerance in addition to 
steatosis and glucose intolerance in response to HFD. The mechanism was 
proposed to be due to impaired mitophagy leading to impaired mitochondrial 
function. Very interestingly, the authors did not find an effect of AMPK on 
lipolysis in vivo (Mottillo et al. 2016).  
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7.1.2 The effects of the RAAS on AMPK in adipocytes 
This study set out to explore the pro-inflammatory effects of RAAS in 
adipocytes, however in the models used here, pro-inflammatory signalling 
with angiotensin II was not demonstrable despite previous reports of this 
available in the literature (Kalupahana et al. 2012). Alternately, there was a 
signal for AMPK activation by angiotensin II which may be AT2 receptor 
mediated. Angiotensin II was found to activate AMPK in skeletal muscle, yet 
decrease AMPK activity in cardiomyocytes and renal cells (Nagata et al. 2004, 
Stuck et al. 2008, Lee et al. 2013). In this report ang 1-7 also activated AMPK 
in adipocytes, yet had no effect on inflammatory processes or on insulin 
signalling. The AMPK activation, although relatively weak, appeared to be 
calcium and Mas receptor dependent. Given previous findings that AMPK 
decreased MR and increased aldosterone secretion from adipocytes, the 
effect of ang 1-7 on aldosterone secretion could be further explored and 
understanding if and how the alternative RAAS may regulate the classic RAAS 
through AMPK. 
 
7.2 Limitations 
This study focused on the actions of AMPK activators and components of the 
RAAS in cultured adipocytes. One significant limitation of adipocyte models is 
the lack of response to molecular biology techniques such as siRNA to 
manipulate protein function. Indeed, in our lab, attempts to up- or down-
regulate AMPK genetically in terminally differentiated adipocytes have been 
unsuccessful. This project therefore utilised two different AMPK activators 
and the AMPK-/- MEFs to explore AMPKs actions as best as possible. Additional 
attempts were made to differentiate AMPK-/- MEFs into adipocytes however 
these also proved unsuccessful. Cultured adipocytes such as those used in this 
study have relatively uniform characteristics whereas adipocytes from 
different origin sites likely have unique behaviour depending on location as 
well as body weight and fitness of the individual they come from. It is 
therefore challenging to create a reliably translatable adipocyte cell model. 
As discussed above, this study employed a global AMPKα1-/- mouse model, an 
adipose tissue specific model would be preferable to elucidate the adipose 
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component of effects seen. Indeed as AMPK is expressed ubiquitously, and 
activation may have adverse effects in the hypothalamus and the heart, 
selective and tissue-targeted pharmacological therapies would be of great 
benefit. To date, targeting specific tissues in humans is not routine practice, 
in particular targeting cells so widespread as adipocytes may be of particular 
complexity. 
 
7.3 Future work 
This study has opened a number of lines for further investigation. One of the 
main points of interest would be to reproduce two of the principal findings, of 
AMPK activation on the MR and of ang 1-7 on AMPK activity, in isolated human 
adipocytes to determine the possible clinical relevance of this. Indeed the 
effect of A769662 on aldosterone secretion and SGK1 would be of great 
interest in isolated human adipocytes but also in an adrenal model to see if 
AMPK regulated adrenal aldosterone secretion. It would be prudent to assess 
the effect of AMPK activators on the secretion of a panel of steroids, not just 
focused on aldosterone. If there were an increase in glucocorticoid this may 
be relevant to the anti-inflammatory effects of AMPK activation.  As 
mentioned above, the systemic use of AMPK activators in primate models and 
the adipose specific AMPK KO mice would certainly add weight to the current 
study. The systemic AMPK activators could be used in a primate study to 
determine the effect on adipose RAAS and inflammation in the context of 
diabetes and clarify the impact on systemic RAAS. Whilst the adipose specific 
models would be very useful to isolate effects on MR expression and 
inflammation in adipose tissue in addition to understanding the full metabolic 
impact of adipose AMPK. A possible clinical study may involve the use of 
metformin, which has been shown to activate AMPK in human adipose tissue, 
to determine whether MR is reduced in adipose tissue and assess the effects 
on adipose classic and alternative RAAS activity (Boyle et al. 2011). 
 
It is not clear at this stage what the functional effects of ang 1-7-mediated 
AMPK activation are, however, whether it activates AMPK in other cell types, 
particularly those of the vasculature would be relevant. In addition, the 
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mechanism of activation has been tested using pharmacological inhibitors, 
genetic tools such as siRNA may be a way to confirm the observations here. 
 
7.4 Summary 
In summary, this study has demonstrated for the first time that the energy 
regulating kinase AMPK regulates the local adipose RAAS and that ang 1-7 is an 
AMPK activator in adipocytes. AMPKα1 may be involved in systemic RAAS 
regulation and does not protect against the effects of HFD. Future studies are 
required to improve our understanding of the therapeutic potential within this 
system given its relevance to the worldwide obesity crisis.  
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Appendix 1: Details of High fat diet 
SDS Diet – 829100 – Western RD (P) 
Specification as % kcal Crude Fat 42%, Crude Protein 15%, Carbohydrate 43%. 
Kcal/g = 4.63 total AFE. 
 
Ingredient g% (w/w) 
Sucrose 33.94 
Milk Fat Anhydrous 20 
Casein 19.5 
Maltodextrin 10 
Corn Strach 5 
Cellulose 5 
Corn Oil 1 
Calcium carbonate 0.4 
L-Cystine 0.3 
Choline Bitartrate 0.2 
Cholesterol 0.15 
Antioxidant 0.01 
AIN-76A-MX 3.5 
AIN-76A-VX 1 
 
 
 
